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ABSTRACT 
 
Expanding Genetic Code for Protein Lysine and Phenylalanine Modifications. (August 2012) 
Yane-Shih Wang, B.S.; M.S., National Cheng-Kung University, Taiwan 
Chair of Advisory Committee: Dr. Wenshe Liu 
 
The naturally occurring pyrrolysine (Pyl) incorporation machinery was discovered 
in methanogenic archaea and some bacteria.  In these organisms, Pyl is cotranslationally 
inserted into proteins and coded by an in-frame UAG codon. Suppression of this UAG 
codon is mediated by a suppressor tRNA,        
    , that has a CUA anticodon and is 
acylated with Pyl by pyrrolysyl-tRNA synthetase (PylRS). The PylRS-       
    pair can 
be directly applied to incorporate Pyl and other lysine derivatives into proteins at amber 
mutation sites in E. coli and mammalian cells. In the approach of amber codon 
suppression, evolved PylRSs were selected to synthesize the proteins genetically with 
lysine and phenylalanine derivatives which contain native or mimic of post-translational 
modifications (PTMs) or active chemical functional groups for protein labelling and 
protein folding studies.  
A photocaged N-methyl-L-lysine has been genetically incorporated into proteins at 
amber codons in Escherichia coli using an evovled PylRS-       
    pair. Its genetic 
incorporation and following photolysis to recover N-methyl-L-lysine at phsyiological pH 
provide a convenient method for the biosythesis of proteins with monomethylated lysines.  
 iv 
Using an evolved PylRS-       
    pair, a Se-alkylselenocysteine was genetically 
incorporated in histone H3. The H3 with mimics of PTMs such as lysine methylation, 
lysine acetylation, and serine phosphorylation has been synthesized by selective oxidative 
elimination of Se-alkylselenocysteine and followed Michael addition reactions with 
different thiol-containing small molecules.  
Using evolved PylRS -        
    pairs, L-phenylalanine, p-iodo-L-phenylalanine and 
p-bromo-L-phenylalanine have been genetically incorporated into proteins at amber 
mutation sites in E. coli. The drastic change of the substrate specificity of PylRS from an 
aliphatic amino acid to short aromatic amino acids indicates that the PylRS-       
    pair 
can be evolved for genetic incorporation of a large variety of NAAs into proteins in E. 
coli. Inspired by the consistent mutations on N346 position, the mutants on N346 and 
C348 were constructed and evaluated with different L-phenylalanine derivatives. Using 
PylRS - N346A/C348A        
    pair, more than 30 L-phenylalanine derivatives have 
been genetically incorporated into proteins at defined sites with amber mutation in E. coli. 
These breakthroughs and development greatly expand the inventory of genetically 
encoded NAAs and our abilities to do protein engineering in these cells.  
 v 
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CHAPTER I  
INTRODUCTION* 
 
Protein Post-Translational Modifications 
With few exceptions, the genetic code of all known organisms specifies the same 
20 amino acid building blocks. However, it is clear that many proteins require additional 
chemical groups beyond what 20 amino acid building blocks can provide to carry out 
their native functions.1, 2 Many of these chemical groups are installed on proteins 
through covalent posttranslational modifications of amino acid side chains. These 
modifications greatly expand the coding capacity especially of eukaryotic genomes and 
lead to proteomes two to three orders of magnitude more complex than the encoding 
genomes would predict. Prominent posttranslational modifications include serine, 
threonine, and tyrosine phosphorylation, tyrosine sulfation, lysine acetylation, lysine and 
arginine methylation, lysine ubiquitination, glycosylation, and hydroxylation, etc 
(Figure I-1). These modifications grant proteins with expanded opportunities for 
catalysis, regulating signal transduction, controlling gene expression, integration of 
information at many metabolic intersections, and alternation of cellular locations.  
____________ 
 
This dissertation follows the style of Biochemistry. 
 
*Reprinted in part from “Synthesis of proteins with defined posttranslational 
modifications using the genetic noncanonical amino acid incorporation approach” 
Wenshe, R. Liu, Yane-Shih Wang, and Wei Wan. Mol. Biosyst. 2011, 7, 38 - 47. 
Copyright 2011, with permission from The Royal Society of Chemistry. 
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Studies of posttranslational modifications will provide fundamental understanding of  
many cellular processes but have been greatly hampered by the difficulty to attain 
homogenously modified proteins. In cells, most posttranslational modifications are 
reversible and delicately regulated. It is usually impossible to drive a protein completely 
to a modified form.3 Separation of themodified form from the unmodified counterpart is 
generally difficult because most posttranslational modifications provide small size 
changes to proteins and do not dramatically change the proteins’ biophysical properties. 
For a lot of eukaryotic proteins, multiple modification sites and multiple modification 
types coexist, adding a great complexity not only to functional investigation of these 
proteins but also to separation of a specific modified form from a largely heterogeneous 
protein pool in their natural sources.4-6 It is obvious that obtaining a homogeneously 
modified protein poses a big challenge for efforts to elucidate the precise regulatory role 
of a posttranslational modification. To resolve this major obstacle, several approaches 
have been developed to synthesize proteins with defined posttranslational modifications. 
A straightforward method is to directly incubate a target protein together with its 
corresponding enzyme or coexpress the two proteins together in living cells. Modified 
protein forms for both histones and p53 have been synthesized in this way.7, 8 However, 
the separation of a modified form from its original protein is a big challenge for 
aforementioned reasons. For large-size modifications such as ubiquitination,9, 10 the 
separation is readily achievable. But small-size modifications including acetylation and 
methylation often lead to modified protein forms inseparable from their unmodified  
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Figure I-1. Representative posttranslational modifications on proteins. The protein 
complex shown in the center is the histone octomer. The structure is based on the PDB 
entry: 1KX5.  
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precursors. Although antibodies have been used to isolate some modified protein forms, 
not every modified protein form has a specific antibody that is readily available.11, 12 
Substrate promiscuity of an enzyme (e.g. CBP/p300 catalyses acetylation of p53 at more 
than 8 sites) may lead to formation of heterogeneous protein forms that are hard to be 
isolated from each other even using antibodies.3, 7, 13-15 One additional problem is that not 
every protein modification has an identified corresponding enzyme. The advances of 
proteomic techniques have led to the discovery of thousands of protein modifications. 
But identifications of enzymes responsible for these modifications have largely fallen 
behind. Alternative approaches for synthesis of proteins with defined modifications 
include selective chemical modifications of proteins, native chemical ligation, and the 
genetic NAA incorporation technique. Shokat and coworkers developed a semi-synthetic 
method in which a protein cysteine selectively reacts with an alkyl halide to form a N-
mono-, N,N-di- or N,N,N-trimethyllysine analog.16, 17 Recently, Cole and coworkers 
extended this method to synthesize proteins with a lysine acetylation mimic.18 Modified 
histones synthesized in this way function similarly as their native counterparts and have 
been applied to study regulatory roles of histone methylations in chromatin.16 One 
limitation associated with the cysteine modification approach is that only a few 
posttranslational modification mimics can be obtained. In addition, non-targeted cysteine 
residues in a protein have to be mutated to other residues to avoid nonspecific 
modifications. Another semi-synthetic method, native chemical ligation together with its 
extension, expressed protein ligation has also been applied to synthesize proteins with 
posttranslational modifications and their mimics.19 This method has been extensively 
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used to synthesize modified histones for investigating epigenetic regulation of 
chromatin. Using this method, an elegant study carried out by Muir and coworkers 
demonstrated that H2B ubiquitination directly stimulates intranucleosomal methylation 
mediated by hDot1L.20 Although powerful and straightforward, native chemical ligation 
requires synthesis of large quantities of peptide thioesters and is still challenging for 
most molecular biology and biochemistry labs. In addition, both the cysteine 
modification method and native chemical ligation are not applicable in living cells. 
Modified proteins have to be synthesized in vitro and introduced into cells by invasive 
approaches such as microinjection for their cellular function studies. In the past several 
years, Schultz, Yokoyama, Chin and Liu groups have focused on applying the genetic 
NAA incorporation approach to synthesize proteins with defined posttranslational 
modifications. One advantage of the NAA incorporation technique is that proteins with 
defined posttranslational modifications can be directly produced in living cells. This 
allows the direct characterization of phenotypic consequences of protein 
posttranslational modification events. Another advantage of the NAA incorporation 
technique is its simplicity. It combines the recombinant DNA technique and relatively 
simple organic synthesis. Most molecular biology and biochemistry groups can easily 
adopt it. In addition, genetic incorporation of a NAA is site-specific regardless of the 
incorporation site or protein size. It is an optimal choice for synthesis of large proteins 
with posttranslational modifications in internal sites, a process that is generally 
cumbersome for native chemical ligation.  
 
 6 
The Genetic NAA Incorporation Approach 
A general method for genetic incorporation of a NAA in living cells was first 
developed by Schultz and coworkers.21-24 This method relies on the read-through of an 
in-frame amber (UAG) stop codon in mRNA by an amber suppressor tRNA (tRNACUA) 
that is specifically acylated with a NAA by an evolved aminoacyl-tRNA synthetase 
(aaRS). This system is equivalent to the naturally occurring pyrrolysine (Pyl) 
incorporation machinery discovered in some methanogenic archaea and a Gram positive 
bacterium Desulfitobacterium hafniense.25, 26 In these organisms, Pyl is cotranslationally 
inserted into proteins by an in-frame amber codon (Figure I-2). Suppression of this 
amber codon is mediated by the Pyl amber suppressor tRNA (       
   ), which has a 
CUA anticodon and is acylated with Pyl by pyrrolysyl-tRNA synthetase (PylRS). The 
PylRS-       
   
  pair in these organisms is orthogonal to and therefore does not cross-
interact with other aaRS-tRNA pairs in cells, ensuring the fidelity of the Pyl 
incorporation at amber codon. Interestingly, the encoded Pyl in the methylamine 
methyltransferase, MtmB, bind to ammonia at the carbon of the imine bond, and the 
pyrrolysine-methylammonium adduct serves to activate methylamines as substrates for 
nucleophilic attack by Cobalt (I) metalloprotein.27  However, the roles of the Pyl 
encoding machinery in archaea and bacteria remain relatively unexplored. Similarly to 
the Pyl incorporation machinery, an orthogonal aaRS-tRNACUA pair can be developed in 
which an aaRS is evolved to specifically charge its cognate tRNACUA with a NAA and 
used to site-specifically incorporate this NAA into a protein at amber codon with high  
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fidelity and efficiency in living cells. Since both the orthogonal aaRS-tRNACUA pair and 
the mRNA with a defined amber codon are genetically encoded, a protein incorporated 
with a NAA can be expressed by just simply growing cells in a medium supplemented 
with the NAA. Using an evolved MjTyrRS-         
   
 pair that was derived from 
Methanococcus jannaschii tyrosyl-tRNA synthetase-       
   
  pair, Schultz and 
coworkers successfully achieved genetic incorporation of sulfotyrosine into proteins in 
E. coli and synthesized hirudin, a naturally occurring sulfated peptide secreted by 
leeches.28, 29 This was the first successful demonstration that proteins with defined 
posttranslational modifications can be directly synthesized cotranslationally. Following 
this outstanding work, proteins with other modifications or their mimics have been 
synthesized using evolved MjTyrRS-         
   
 pairs and PylRS-        
   
  pairs, as 
detailed in the following sections.   
 
Protein Tyrosine Sulfation 
The posttranslational tyrosine sulfation is an enzymatic process catalyzed by two 
tyrosylprotein sulfotransferases, TPST1 and TPST2 in human.30 The sulfation occurs in 
the Golgi apparatus before newly synthesized proteins are sorted and shipped to their 
correct destinations. The natural occurrence of tyrosine sulfation was first discovered in 
1954 in a peptide derived from bovine fibrinogen.31 In the following four decades, 
sulfated peptide hormones and proteins were only sporadically identified. Owing to the 
emergence of new proteomic tools, many proteins with sulfated tyrosine residues have 
been found in the past decade, revealing that tyrosine sulfation is prevalent in human 
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cells. It was also recently discovered that tyrosine sulfation plays a crucial role in human 
physiology and pathology. Numerous secreted and integral membrane proteins in human 
contain sulfated tyrosine residues. Among these proteins, CCR5 and CXCR4 are 
probably the most prominent because of their roles in the entry of human 
immunodeficiency virus type 1 (HIV-1) into host cells.32, 33 Entry of HIV-1 requires its 
gp120 envelop glycoprotein to bind to two cell-surface receptors, CD40 and a 
coreceptor, either CCR5 or CXCR4. The interaction of either CCR5 or CXCR4 with 
gp120 requires sulfation of several tyrosine residues at its N-terminus. Coincidently, 
several human monoclonal HIV-1 antibodies also contain sulfated tyrosine residues and 
target the same coreceptor binding site on gp120.34, 35 Other human proteins containing 
tyrosine sulfation include P-selectin glycoprotein ligand-1, most chemokine receptors, 
and some other G-protein coupled receptors.36, 37 It is evident that tyrosine sulfation in 
these proteins is critical for their interactions with binding partners. Although tyrosine 
sulfation is important in both physiology and pathology of human, biochemical studies 
of this modification is very difficult to pursue because of low expression levels of most 
sulfated proteins. Synthesis of sulfated peptides using organic chemistry is also 
challenging because of the instability of the sulfate group.38 A major technology 
breakthrough for biosynthesis of sulfated proteins was achieved in 2006. Using an 
evolved MjTyrRS-         
   
 pair, Schultz and coworkers successfully incorporated 
sulfotyrosine into proteins at amber mutation sites in E. coli and achieved 
overexpression of the naturally occurring hirudin. Hirudin is secreted by leeches and 
contains 65 residues.29 Its Tyr65 is naturally sulfated. Hirudin is the most potent 
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naturally occurring direct thrombin inhibitor known and is used clinically as an 
anticoagulant. It exhibits a Ki towards thrombin of approximately 25 fM. Although the 
therapeutic form of hirudin have been produced recombinantly in E. coli and yeast, the 
recombinant hirudin is lack of sulfation at Tyr63 and exhibits a Ki of approximately 300 
fM. The activity difference between the natural form and the recombinant form clearly 
arises from the additional sulfate group on the natural form. It was proposed that the 
enhanced binding of the natural hirudin to thrombin is due to the salt bridge interaction 
between the sulfate group and K81H of thrombin, but there was no direct structural 
evidence to support the claim. The natural hirudin is extracted from leech heads in very 
low yields, causing a huge obstacle to directly crystallize its complex with thrombin. 
Although structures of synthetic sulfated C-terminal peptide fragments of hirudin bound 
to thrombin were solved, they either showed distorted structures around the sulfate group 
or did not reveal direct interactions between the sulfate group and thrombin. Since the 
natural hirudin could be simply expressed in E. coli, a large quantity of this protein was 
later obtained and used directly to undergo X-ray crystallographic studies of its 
interactions with thrombin. The structure determined clearly shows a sulfate group 
covalently linked to Tyr63 and revealed a network of hydrogen bonding/salt bridge 
interactions between the sulfate group and thrombin (Figure I-3).39 This work 
unprecedentedly demonstrated potential applications of the genetic NAA incorporation 
approach in basic biochemistry studies of protein posttranslational modifications. Given 
the prevalence of tyrosine sulfation in higher organisms, it is expected that the genetic 
sulfotyrosine incorporation will be used broadly to understand many basic biological 
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questions related to tyrosine sulfation. In addition to its applications in basic 
biochemistry studies, the genetic sulfotyrosine incorporation may also be applied to 
evolve synthetic antibodies with enhanced binding potentials toward antigens. By 
coupling phage display and the genetic sulfotyrosine incorporation, Schultz and 
coworkers recently identified a single-chain variable fragment that shows a 10 fold 
higher binding potential toward gp120 than the monoclonal antibody 412d.28 
 
Protein Tyrosine Phosphorylation 
The addition of a phosphate group to a protein tyrosine phenolic hydroxyl group 
is catalyzed by a tyrosine kinase. This phosphorylation process plays a main role in a 
wide range of cellular processes in eukaryotes, regulating protein structure and function, 
modulating protein localization, and controlling protein complex formation and 
degradation. Accordingly, it affects every basic cellular process, including metabolism, 
growth, division, differentiation, motility, organelle trafficking, membrane transport, 
muscle contraction, immunity, learning and memory.40 Protein tyrosine phosphorylation 
contributes to the development of many diseases such as cancer and diabetes when going 
awry. Because of its key role in many biological processes and human diseases, many 
efforts have been made to synthesize proteins with phosphorylated tyrosine residues to 
study individual phosphorylation events, mainly by the enzymatic method and native 
chemical ligation. The direct incorporation of phosphotyrosine into proteins using the 
genetic NAA incorporation approach has not been successful yet. The two negative 
charges of phosphotyrosine apparently prevent it from permeating through E. coli cell 
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membrane. For this reason, several alternative methods based on the genetic NAA 
approach have been developed to synthesize proteins with tyrosine phosphorylation 
mimics. Sulfotyrosine and phosphotyrosine are highly structurally similar. Although 
sulfotyrosine contains only one negative charge instead of two on its side chain, its 
potential to form hydrogen bonding interactions with others is identical to 
phosphotyrosine. We expect genetic incorporation of sulfotyrosine will be soon adopted 
to study protein tyrosine phosphorylation events. Another phosphotyrosine mimic that 
has been genetically incorporated into proteins is p-carboxylmethyl-phenylalanine 
(pCMF) (Scheme I-1).41, 42 pCMF was previously used to mimic phosphotyrosine in a 
pentapeptide-based inhibitor of the interaction between the Src SH3-SH2 domain and 
phosphorylated epidermal growth factor receptor. Both molecular modeling and X-ray 
crystallographic studies indicated that the side chain of pCMF has good spatial overlap 
with two of the phosphotyrosine oxygen atoms that interact with positively charged 
arginine residues in SH2 domains. The one negative charge nature of its side chain 
apparently does not prevent its transport into the E. coli cytoplasm. Genetic 
incorporation of pCMF in E. coli was also achieved using evolved MjTyrRS-
         
   
  pairs.42 Using an evolved pair, STAT1 with a pCMF at Tyr701 was 
recombinantly expressed and purified to homogeneity. It is known that phosphorylation 
of STAT1 on Tyr701 leads to its homodimerization and the resulting dimer binds tightly 
to DNA containing M67 sites. The purified mutant STAT1 shows a similar feature. 
Since pCMF can be easily prepared and its incorporation is more efficient than 
sulfotyrosine, we expect its genetic incorporation will also have utility for a wide variety  
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Y76H
K81H
E80H
N78H
Figure I-3. Structure of sulfotyrosine (Tys) and amino acid residues that directly or 
indirectly interact with the sulfate group of Tys in the hirudin-thrombin complex. The 
structure is derived from the PDB entry: 2PW8. The superscripts in labels indicate 
which chains the residues are located in (I: hirudin; H: the heavy chain of thrombin).  
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Scheme I-1 Chemical structure of p-carboxymethyl-phenylalanine (pCMF) and 3-
Nitrotyrosine 
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of signaling experiments. Another interesting development to synthesize proteins with 
tyrosine phosphorylation mimics was to produce a phosphotyrosine mimic with two 
negative charges on its side chain by modifying a genetically incorporated p-
azidophenylalanine (pAZF). The genetic incorporation of pAZF has been achieved in E. 
coli, yeast, and mammalian cells.21, 43, 44 In E. coli, evolved MjTyrRS-         
   
  pairs 
allow efficient incorporation of pAZF at amber codon, leading to overexpression of 
proteins containing pAZF. As shown in Figure I-4, a selective modification of pAZF in 
a protein using a phosphite through Staudinger reaction followed by photolysis results in 
a p-(phosphonoamino)-phenylalanine at the pAZF site.45 Since p-(phosphonoamino)-
phenylalanine has two negative changes and maintains the hydrogen bonding/salt bridge 
interaction potential of phosphotyrosine, it closely resembles phosphotyrosine and is the 
best mimic of phosphotyrosine that can be genetically installed so far. Using this 
chemoselective phosphorylation generation strategy to study biologically relevant 
signaling processes has been proposed by the original developers of the technique and 
will be, to our conviction, adopted by other scientists. 
 
Protein Tyrosine Nitration 
Protein tyrosine nitration is a nonenzymatic covalent modification, introducing a 
nitro group to one of ortho carbons of the phenolic ring of tyrosine residues. (Scheme I-
1) This modification primarily arises from reactive nitrosative species such as 
peroxynitrite that are generated by nitric oxide. The addition of a nitro group confers  
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particular physiological properties to tyrosine such as a much lower pKa of the 
corresponding proteins. The impact of tyrosine nitration may affect protein function and 
structure, and change the rate of proteolytic degradation of nitrated proteins.46, 47 Many 
recent studies have shown that tyrosine nitration is a pivotal physiological event 
implicated in numerous biological processes and a number of diseases such as cancer, 
neurodegenerative diseases, and cardiovascular injury.48 The availability of a method for 
synthesis of proteins with defined tyrosine nitration is critical to elucidate detrimental 
effects of most tyrosine nitration events. Although protein tyrosine nitration can be 
achieved by chemically modifying an expressed protein with tetranitromethane in 
ambient conditions, this modification is not selective and adds nitro to most solvent 
accessible tyrosine residues.49 Alternatively, a 3-nitrotyrosine can be selectively 
incorporated into a protein at amber codon using the genetic NAA incorporation 
approach. Chin and coworkers recently showed that proteins with defined tyrosine 
nitration can be expressed to large quantities in E. coli using evolved MjTyrRS-
         
   
  pairs.50 Human manganese superoxide dismutase incorporated with 3-
nitrotyrosine at Tyr34 synthesized using this method displays a diminished activity 
which is only 3% of that for the wild-type enzyme. Manganese superoxide dismutase is 
known to undergo near-quantitative nitration on Tyr34 in cardiovascular disease and 
aging and is also nitrated in acute and chronic inflammatory processes in both animal 
models and human diseases. The work by Chin and coworkers clearly showed a 
deleterious effect of a single nitration to an enzyme’s activity. Since many other proteins 
such as p53 and tau undergo tyrosine nitration in neurodegenerative disease and 
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atherosclerosis, applications of the genetic 3-nitrotyrosine incorporation to understand 
basic functions of tyrosine nitration in these proteins are expected.51 
 
Protein Lysine Acetylation 
Protein lysine acetylation is a reversible enzymatic process catalyzed by histone 
acetyltransferases and histone deacetylases (HDACs). Originally identified in histones 
40 years ago, lysine acetylation is now known to occur in more than 80 transcription 
factors such as p53 and p300/CBP, many other nuclear regulators, and various 
cytoplasmic proteins.6 As a result, lysine acetylation is both crucial for the transcription 
regulation in the nucleus and important for regulating different cytoplasmic processes, 
including cytoskeleton dynamics, energy metabolism, endocytosis, autophagy, and even 
signaling from the plasma membrane. Recently the histone code that involves histone 
acetylation has garnered considerable attention for its role in regulating the chromatin 
structure and gene expression. To date, biochemical studies of histone acetylation have 
mainly been attributed to native chemical ligation. Recently genetic incorporation of N-
acetyllysine in E. coli for synthesis of proteins with lysine acetylation was also 
developed. The incorporation of N-acetyllysine takes advantage of an evolved PylRS-
       
   
  pair originally from Methanosarcina barkeri.52 Using this evolved pair, Chin 
and coworkers expressed homogenous histone proteins with acetylation at different sites 
and reconstituted nucleosomes bearing defined acetylated lysine residues. Studies of H3 
Lys56 acetylation revealed that this modification does not directly affect the compaction 
of chromatin, has modest effects on remodeling by SWI/SNF and RSC, and increases 
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DNA breathing.53 A most recent application of this technique was to elucidate the 
regulatory role of Lys125 acetylation in cyclophilin A (CypA), a ubiquitous cis-trans 
prolyl isomerase. CypA has a key role in immunity and is required for effective HIV-1 
replication in host cells. Chin & James showed that Lys125 acetylation markedly inhibits 
CypA catalysis of cis to trans isomerization and stabilizes cis rather than trans forms of 
the HIV-1 capsid.54 This modification also antagonizes the immunosuppressive effects 
of cyclosporine by inhibiting cyclosporine binding and calcineurin inhibition. Given that 
a lot of proteins including all four histone proteins, p53, p300/CBP, PGC-1, and 
RIP140 contain multiple lysine acetylation sites, one intriguing interest is to study 
regulatory roles of concomitant lysine acetylation at multiple sites of a single protein.6 
To this end, our group has extended the genetic N-acetyllysine incorporation technique 
to incorporate three N-acetyllysine residues into a single green fluorescent protein in E. 
coli.55 This was achieved by overexpressing a truncated large ribosomal protein L11 to 
enhance amber suppression in E. coli. In the future, we will apply this technique to study 
concomitant lysine acetylation at multiple sites in four histone proteins. One advantage 
of the PylRS-       
   
  pair is its orthogonality in yeast and mammalian cells. This 
makes it possible to apply the evolved PylRS-       
   
  pair specific for N-acetyllysine 
directly in eukaryotic cells for cellular functional analysis of certain lysine acetylation 
events. However, lysine acetylation is a reversible process. After genetic incorporation 
of N-acetyllysine into proteins in eukaryotic cells, its deacetylation by HDACs is 
anticipated. This will certainly complicate the in vivo functional analysis of lysine 
acetylation events. To resolve this obstacle, we designed an unhydrolysable N-
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acetyllysine analog, 2-amino-8-oxononanoic acid and took advantage of the evolved 
PylRS-       
   
  pair specific for N-acetyllysine to incorporate it into proteins.56 
Further tests need to be carried out to assess whether this analog can closely mimic N-
acetyllysine in mammalian cells. 
 
Protein Lysine Methylation 
Protein lysine methylation, a reversible enzymatic process catalyzed by histone 
methyltransferases and histone demethylases, was also originally discovered in 
histones.57 It represents one of the most important posttranslational modifications and is 
crucial in modulating chromatin-based transcriptional control and shaping inheritable 
epigenetic programs in the eukaryotic cells.58 Similarly to lysine acetylation, lysine 
methylation was also found in non-histone transcription factors such as p53 and 
p300/CBP in the nucleus.59-62 A recent discovery of histone methyltransferase Ezh2 in 
the cytosol of various mouse and human T cells has led to expectation that lysine 
methylation is also prevalent in the cytosol.63 There are three lysine methylation 
patterns, monomethylation, dimethylation and trimethylation, which may serve different 
regulatory roles.64 As evidenced in the literature, distinctive histone methyltransferases 
are responsible for these three methylation patterns. So far, studies of histone lysine 
methylation have been attributed to native chemical ligation.65 But several technological 
breakthroughs in 2009 could drive applications of the genetic NAA incorporation 
approach in this important research area to surge. Given the structural similarity between 
N
-methyllysine and N-acetyllysine, one would think it is possible to evolve the PylRS-  
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  pair for genetic incorporation of N-methyllysine. However, creating a 
synthetase that recognizes N-methyllysine but discriminates against lysine is difficult 
since the two amino acids differ only by a single methyl group. For this reason, we and 
other two groups developed indirect biosynthesis methods for production of proteins 
with lysine monomethylation as shown in Figure I-5. Directly using the wild-type 
PylRS-       
   
  pair from Mathanosarsina barkeri, Chin and coworkers managed to 
incorporate N-Boc-N-methyllysine site-specifically at Lys9 of histone H3.66 The 
deprotection of Boc from the incorporated N-Boc-N-methyllysine to recover N-
methyllysine was achieved using 2% TFA. Although the deprotection condition 
denatures proteins, the small proteins such as histones can be easily refolded afterward. 
H3K9me1 (monomethylation at Lys 9 of H3) synthesized in this way can be specifically 
recognized by heterochromatin protein 1, a chromodomain protein that binds H3K9me1 
but not unmethylated H3. Liu and Schultz groups developed alternative methods that 
undergo deprotection to recover N-methyllysine at mild conditions.67, 68 Both groups 
independently evolved the PylRS-       
   
  pair for genetic incorporation of N-(o-
nitrobenzyloxycarbonyl)-N-methyllysine into proteins in E. coli. The o-
nitrobenzyloxycarbonyl group is photolytic. Deprotection of this group from the 
incorporated NAA to recover N-methyllysine can be simply achieved using UV light. 
This photo deprotection process (360 nm UV light, 30 min, room temperature) is very 
mild to proteins and has been performed on proteins incorporated with N-(o-
nitrobenzyloxycarbonyl)-N-methyllysine in living mammalian cells. We have also 
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achieved the incorporation of N-Cbz-N-methyllysine into proteins using an evolved 
PylRS-       
   
  pair. Deprotection of Cbz to recover N-methyllysine in mild 
conditions is in theory feasible by catalytic hydrogenation but have not been achieved 
yet in practice. Another protected N-methyllysine that has been genetically incorporated 
into proteins is N-allylcarbamoyl-N-methyllysine. Its incorporation was achieved using 
a modified PylRS-       
   
  pair. Deprotection of the allylcarbamoyl group can be 
carried out using chloro-pentamethylcyclopentadienyl-cyclooctadiene-ruthenium(II) 
([Cp*Ru(cod)Cl]) under conditions compatible with living cells.69 Besides the direct 
installation of N-methyllysine in proteins, Schultz and coworkers also developed a 
method to site-specifically install a N-methyllysine analog into proteins. This method 
takes advantage of the unique chemical reactivity of phenylselenocysteine that can be 
genetically incorporated into proteins in E. coli using evolved MjTyrRS-         
   
  
pairs.70 After its incorporation into proteins, phenylselenocysteine can be efficiently 
converted to dehydroalanine under relatively mild conditions, followed by Michael 
addition reaction  with a corresponding thiol-containing nucleophilic compound to form 
a N-methyllysine analog (Figure I-6).71 Using this method, histone H3 with a N-
methyllysine analog at Lys9 was homogenously synthesized. The same method has also 
been extended to synthesize proteins incorporated with N,N-dimethyllysine and 
N
,N,N-trimethyllysine analogs. Although the oxidation of phenylselenocysteine to 
dehydroalanine requires a high concentration of H2O2 that also modifies cysteine and  
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methionine residues, this method is a very useful tool to study proteins in which 
mutating cysteine and methionine to other residues does not affect protein functions. 
 
Protein Lysine Ubiquitination 
Ubiquitination is another important posttranslational lysine modification. It is a 
process that covalently attaches the 76-residue protein ubiquitin to a target via an 
isopeptide bond formed between the C-terminal carboxylate of ubiquitin and the side 
chain amino group of a lysine.72 This process consists of a series of steps that involve 
three enzymes E1, E2, and E3.73 The most prominent function of ubiquitination is to 
label proteins for proteasomal degradation. Besides this function, ubiquitination also 
controls the stability, function, and intracellular localization of a wide variety of 
proteins.74 Although functionally important, the study of protein ubiquitination is 
hampered by the difficulty of obtaining homogenous ubiquitinated proteins. Isolation 
from an in vivo source usually has a low yield. The in vitro reconstruction of an 
ubiquitinated protein using corresponding enzymes suffers from low productivity. 
Native chemical ligation has been proved an efficient way to synthesize homogenous 
ubiquitinated proteins,75 but the synthesis is challenging and can not be easily handled in 
most biochemistry groups. Recently two groups assembled a relative straightforward 
method that combines cysteine chemistry and native chemical ligation to make 
ubiquitinated protein mimics.76, 77 However, using a disulfide linkage to replace one 
methylene in the LysGly isopeptide generates a much less rigid linkage whose length is 
also 3 Å longer than the original LysGly isopeptide. To assemble a method for easy  
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preparation of proteins with defined ubiquitination, Chan and coworkers used the wild 
type PylRS-        
   
  pair to genetically install a protein with N-(D-cysteinyl)lysine 
that can be subsequently linked to ubiquitin by expressed protein ligation (Figure I-7). 
78
N
-(D-cysteinyl)lysine closelymimics the LysGly isopeptide. Similar to its natural 
counterpart, an ubiquitinated calmodulin synthesized using this method displays an 
inhibitory effect on phosphorylase kinase. In order to synthesize ubiquitinated proteins 
with a natural LysGly isopeptide linkage, Chin and coworkers recently developed a 
method termed GOPAL (genetically encoded orthogonal protection and activated 
ligation) that combines genetic incorporation of Nε-Boc-lysine and chemoselective 
protein chemistry (Figure I-8).79 Using this method, diubiquitins with atypical linkages 
at Lys6 and Lys29 were synthesized. The structure of Lys6-linked ubiquitin reveals an 
asymmetric compact conformation distinct from other ubiquitin chain structures. The 
screening of human deubiquitinases against Lys29-linked diubiquitin revealed that 
TRABID cleaves the Lys29-linkage 40-fold more efficiently than the Lys63 linkage. 
Since enzymes catalyzing atypical ubiquitin linkages at Lys6, Lys11, Lys27, Lys29, and 
Lys33 are unknown, the method developed by Chin and coworkers is indispensable in 
promoting research interests in this area. 
In summary, multiple methods based on the genetic NAA incorporation approach 
have been developed for the synthesis of proteins with defined posttranslational 
modifications and their mimics. The intrinsic simplicity of these methods will promote 
their adoption by many scientists and accelerate our understanding of protein 
posttranslational modifications. 
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Although considerable efforts have made several methods available for the 
synthesis of proteins with defined posttranslational modifications and their mimics using 
the genetic NAA incorporation approach, challenges still exist in this research area. 
Bothsulfotyrosine and phosphotyrosine mimics can only be incorporated into proteins in 
E. coli. Studies of cellular functions of these modifications require the use of invasive 
methods to introduce them to their eukaryotic cell hosts. A method that allows the 
incorporation of these NAAs directly into eukaryotic cells is necessary for functional 
studies of these modifications in cells for which microinjection is not readily available. 
 
Protein Labeling 
Site-selective covalent modification is an important biotechnological strategy to 
introduce new functionalities to proteins. Examples include the PEGylation of 
therapeutic proteins to prolong their in vivo half-lives, fluorescent labeling of proteins 
for protein folding/unfolding analysis and biosensor development, linking proteins with 
photocrosslinkers for protein-protein/DNA interaction analysis, and introducing NMR, 
EPR, and IR probes for protein functional investigations. Traditionally, protein 
modifications exploit the high reactivities of cysteine and lysine side chains in proteins. 
This approach has poor selectivity due to the existence of multiple copies of cysteine or 
lysine in a single protein. Modern techniques that attempt to achieve site-selective 
protein modification include the genetic noncanonical amino acid (NAA) incorporation, 
native chemical ligation and its extension expression protein ligation, enzymatic and 
chemical modifications of peptide tags, and specific modifications of protein N- and C-
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termini. These techniques, in general, seek to introduce bioorthogonal functional groups 
into proteins whose reactions do not cross-interact with the 20 canonical amino acids 
(CAAs). Using orthogonal aminoacyl-tRNA synthetase (aaRS)-amber suppressing 
        pairs in Escherichia coli, Saccharomyces cerevisiae, and mammalian cells, 
several groups have successfully demonstrated that NAAs with bioorthogonal functional 
groups such as keto, alkyne, azide, and phenylhalide groups could be genetically 
incorporated into proteins at amber mutation sites. However, the genetic encoding of 
each NAA is usually required to use a uniquely evolved aaRS. AaRS-        pairs 
with different origins might have to be used in different cell lines due to unorthogonal 
nature of some aaRS-        pairs in certain cell lines.  
The goals of the research are evolving the PylRS for lysine and phenylalanine 
derivatives incorporations genetically and applying the synthesized proteins for the 
protein functional studies according to the protein post-translational modifications, 
protein folding mechanism and protein labeling. 
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CHAPTER II  
A GENETICALLY ENCODED PHOTOCAGED METHYLLYSINE* 
 
Introduction 
Protein lysine methylation is an enzymatic process that involves the transfer of a 
methyl group from S-adenosyl-L-methionine to a lysine side-chain amine in a protein. It 
represents one the most important posttranslational modification and is crucial in 
modulating chromatin-based transcriptional control and shaping inheritable epigenetic 
programs in the eukaryotic cells.5, 80-82 There are three lysine methylation patterns, 
mono-, di- and trimethylation, which may serve different regulatory roles.64 The study of 
protein lysine methylation is critical to understanding chromatin epigenetics and 
transcription factor regulation but has long been impeded by the challenge of 
synthesizing site-specifically and quantitatively methylated proteins.6 Several methods 
including enzymatic protein methylation, native chemical ligation, and chemical 
modification of cysteines have been introduced to synthesize proteins with a defined 
lysine methylation. 3, 17, 65However, they all suffer limitations. Enzymatic protein 
methylation hardly reaches completeness and the separation of the modified protein from 
the original one is difficult. Native chemical ligation requires a cysteine to mediate the  
____________ 
 
*Reprinted in part from “A genetically encoded photocaged N-methyl-L-lysine”, Yane-
Shih Wang, Bo Wu, Zhiyong Wang, Ying Huang, Wei Wan , William K. Russell, Pei-
Jing Pai, Yin N. Moe, David H. Russell and Wenshe, R. Liu. Mol. Biosyst. 2010, 6, 1557 
- 1560. Copyright 2010, with permission from The Royal Society of Chemistry. 
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ligation and the installation of a methylated lysine in the middle of a protein is 
problematic. The cysteine modification method can only install a methylated lysine 
analog into a protein. We sought to resolve limitations associated with the methods 
discussed above by applying the genetic noncanonical amino acid (NAA) incorporation 
method to synthesize methylated proteins. Originally developed by Schultz et al.,23, 24 
the genetic NAA incorporation method relies on the read-through of an in-frame amber 
UAG codon in mRNA by an amber suppressor tRNA that is specifically acylated with a 
NAA by an evolved aminoacyl-tRNA synthetase (aaRS). This method is equivalent to 
the naturally occurring pyrrolysine (Pyl) incorporation machinery discovered in 
methanogenic archaea and some bacteria.25, 26 In these organisms, Pyl is 
cotranslationally inserted into proteins and coded by an in-frame UAG codon. 
Suppression of this UAG codon is mediated by a suppressor tRNA,        
   
  that has a 
CUA anticodon and is acylated with Pyl by pyrrolysyl-tRNA synthetase (PylRS). 
Similarly, the PylRS-       
   
  pair can be directly applied to incorporate Pyl and 
several other lysine derivatives into proteins at amber mutation sites in E. coli.83-86 
Together with        
   , evolved PylRSs have also been applied to incorporate N-
acetyl-L-lysine into proteins in both E. coli and mammalian cells.52, 55, 85 Inspired by 
these advances, we thought it might be possible to incorporate either N-methyl-L-lysine 
or its derivatives into proteins at amber mutation sites using an evolved PylRS-       
   
  
pair. This may allow the synthesis of proteins with monomethylated lysines for their 
functional investigations. Herein, we wish to show that a N-methyl-L-lysine can be site-
 33 
specifically installed into a protein by the genetic incorporation of a photocaged N-
methyl-L-lysine using an evolved PylRS-       
   
 pair and the following deprotection 
under UV irradiation. 
 
Experimental Section 
General Experimental 
All reactions involving moisture sensitive reagents were conducted in oven-dried 
glassware under an argon atmosphere. Anhydrous solvents were obtained through 
standard laboratory protocols. Analytical thin-layer chromatography (TLC) was 
performed on Whatman SiO2 60 F-254 plates. Visualization was accomplished by UV 
irradiation at 254 nm or by staining with ninhydrin (0.3% w/v in glacial acetic acid/n-
butyl alcohol 3:97). Flash column chromatography was performed with flash silica gel 
(particle size 32-63 m) from Dynamic Adsorbents Inc (Atlanta, GA). 
Specific rotations of chiral compounds were obtained at the designated 
concentration and temperature on a Rudolph Research Analytical Autopol II polarimeter 
using a 0.5 dm cell. Proton and carbon NMR spectra were obtained on Varian 300 and 
500 MHz NMR spectrometers. Chemical shifts are reported as  values in parts per 
million (ppm) as referenced to the residual solvents: chloroform (7.27 ppm for 1H and 
77.23 ppm for 13C) or water (4.80 ppm for 1H). A minimal amount of 1,4-dioxane  was 
added as the reference standard (67.19 ppm for 13C) for carbon NMR spectra in 
deuterium oxide, and a minimal amount of sodium hydroxide pellet was added to the 
NMR sample to aid in the solvation of amino acids which have low solubility in 
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deuterium oxide under neutral or acidic conditions. 1H NMR spectra are tabulated as 
follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet), number of protons, and coupling constant(s). Mass 
spectra were obtained at the Laboratory for Biological Mass Spectrometry at the 
Department of Chemistry, Texas A&M University. 
H-Lys(Z)-OH (5) and H-Lys(Me)-OH·HCl (17) was obtained from Chem-Impex 
International, Inc. (Wood Dale, IL). Compound 7 was synthesized as reported.87 All 
other reagents were obtained from commercial suppliers and used as received. 
Chemical Synthesis 
Compounds 6 and 8 were synthesized from 1288 in a scalable route (Scheme II-
1). For comparison, a shorter synthesis from the relatively expensive N-methyl-L-lysine 
hydrochloride (17) following the standard protocol of copper complexation, reaction 
with appropriate chloroformate, and decomplexation with 8-hydroxyquinoline89 was also 
developed. (Scheme II-2) 
2-Nitrobenzyl chloroformate (10) and 2-nitrobenzyl trichloromethyl carbonate (11).  
To a solution of 2-nitrobenzyl alcohol (9, 1.97 g, 12.9 mmol) in anhydrous 
dichloromethane (55 mL) cooled in an ice bath was added diphosgene (1.71 mL, 14.2 
mmol) in dichloromethane (10 mL) dropwise over 10 min followed by 
diisopropylethylamine (2.25 mL, 12.9 mmol) in dichloromethane (10 mL) dropwise over 
10 min. The reaction mixture was then stirred at room temperature for 2 h, and sodium 
hydroxide (1 N, 20 mL) was added and stirred further at room temperature for 30 min. 
The mixture was washed with water (30 mL), saturated sodium bicarbonate (30 mL x 2)  
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Scheme II-1. Longer synthesis of 6 and 8.  
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Scheme II-2. Shorter synthesis of 6 and 8. 
 
and brine (30 mL), dried (Na2SO4), and flash chromatographed (EtOAc/hexanes, 1:20) 
to give a mixture of 10 and 11 (2.71 g, 98%) as a yellow oil. A minor fraction of 
impurity, presumably 11, was evident from NMR analysis but did not interfere with the 
next step reaction. No further purification was performed. For 1090: 1H NMR (CDCl3, 
500 MHz)  8.19 (d, 1 H, J = 8.0 Hz), 7.74 (t, 1 H, J = 7.8 Hz), 7.65 (d, 1 H, J = 8.0 Hz), 
7.58 (t, 1 H, J = 7.8 Hz), 5.75 (s, 2 H); 13C NMR (CDCl3, 125 MHz)  150.6, 147.7, 
134.4, 129.9, 129.8, 129.2, 125.6, 69.7. For 11: 1H NMR (CDCl3, 500 MHz)  8.20 (d, 1 
H, J = 6.5 Hz), 7.74 (t, 1 H, J = 7.7 Hz), 7.68 (d, 1 H, J = 8.0 Hz), 7.58 (t, 1 H, J = 7.7 
Hz), 5.75 (s, 2 H); 13C NMR (CDCl3, 125 MHz)  147.3, 147.2, 134.5, 130.2, 129.8, 
129.0, 108.0, 68.0. 
N

-Boc-N

-benzyl-L-lysine methyl ester (13)  
A solution of 12 (4.20 g, 10.6 mmol) in methanol (100 mL) was hydrogenated 
under a H2 balloon in the presence of palladium on alumina (10 wt.% Pd, 0.71 g, 0.67 
mmol) at room temperature for 3 h, and TLC analysis showed a complete conversion. 
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The mixture was then filtered over a pad of Celite and the solution was directly used for 
the next step reaction. The material should be immediately used without purification 
since prolonged storage at room temperature or flash chromatography would contribute 
to lactam formation. 
To a solution of the above amine (~10.6 mmol) in methanol was added 
benzaldehyde (4.00 mL, 39.4 mmol), and the reaction mixture was stirred at room 
temperature for 30 min. The mixture was then cooled in an ice bath, and sodium 
borohydride (0.75 g, 19.8 mmol) was added portionwise. The mixture was then stirred at 
room temperature overnight, and water (10 mL) was added dropwise to quench the 
reaction. Most of the methanol was evaporated under a reduced pressure, and the residue 
was dissolved in ethyl acetate (100 mL), washed with water (30 mL), saturated sodium 
bicarbonate (30 mL) and brine (30 mL), dried (Na2SO4), and evaporated to give the 
crude 13 as a yellow oil, which was used in the next step reaction without further 
purification. A small fraction of pure 13 was obtained by flash chromatography (10% 
methanol with 5% triethylamine in dichloromethane) for characterization. []D
19 +7.4 (c 
4.85, CH2Cl2); 
1H NMR (CDCl3, 500 MHz)  7.35-7.30 (m, 4 H), 7.27-7.24 (m, 1 H), 
5.05 (d, 1 H, J = 7.0 Hz), 4.32-4.28 (m, 1 H), 3.78 (s, 2 H), 3.74 (s, 3 H), 2.63 (t, 2 H, J 
=7.0 Hz), 1.83-1.78 (m, 1 H), 1.67-1.60 (m, 1 H), 1.58-1.48 (m, 3 H), 1.44 (s, 9 H), 
1.41-1.36 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  173.5, 155.5, 140.5, 128.5, 128.2, 
127.0, 79.9, 54.1, 53.5, 52.3, 49.1, 32.7, 29.7, 28.4, 23.2; HRMS (ESI) calcd for 
C19H31N2O4 ([M + H]
+) 351.2284, found 351.2282. 
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N

-Boc-N

-benzyl-N

-methyl-L-lysine methyl ester (14)  
To a solution of crude 13 (~10.6 mmol) in methanol (100 mL) in methanol was 
added formaldehyde (37% aqueous solution, 3.00 mL, 40.3 mmol), and the reaction 
mixture was stirred at room temperature for 30 min. The mixture was then cooled in an 
ice bath, and sodium borohydride (0.77 g, 20.4 mmol) was added portionwise. The 
mixture was then stirred further at room temperature for 4 h, and water (30 mL) was 
added dropwise to quench the reaction. Most of the methanol was evaporated under a 
reduced pressure, and the residue was dissolved in ethyl acetate (100 mL), washed with 
water (30 mL), hydrochloric acid (1 N, 30 mL), sodium hydroxide (1 N, 30 mL) and 
brine (30 mL), dried (Na2SO4), evaporated, and flash chromatographed (EtOAc/hexanes, 
1:1 then 5% to 10% methanol in dichloromethane) to give 14 (3.32 g, 86% yield for 
three steps) as a yellow oil. []D
20 +7.7 (c 2.37, CH2Cl2); 
1H NMR (CDCl3, 500 MHz)  
7.33-7.29 (m, 4 H), 7.26-7.23 (m, 1 H), 5.08 (d, 1 H, J = 8.5 Hz), 4.31-4.27 (m, 1 H), 
3.73 (s, 3 H), 3.46 (s, 2 H), 2.35 (t, 2 H, J =7.2 Hz), 2.17 (s, 3 H), 1.82-1.76 (m, 1 H), 
1.66-1.47 (m, 3 H), 1.44 (s, 9 H), 1.40-1.32 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  
173.6, 155.6, 139.3, 129.2, 128.4, 127.1, 80.0, 62.5, 57.1, 53.6, 52.4, 42.4, 32.7, 28.5, 
27.0, 23.3; HRMS (ESI) calcd for C20H33N2O4 ([M + H]
+) 365.2440, found 365.2437. 
N

-Boc-N

-Cbz-N

-methyl-L-lysine methyl ester (15)  
A solution of 14 (2.58 g, 7.07 mmol) in methanol (50 mL) was hydrogenated 
under a H2 balloon in the presence of palladium on alumina (10 wt.% Pd, 0.50 g, 0.47 
mmol) at room temperature for 5 h. The mixture was then filtered over a pad of Celite 
and evaporated to give the crude amine (Boc-Lys(Me)-OMe) as a grey oil. A small 
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fraction of pure amine was obtained by flash chromatography (10% methanol with 5% 
triethylamine in dichloromethane) for characterization. []D
19 +6.9 (c 1.90, CH2Cl2); 
1H 
NMR (CDCl3, 500 MHz)  5.38 (d, 1 H, J = 7.0 Hz), 4.14-4.12 (m, 1 H), 3.59 (s, 3 H), 
2.95 (s, 1 H), 2.46 (t, 2 H, J =7.2 Hz), 2.29 (s, 3 H), 1.69-1.64 (m, 1 H), 1.55-1.48 (m, 1 
H), 1.43-1.33 (m, 2 H), 1.30 (s, 9 H), 1.27-1.22 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  
173.4, 155.5, 79.6, 53.3, 52.1, 51.2, 35.8, 32.2, 28.8, 28.2, 23.0; HRMS (ESI) calcd for 
C13H27N2O4 ([M + H]
+) 275.1971, found 275.1968. 
To a solution of the above amine (~7.07 mmol) and diisopropylethylamine (2.00 
mL, 11.5 mmol) in anhydrous dichloromethane (40 mL) cooled in an ice bath was added 
benzyl chloroformate (95%, 1.50 mL, 10.5 mmol) dropwise over 10 min, and the 
mixture was stirred at room temperature for 12 h. The mixture was then diluted in ethyl 
acetate (100 mL), washed with sodium hydroxide (0.5 N, 40 mL) and brine (40 mL), 
dried (Na2SO4), evaporated, and flash chromatographed (EtOAc/hexanes, 1:3) to give 15 
(2.59 g, 90% for two steps) as a colorless oil. []D
19 +1.2 (c 1.51, CH2Cl2); 
1H NMR 
analysis showed a 1.5:1 mixture of rotamers at room temperature. Major rotamer: 1H 
NMR (CDCl3, 500 MHz)  7.33-7.32 (m, 4 H), 7.29-7.26 (m, 1 H), 5.26 (d, 1 H, J = 6.0 
Hz), 5.10 (s, 2 H), 4.24 (m, 1 H), 3.69 (s, 3 H), 3.32-3.19 (m, 2 H), 2.87 (s, 3 H), 1.78-
1.66 (m, 2 H), 1.57-1.51 (m, 2 H), 1.41 (s, 9 H), 1.36-1.28 (m, 2 H); 13C NMR (CDCl3, 
125 MHz)  173.4, 156.5, 155.6, 137.0, 128.5, 128.0, 127.9, 79.7, 67.0, 53.4, 52.2, 48.4, 
33.9, 32.0, 28.4, 26.9, 22.2; Characteristic peaks of the minor rotamer: 1H NMR (CDCl3, 
500 MHz)  5.05 (d, 1 H, J = 6.0 Hz); 13C NMR (CDCl3, 125 MHz)  156.3, 155.4, 
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79.9, 53.3, 34.6, 32.4, 27.5, 22.5; HRMS (ESI) calcd for C21H33N2O6 ([M + H]
+) 
409.2339, found 409.2332. 
BocHN COOCH3
N
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i-Pr2NEt, CH2Cl2
MeOH
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NH
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N

-Boc-N

-(2-nitrobenzyl)oxycarbonyl-N

-methyl-L-lysine methyl ester (16) and 
N

-Boc-N

-chlorocarbonyl-N

-methyl-L-lysine methyl ester (18)  
Compound 14 (1.06 g, 2.91 mmol) was converted into the corresponding amine 
by hydrogenolysis, which was then treated with crude 10 (0.94 g, 4.38 mmol) according 
to the procedure for 15 to give 16 (0.91g, 69% for two steps) as a yellow oil. A small 
amount of 18 (yield not determined), the structure of which was assigned based on NMR 
and MS analysis data, was obtained as a colorless oil. Presumably Boc-Lys(Me)-OMe 
reacts with 11 to give 16 and generates one molecule of phosgene at the same time, 
which then acylates the residual Boc-Lys(Me)-OMe to afford 18. 
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 For 16: []D
20 +8.9 (c 1.70, CH2Cl2); Rf = 0.46 (EtOAc/hexanes, 1:1); 
1H NMR 
analysis showed a 1.1:1 mixture of rotamers at room temperature. Major rotamer: 1H 
NMR (CDCl3, 500 MHz)  7.96 (d, 1 H, J = 8.0 Hz), 7.58 (t, 1 H, J = 7.5 Hz), 7.50-7.47 
(m, 1 H), 7.39 (t, 1 H, J = 8.2 Hz), 5.42 (s, 2 H), 5.21 (d, 1 H, J = 7.5 Hz), 4.20-4.16 (m, 
1 H), 3.63 (s, 3 H), 3.21 (appar. nonet, 2 H, J = 7.1 Hz), 2.86 (s, 3 H), 1.74-1.44 (m, 4 
H), 1.34 (s, 9 H), 1.30-1.24 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  173.2, 155.6, 
155.4, 147.5, 133.6, 133.1, 128.7, 128.5, 124.8, 79.6, 63.7, 53.2, 48.5, 33.8, 31.9, 28.2, 
26.7, 22.2; Characteristic peaks of the minor rotamer: 1H NMR (CDCl3, 500 MHz)  
5.13 (d, 1 H, J = 7.5  Hz), 2.83 (s, 3 H); 13C NMR (CDCl3, 125 MHz)  173.1, 155.5, 
155.4, 147.5, 128.9, 128.5, 79.7, 52.1, 48.4, 34.6, 32.3, 27.4, 22.4. 
 For 18: []D
20 +6.6 (c 2.20, CH2Cl2); Rf = 0.61 (EtOAc/hexanes, 1:1); 
1H NMR 
analysis showed a 1.2:1 mixture of rotamers at room temperature. Major rotamer: 1H 
NMR (CDCl3, 500 MHz)  5.06 (d, 1 H, J = 8.0 Hz), 4.30 (m, 1 H), 4.20-3.73 (s, 3 H), 
3.44 (t, 1 H, J = 7.5 Hz), 3.40-3.36 (m, 1 H), 3.10 (s, 3 H), 1.85-1.56 (m, 4 H), 1.43 (s, 9 
H), 1.40-1.31 (m, 2 H); 13C NMR (CDCl3, 125 MHz)  173.3, 155.5, 149.8, 80.1, 53.2, 
52.8, 51.2, 38.6, 32.5, 28.5, 26.7, 22.4; Characteristic peaks of the minor rotamer: 1H 
NMR (CDCl3, 500 MHz)  3.74 (s, 3 H), 3.02 (s, 3 H); 
13C NMR (CDCl3, 125 MHz)  
149.3, 80.2, 52.5, 36.8, 32.7, 27.4, 22.4; HRMS (ESI) calcd for C14H25ClN2O5Na ([M + 
Na]+) 361.1320 (37Cl)/359.1350 (35Cl), found 361.1348/ 359.1359; calcd for 
C14H26ClN2O5 ([M + H]
+) 339.1505/337.1530, found 339.1585/ 337.1557. 
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N

-Benzyloxycarbonyl-N

-methyl-L-lysine (6)  
To a solution of 15 (2.59 g, 6.34 mmol) in THF (20 mL) was added lithium 
hydroxide solution (0.5 M, 25.0 mL, 12.5 mmol), and the mixture was stirred at room 
temperature for 3 h. The mixture was diluted in water (20 mL) and extracted with ether 
(30 mL x 2). The ether extracts were discarded, and the remaining aqueous solution was 
adjusted to pH 3 with hydrochloric acid (3 N), with the concomitant formation of white 
precipitate. The suspension was extracted with ethyl acetate (50 mL x 2), and the 
combined organic phases were washed once with brine (30 mL), dried (Na2SO4), and 
evaporated to give the crude carboxylic acid as a colorless oil, which was directly used 
without further purification. 
 The above crude acid (~6.34 mmol) was dissolved in 1,4-dioxane (15 mL), and  
hydrogen chloride in 1,4-dioxane (4.0 M, 5.0 mL, 20.0 mmol) was added. The resulting 
white suspension was stirred at room temperature for 12 h, evaporated, redissolved in a 
minimal amount of water, and loaded onto an ion-exchange column made from Dowex 
50WX4-400 cation-exchange resin (~14 mL bed volume). The column was washed with 
excessive water (300 mL) and then eluted with pyridine (1 M, 450 mL) to give 6 (1.51 g, 
81% for two steps) as a white powder. []D
20 +14.1 (c 1.07, 3 N HCl) (lit.91 []D
25 +14.0 
(c 0.5, acetic acid)); 1H NMR analysis showed a 1:1 mixture of rotamers at room 
temperature. Major rotamer: 1H NMR (D2O, 500 MHz)  7.46-7.42 (m, 5 H), 5.16 (s, 2 
H), 3.68 (m, 1 H), 3.34 (m, 2 H), 2.90 (s, 3 H), 1.83 (m, 2 H), 1.60 (quintet, 2 H, J = 7.3 
Hz), 1.34 (m, 2 H); 13C NMR (D2O, 75 MHz)  184.1, 158.4, 137.1, 129.4, 129.0, 128.5, 
68.0, 56.5, 49.0, 35.1, 34.8, 27.6, 22.8; Characteristic peaks of the minor rotamer: 1H 
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NMR (D2O, 500 MHz, pH = 14)  2.95 (s, 3 H); 
13C NMR (D2O, 75 MHz)  128.2, 
67.2, 49.2, 34.2, 27.3. HRMS (ESI) calcd for C15H23N2O4 ([M + H]
+) 295.1658, found 
295.1656. 
N

-(2-Nitrobenzyl)oxycarbonyl-N

-methyl-L-lysine (8)  
According to the same procedure for 6, 16 (0.914 g, 2.02 mmol) afforded 8 
(0.514 g, 75% for two steps) as a pale yellow solid. []D
20 +14.2 (c 1.16, 3 N HCl); 1H 
NMR analysis showed a 1.1:1 mixture of rotamers at room temperature. Major rotamer: 
1H NMR (D2O, 500 MHz, pH = 14)  8.00 (d, 1 H, J = 8.0 Hz), 7.64 (t, 1 H, J = 7.7 Hz), 
7.50 (d, 1 H, J = 8.5 Hz), 7.47 (t, 1 H, J = 8.2 Hz), 5.32 (s, 2 H), 3.95 (m, 1 H), 3.20 (m, 
2 H), 2.77 (s, 3 H), 1.84 (m, 2 H), 1.49 (m, 2 H), 1.31-1.27 (m, 2 H); 13C NMR (D2O, 75 
MHz)  184.2, 158.0, 147.6, 135.1, 132.7, 129.8, 129.4, 125.7, 65.0, 56.5, 49.2, 35.1, 
34.9, 27.6, 22.8; Characteristic peaks of the minor rotamer: 1H NMR (D2O, 500 MHz, 
pH = 14)  2.82 (s, 3 H); 13C NMR (D2O, 75 MHz)  133.0, 129.7, 64.9, 49.3, 34.2, 
27.2; HRMS (ESI) calcd for C15H22N3O6 ([M + H]
+) 340.1509, found 340.1513. 
Synthesis of 6 from the shorter pathway  
To a solution of 17 (1.50 g, 7.63 mmol) in water (30 mL) was added cupric 
sulfate pentahydrate (1.00 g, 4.00 mmol), followed by sodium bicarbonate (1.42 g, 16.90 
mmol) in small portions to prevent excessive bubble formation. Benzyl chloroformate 
(2.53 g, 13.36 mmol) in dioxane (5 mL) was then added dropwise in 5 min, followed by 
sodium hydroxide (0.49 g, 12.25 mmol) in one portion. The reaction mixture was stirred 
at room temperature for 16 h, filtered, washed with water (100 mL), ethanol (50 mL) and 
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diethyl ether (50 mL), and dried in the open air for 1 h to give the crude copper complex 
(2.40 g, 97%) as a blue solid. 
All the above copper complex (2.40 g, ~7.40 mmol) was suspended in sodium 
hydroxide solution (0.2 N, 100 mL, 20 mmol), and a solution of 8-hydroxylquinoline 
(1.40 g, 9.64 mmol) in 1,4-dioxane (10 mL). The resulting green suspension was stirred 
at room temperature overnight and filtered. The filtrate was adjusted to pH 3 with 
hydrochloric acid (3 N) and extracted with ethyl acetate (40 mL x 2). The organic 
extracts were discarded, and the aqueous phase was concentrated to about 20 mL and 
loaded onto an ion-exchange column made from Dowex 50WX4-400 cation-exchange 
resin (~14 mL bed volume). The column was washed with excessive water (300 mL) and 
then eluted with pyridine (1 M, 450 mL) to give a yellow solid upon evaporation, which 
was suspended in ethanol, filtered, washed ethyl acetate dried to give 6 (1.46 g, 65% for 
two steps) as a white solid. []D
22 +15.3 (c 1.02, 3 N HCl). All other characterization 
data were identical to that of 6 from the longer route. 
Synthesis of 8 from the shorter pathway  
According to the same procedure for 6, 17 (0.50 g, 2.54 mmol) afforded 8 (0.39 
g, 45% yield for two steps). The compound was identical to 8 from the longer route in all 
aspects. 
DNA and Protein Sequences 
DNA Sequences 
Z Domain: 
atgactagtgtagacaactagatcaacaaagaacaacaaaacgccttctatgagatcttacatttacctaacctgaatgaggagc
 45 
agcgtgatgccttcatccaaagtttaaaagatgacccaagccaaagcgctaaccttttagcagaagctaaaaagctaaatgatgc
tcaggcgcctaagggatctgagctccatcaccatcaccatcactaa 
GFPUV: 
Atgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtca
gtggagagggtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatggcca
acacttgtcactactttctcttatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatg
cccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcgtgctgaagtcaagtttgaaggt
gatacccttgttaatcgtatcgagttaaaaggtattgattttaaagaagatggaaacattctcggacacaaactcgaatacaactat
aactcacacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacattgaagat
ggatccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtc
gacatagtctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacac
atggcatggatgaactctacaaagagctccatcaccatcaccatcactaa 
pylT: 
ggaaacctgatcatgtagatcgaatggactctaaatccgttcagccgggttagattcccggggtttccgcca 
Methanosarcina mazei PylRS: 
atggataaaaaaccactaaacactctgatatctgcaaccgggctctggatgtccaggaccggaacaattcataaaataaaacac
cacgaagtctctcgaagcaaaatctatattgaaatggcatgcggagaccaccttgttgtaaacaactccaggagcagcaggact
gcaagagcgctcaggcaccacaaatacaggaagacctgcaaacgctgcagggtttcggatgaggatctcaataagttcctcac
aaaggcaaacgaagaccagacaagcgtaaaagtcaaggtcgtttctgcccctaccagaacgaaaaaggcaatgccaaaatcc
gttgcgagagccccgaaacctcttgagaatacagaagcggcacaggctcaaccttctggatctaaattttcacctgcgataccg
gtttccacccaagagtcagtttctgtcccggcatctgtttcaacatcaatatcaagcatttctacaggagcaactgcatccgcactg
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gtaaaagggaatacgaaccccattacatccatgtctgcccctgttcaggcaagtgcccccgcacttacgaagagccagactga
caggcttgaagtcctgttaaacccaaaagatgagatttccctgaattccggcaagcctttcagggagcttgagtccgaattgctct
ctcgcagaaaaaaagacctgcagcagatctacgcggaagaaagggagaattatctggggaaactcgagcgtgaaattaccag
gttctttgtggacaggggttttctggaaataaaatccccgatcctgatccctcttgagtatatcgaaaggatgggcattgataatgat
accgaactttcaaaacagatcttcagggttgacaagaacttctgcctgagacccatgcttgctccaaacctttacaactacctgcg
caagcttgacagggccctgcctgatccaataaaaatttttgaaataggcccatgctacagaaaagagtccgacggcaaagaac
acctcgaagagtttaccatgctgaacttctgccagatgggatcgggatgcacacgggaaaatcttgaaagcataattacggactt
cctgaaccacctgggaattgatttcaagatcgtaggcgattcctgcatggtctatggggatacccttgatgtaatgcacggagac
ctggaactttcctctgcagtagtcggacccataccgcttgaccgggaatggggtattgataaaccctggataggggcaggtttc
gggctcgaacgccttctaaaggttaaacacgactttaaaaatatcaagagagctgcaaggtccgagtcttactataacgggattt
ctaccaacctgtaa  
 Proteins Sequences 
Z Domain: 
MTSVDNXINKEQQNAFYEILHLPNLNEEQRDAFIQSLKDDPSQSANLLAEAKKL
NDAQAPKGSELHHHHHH    X represents a noncanonical amino acid. 
GFPUV: 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLP
VPWPTLVTTFSYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYITADKQKNGI
KANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTXSALSKDPNEKR
DHMVLLEFVTAAGITHGMDELYKELHHHHHH 
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X represents a noncanonical amino acid. 
Methanosarcina mazei PylRS: 
MDKKPLNTLISATGLWMSRTGTIHKIKHHEVSRSKIYIEMACGDHLVVNNSRSS
RTARALRHHKYRKTCKRCRVSDEDLNKFLTKANEDQTSVKVKVVSAPTRTKK
AMPKSVARAPKPLENTEAAQAQPSGSKFSPAIPVSTQESVSVPASVSTSISSISTG
ATASALVKGNTNPITSMSAPVQASAPALTKSQTDRLEVLLNPKDEISLNSGKPFR
ELESELLSRRKKDLQQIYAEERENYLGKLEREITRFFVDRGFLEIKSPILIPLEYIER
MGIDNDTELSKQIFRVDKNFCLRPMLAPNLYNYLRKLDRALPDPIKIFEIGPCYR
KESDGKEHLEEFTMLNFCQMGSGCTRENLESIITDFLNHLGIDFKIVGDSCMVYG
DTLDVMHGDLELSSAVVGPIPLDREWGIDKPWIGAGFGLERLLKVKHDFKNIKR
AARSESYYNGISTNL 
Construction of Plasmids 
Constructions of pY+ and pY-  
The plasmid pY+ was derived from the pRep plasmid by replacing the 
suppressor tRNA in pRep by pylT.92 The gene of pylT flanked by the lpp promoter at the 
5’ end and the rrnC terminator at the 3’ end was amplified from pBK-AcKRS-pylT.55, 56 
The plasmid pY- was derived from the pNeg plasmid by replacing the suppressor tRNA 
with pylT. Similarly, the gene of pylT flanked by the lpp promoter at the 5’ end and the 
rrnC terminator at the 3’ end was amplified from pBK-AcKRS-pylT. pY+ has a 
tetracycline selection marker, a chloramphenicol acetyltransferase gene with an amber 
mutation at D112. pY- has an ampicillin selection marker and a barnase gene with two 
amber mutations at Q2 and D44. The barnase gene is under control of a pBad promoter. 
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Construction of pET-pylT-GFP  
Plasmid pET-pylT-GFP was derived from the plasmid pAcKRS-pylT-
GFP1Amber in which GFPUV has an amber mutation at Q204. 
55, 56 The restriction 
enzyme BglII was used to cut off the ACKRS gene. The digested pAcKRS-pylT-
GFP1Amber plasmid was ligated to form pET-pylT-GFP. 
Construction of pET-pylT-Z  
The pET-pylT-Z plasmid was derived from pET-pylT-GFP. This gene was 
amplified from the pLeiZ plasmid.93 Two restriction sites, NdeI at the 5’ end and SacI at 
the 3’ end, were introduced in the PCR product which was subsequently digested and 
used to replace GFPUV in pET-pylT-GFP. 
Construction of the pRS1 Library 
The plasmid pBK-mmPylRS that encodes wild-type Methanosarcina mazei 
PylRS was derived from a pBK plasmid containing p-iodophenylalanyl-tRNA 
synthetase.94 The pylRS gene is under the control of E. coli glnS promoter and 
terminator. It was amplified from genomic DNA of Methanosarcina mazei strain DSM 
3647 (ATCC) by flanking primers, pBK-mmPylRS-NdeI-F and pBK-mmPylRS-
PstI~NsiI-R. To construct the pRS1 library, NNK (N=A or C or G or T, K=G or T) 
mutations were introduced at six sites by overlap extension PCR.95 The following pairs 
of primers were used to generate a PylRS gene library with randomization at six sites: 
(1) pBK-mmPylRS-NdeI-F (5'-gaatcccatatggataaaaaaccactaaacactctg-3') and mmPylRS-
Mutlib01-R (5'-ggccctgtcaagcttgcgmnngtagttmnnmnngtttggagcaagca tggg-3'); (2) 
mmPylRS-Mutlib02-F (5'-cgcaagcttgacagggccctgcctgatcc-3') and mmPylRS-Mutlib03-R 
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(5'-gcatcccgatcccatctgmnngaamnncagcatggtaaactcttc-3'); (3)  mmPylRS-Mutlib04-F (5'-
cagatgggatcgggatgcacacg-3') and mmPylRS-Mutlib05-R (5'-
ccgaaacctgcccctatmnngggtttatcaatacccca-3'); (4) mmPylRS-Mutlib06-F (5'-
ataggggcaggtttcgggctcgaacgcc-3') and pBK-mmPylRS-PstI~NsiI-R (5'-
gtttgaaaatgcatttacaggttggtagaaatccc-3'). The gene library was digested with the 
restriction enzymes NdeI and NsiI, gel-purified, and ligated back into the pBK vector 
digested by NdeI and PstI to afford plasmid the pRS1 library. 1 g of the ligation 
products were then electroporated into E. coli Top10 cells. Electroporated cells were 
recovered in SOC medium for 60 min at 37 °C, transferred into a 2 L 2YT medium with 
kanamycin (25 μg/mL) and were incubated at 37°C to OD600 at 1.0. To calculate the 
library size, 1 μL recovered SOC culture was subjected to serial dilutions in 2YT, then 
plated on LB agar plates with kanamycin (25 μg/mL), and grown overnight in a 37°C 
incubator. Based on the colony numbers on these plates, the pRS1 library contains 
approximately 1.01 × 109 independent transformants. Sequencing pylRS variants in 20 
clones did not reveal any significant bias at the randomization sites. 
Selection Procedure for Evolving Pyrrolysyl-tRNA Synthetase 
The selections followed the scheme shown in Scheme II-4. For the positive 
selection, the pRS1 library was used to transform E. coli TOP10 competent cells 
harboring pY+ to yield a cell library greater than 1 × 109 cfu, ensuring complete 
coverage of the pRS1 library. Cells were plated on LB agar plates containing 12 μg/mL 
tetracycline (Tet), 25 μg/mL kanamycin (Kan), 68 μg/mL chloramphenicol (Cm) and 1 
mM 5. After incubation at 37°C for 72 h, colonies on the plates were collected. Total 
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plasmids were isolated and separated by 1 % agarose gel electrophoresis. pRS1 plasmids 
were extracted using a Gel-extraction kit (QIAGEN). The extracted pRS1 plasmids from 
the positive selection were used to transform E. coli TOP10 harboring pY− for the 
negative selection. After electroporation, the cells were allowed to recover for 1 h at 
37°C in SOC media before being plated on LB agar plates containing 50 μg/mL Kan, 
200 μg/mL ampicillin (Amp) and 0.2% arabinose. The plates were incubated for 16 h at 
37°C. Survived cells were then pooled and pRS1 plasmids were extracted. The selection 
power to exclude out the mutants that also took endogenous amino acids was tested on 
LB agar plates containing 50 μg/mL Kan, 200 μg/mL Amp, 0.2% arabinose and 1mM 5. 
The plate contains 1 mM 5 showed much fewer colony numbers as times of negative 
selections increased. Five alternative selections (three positive + two negative) finally 
yielded many colonies. 22 single colonies after the third positive selection were selected 
and the plasmids were isolated for sequencing. 96 single colonies from the third positive 
selection were also chosen for testing their ability to grow on plates with 102 μg/mL 
chloramphenicol, 25 μg/mL Kan, 12 μg/mL Tet, and 1 mM of 5, 6, 7 or 8. A plate 
without NAA supplementary was used as a control. Images of colonies growing on 
different plates were shown in Figure II-1. Sequences of PylRS variants that charge 
pylT with different NAAs are presented in Table II-1&2. 
Protein Purification and Photolysis to Form the Monomethylated Protein 
To express GFPUV incorporated with a NAA, we cotransformed E. Coli 
BL21(DE3) cells with pBK-mKRS1 and pET-pylT-GFP. Cells were recovered in 1 mL 
of LB medium for 1 h at 37 ºC before being plated on LB agar plate containing Kan (25  
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Figure II-1. Growth of 96 single colonies from the third positive selection of 5 on LB 
plates with different supplements. (A) 68 g/mL Cm, 25 g/mL Kan and 12 g/mL Tet; 
(B) 102 g/mL Cm, 25 g/mL Kan and 12 g/mL Tet; (C) 1 mM 5, 102 g/mL Cm, 25 
g/mL Kan and 12 g/mL Tet; (D) 1 mM 6, 102 g/mL Cm, 25 g/mL Kan and 12 
g/mL Tet; (E1 mM 7, 102 g/mL Cm, 25 g/mL Kan and 12 g/mL Tet; (F) 1 mM 8, 
102 g/mL Cm, 25 g/mL Kan and 12 g/mL Tet. The pY+ plasmid has a GFPUV gene 
under control of a T7 promoter. Its expression is promoted by the suppression of two 
amber mutations at positions 1 and 107 of a T7 RNA polymerase gene in pREP. The 
fluorescent intensity of the expression of GFPUV roughly represents the suppression 
efficiency at amber codons. 
 
(A
) 
(B
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μg/mL) and Amp (100 μg/mL). A single colony was then selected and grown overnight 
in a 10 mL culture. This overnight culture was used to inoculate 100 mL of M9 minimal 
media supplemented with 1% glycerol, 300 M leucine, 2 mM MgSO4, 0.1 mM CaCl2, 
0.2% NaCl, 25 μg/mL Kan and 100 μg/mL Amp. Cells were grown at 37ºC in an 
incubator (300 r.p.m.) and protein expression was induced when OD600 was 0.7 by 
adding IPTG to a final concentration of 1 mM and 5 to a final concentration of 1 mM. 
After 6 h induction, cells were harvested, resuspended in a lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and sonicated. The cell lysate was 
clarified by centrifugation (60 min, 11,000 g, 4ºC). The supernatant was injected into a 
30 mL Ni2+-NTA column (Qiagen) on FPLC (ÄKTApurifierTM, GE Healthcare Bio-
Sciences Corp) and washed with 45 mL lysis buffer and 45 mL wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 40 mM imidazole, pH 8.0). Protein was finally eluted out by 
running an imidazole gradient from 40 mM to 250 mM in lysis buffer. Pure fractions 
were collected and concentrated. The buffer was later changed to 1 mM ammonium 
bicarbonate using an Amicon Ultra -15 Centrifugal Filter Devices (10,000 MWCO cut) 
(Millopore). The purified proteins were analyzed by 15% SDS-PAGE. GFPUV
 proteins 
incorporated with other NAAs were expressed and purified similarly except the 
supplemented NAA was changed. For all NAAs, 1 mM final concentration was used. 
Z domain proteins incorporated with different NAAs were expressed and purified 
as same as the expression of GFPUV proteins except pET-pylT-Z was used to 
cotransform E. coli BL21(DE3) together with pBK-mKRS1. 1 mM final concentration 
was used for all four NAAs. The buffer of the finally purified Z domain proteins was 
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changed to 1 mM ammonium bicarbonate using an Amicon centriplus YM-3 (3,000 
MWCO cut) (Millopore). The purified proteins were analyzed by 15% SDS-PAGE. Z-7, 
Z-8, and GFP-8 (1 mg/mL) in 1 mM ammonium bicarbonate solution were treated with 
365 nm UV light form hand-held UV light source for one hour. 
Protein LC-ESI-MS Analysis 
An Agilent (Santa Clara, CA) 1200 capillary HPLC system was interfaced to an 
API QSTAR Pulsar Hybrid QTOF mass spectrometer (Applied Biosystems/MDS Sciex, 
Framingham, MA) equipped with an electrospray ionization (ESI) source. Liquid 
chromatography (LC) separation was achieved using a Phenomenex Jupiter C4 
microbore column (150 × 0.50 mm, 300 Å) (Torrance, CA) at a flow rate of 10 μL per 
min. The proteins were eluted using a gradient of (A) 0.1% formic acid versus (B) 0.1% 
formic acid in acetonitrile. The gradient timetable was as follows: 2% B for 5 min, 2-
30% in 3 min, 30-60% in 44 min, 60-95% in 8 min, followed by holding the gradient at 
95% for 5 min, for a total run time of 65 min. The MS data were acquired in positive ion 
mode (500-1800 Da) using spray voltage of +5000 V. BioAnalyst software (Applied 
Biosystems) was used for spectral deconvolution. For the GFPuv protein analysis, a 
mass range of m/z 500-1800 was used for deconvolution and the output range was 
10000-50000 Da using a step mass of 0.1 Da and a S/N threshold of 20. For the Z-
Domain protein analysis, a mass range of m/z 500-2000 was used for deconvolution and 
the output range was 5000-15000 Da for Z-domain-His6X using a step mass of 0.1 Da 
and a S/N threshold of 20. 
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Results and Discussion 
We chose to work on the genetic incorporation of protected N-methyl-L-lysines 
instead of N-methyl-L-lysine itself because it would be difficult to identify an evolved 
PylRS that specifically recognizes N-methyl-L-lysine but not cellularly abundant lysine. 
Three protected N-methyl-L-lysines (4, 6 and 8 in Scheme II-3) were initially 
considered but eventually we chose 6 and 8. The cleavage of the Boc protection group 
from 4 to recover N-methyl-L-lysine needs to be carried out under a strong acidic 
condition. Although it has been demonstrated that wild type PylRS-       
   
  pair can 
genetically incorporate 385 that is structurally close to 4 into proteins at amber codons 
and it is highly possible the same pair will also incorporate 4 into proteins, we thought 
the harsh condition for the deprotection is not suitable for many proteins (the 
incorporation of 4 into proteins using wild type PylRS-       
   
  pair in E. coli was 
published by Chin et al.66). The strong acidic condition for the deprotection denatures 
proteins that have to be refolded later. However, refolding is problematic for most large 
size proteins. On the contrary, the deprotection of 6 by catalytic hydrogenation and 8, a 
photocaged N-methyl-L-lysine by UV photolysis can be achievable under mild 
conditions that are suitable for most proteins. In addition, the photolysis of 8 after its 
incorporation into proteins may also be carried out in living cells. This may allow the 
synthesis of methylated proteins directly in cells for their functional investigations. 
The synthesis of both 6 and 8 started from lysine derivative96 (Scheme II-3) and 
finished in gram quantities. To expand the substrate scope of PylRS to accommodate 6  
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Scheme II-3: L-Lysine and N-methyl-L-lysine derivatives and their deprotection.  
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or 8, we constructed an active-site mutant library of the Methanosarcina mazei PylRS 
gene with randomization at six active site residues (L305, Y306, L309, N346, C348, and 
W417) (Figure II-2) according to a standard protocol.97 This gene library was then 
cloned into a pBK plasmid to form a pRS1 plasmid library in which mutant PylRS 
variants are under control of a constitutive glnS promoter.97 Together with two selection 
plasmids, pY+ for positive selection and pY- for negative selection, this plasmid library 
was then subjected to alternative positive and negative selections to identify PylRS 
variants specific for 6 or 8 (Scheme II-4).52, 96 The positive selection plasmid, pY+ 
contains genes encoding pylT and type I chloramphenicol (Cm) acetyltransferase with an 
amber mutation at D112. Cotransforming E. coli with pY+ and pRS1 and then growing 
cells in Cm and NAA-containing plates conferred the selection of PylRS variants that 
charge pylT with native amino acids or the supplied NAA. The negative selection 
plasmid, pY- contains genes encoding pylT and toxic barnase that has two amber 
mutations at Q2 and D44. Cotransforming E. coli with pY- and pRS1 and then growing 
cells in plates without NAA conferred the selection of PylRS variants that do not charge 
pylT with a native amino acid. Only PylRS variants that charge pylT with the provided 
NAA but not any native amino acid will survive from both positive and negative 
selections. However, a series of selections (three positive selections + two negative 
selections) yielded no viable clones. The selected mutants of N-acetyl-L-lysyl-tRNA 
synthetase (AcKRS) from Söll amd Chin Groups were reported in high Km vales around 
7 to 35 mM recently.98 It suggested the selection system is able to selected low affinity 
mutant amd the possible colnes charging 6 and 8 have too high Km to be stabilized in the  
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Figure II-2: The active site of PylRS. The structure was derived from pdb entry: 2Q7E.  
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Scheme II-4. The selection scheme to identify PylRS variants specific for a 
noncanonical amino acid. 
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active site of PylRS. We then chose an indirect route to identify clones specific for 6 or 
8. Since 5 and 7 are structurally close to 6 and 8, respectively. We thought PylRS 
variants selected for 5 or 7 might also charge pylT with 6 or 8, respectively. We carried 
out the selections of the pRS1 library to identify PylRS variants that are specific for 5. 
After a series of selections, many colonies survived and most of them converge to two 
specific clones, in which mKRS1 shows the highest suppression efficiency and has 
mutations Y306M/L309A/C348T/T364K (Table II-1&2). We then tested the efficiency 
of the evolved mKRS1-       
   
  pair to suppress an amber mutation at Q204 of GFPUV 
in E. coli. A plasmid pET-pylT-GFP was constructed. It contains genes encoding 
       
   
  and GFPUV with an amber mutation at Q204. The GFPUV gene is under 
control of a T7 promoter. Cotransforming E. coli BL21(DE3) cells with the selected 
pBK-mKRS1 and pET-pylT-GFP and growing cells in minimal medium supplemented 
with 5 afforded full-length GFPUV. No full-length GFPUV was expressed when 5 was 
excluded from the medium (Figure II-3). As what we expected, the evolved mKRS1-
       
   
  pair could also incorporate 6 at an amber codon position. When 6 instead of 5 
was provided in the medium, full-length GFPUV was also expressed (Figure II-3). To 
our surprise, the evolved mKRS1 can also charges        
   
  with 7 and 8. When 7 or 8 
was provided in the medium, growing cells transformed with pBK-mKRS1 and pET-
pylT-GFP also afforded full-length GFPUV (Figure II-3). We also tested the efficiency 
of the mKRS1-pylT pair to suppress an amber mutation at K7 of Z domain. A plasmid 
pET-pylT-Z was constructed by replacing the GFPUV gene in pET-pylT-GFP with Z 
domain that contains an amber mutation at K7. Cotransforming E. coli BL21(DE3) cells   
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Table II-1: Sequences of selected PylRS variants that charge pylT with all four NAAsa 
PylRS Frequency L305 Y306 L309 N346 C348 W417 
mKRS1b 7/22 L M A N T W 
mKRS3 6/22 L M A N C W 
mKRS5 1/22 L M P N C W 
 
aOther PylRS clones are presented in Table II-2. bThis clone has an additional mutation 
T364K. 
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Table II-2. Evolved PylRS variants that charge pylT with different NAAs. 
Position 305 306 309 346 348 477 Remark1 
WT L Y L N C W  
mKRS12 L M A N T W 5, 7,6, 8 
mKRS2 L V A N A W 5, 7, 6 
mKRS33 L M A N C W 5, 7,6, 8 
mKRS4 L A A H L W 5, 6 
mKRS5 L M P N C W 5, 6,7, 8 
mKRS6 L M A N S W 5 
mKRS7 L Y A N A W 5 
mKRS84 L M T N A W 5 
mKRS9 L A A N A W 5 
mKRS10 L A L N A W 5, 7 
mKRS115 L A L N C W 5, 7 
1 This column represents the NAAs that can be taken by mutant PylRS variants. The 
order of compounds also indicates the decreasing encoding efficiency based on the 
screening results. 
2 The mutant was found seven times from 22 sequenced mutants and has extra mutation 
on T364K. 
3 The mutant was found six times from 22 sequenced mutants. 
4The mutant has extra mutation on P297S.  
5 The mutant was found twice from 22 sequenced mutants.  
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Figure II-3: The expression of GFPUV and Z domain at different conditions. 
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with pBK-mKRS1 and pET-pylT-Z and then growing cells in the medium supplemented 
with either of 5, 6, 7, and 8 afforded full-length Z domain. A trace amount of Z domain 
was expressed when no NAA was provided in the medium (Figure II-3). 
To prove the incorporation of NAAs, purified Z domain proteins were then 
analyzed by electrospray ionization mass spectrometry (ESI-MS). (Figure II-4-8) 
Before analysis, Z domain containing 7 (Z-7) and Z domain containing 8 (Z-8) were 
photolysed under 365 nm UV light for an hour. As demonstrated previously, this 
treatment should efficiently cleave the photocaging group. The ESI-MS analysis 
confirmed the expected mass for all four Z domain proteins (Table II-3). For both Z-7 
and Z-8, the photocaging group was efficiently cleaved off. Only peaks corresponding to 
Z domain that contains lysine or N-methyl-L-lysine at K7 could be detected. The ESI-
MS analysis of the deprotected Z-8 also revealed two additional peaks at 8005 Da and 
8136 Da. These two peaks match mass of Z domain that contains lysine, glutamate or 
glutamine at K7. Since mKRS1 was evolved against endogenous native amino acids and 
these two additional peaks are significant in the ESI-MS spectrum, direct incorporation 
of lysine, glutamate, or glutamine at K7 is not likely. We thought the additional mass 
peak was due to the incorporation of 7 that happened to be a contaminant in 8. this is 
highly possible since we synthesized 8 from lysine. A very small amount of 7 might end 
up in 8. We carefully examined all the NMR and MS data of 8 and concluded the 
contaminant was lower than 1% and insignificant. However, 7 could become significant 
after its incorporation into Z domain because the evolved mKRS1 has a higher affinity to 
7 than 8. Similarly, two additional mass peaks at 8139 Da and 8181 Da corresponding to  
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Table II-3: Z domain expression yields and MS characterization 
 
Proteins Yielda 
(mg/L) 
Calculated Mass  
(Da) 
Detected Mass  
(Da) 
Z-5 9.3 8270b 
8181c 
8139d 
8270 
8180 
8138 
Z-6 4.0 8284b 
8195c 
8153d 
 
8195 
8153 
Z-7
e 5.3 8136b 
8047c 
8005d 
8136 
8047 
8004 
Z-8
e 1.2 8150b 
8061c 
8019d 
8150 
8061 
8019 
aProteins were expressed in minimal media supplemented with 1% glycerol and 1 mM 
NAA. bFull-legnth Z domain proteins. cFull-length Z domain without N-terminal 
methionine but with a N-terminal acetylation. dFull-length protein without N-terminal 
methionine. eBoth proteins were deprotected by UV irradiation.  
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Z domain containing 5 (Z-5) was also present in the ESI-MS spectrum of Z domain 
incorporated with 6 (Z-6). These two peaks are clearly the mass peaks of Z-5. This 
indicates the existance of 5 as a contaminant in 6, though the contaminant was also 
lower than 1%. To eliminate 7 from 8, we synthesized 8 from commerically available 
N

-methyl-L-lysine following a route presented in Scheme II-2. The purified 8 was then 
used to express GFPUV containing 8 at Q204 (GFP-8). The purified GFP-8 before and 
after 1 hour photolysis was then analyzed by ESI-MS (Figure II-9&10). The spectrum 
of GFP-8 before photolysis showed one major peak at 27904 Da corresponding to GFP-8 
without N-terminal methionine (calculated mass: 27903 Da).  No mass peak 
corresponding to GFPUV incorporated with 7 (GFP-7) was identified. Similarly, the 
spectrum of GFP-8 after photolysis showed one major peak at 27725 Da. It matches the 
calculated mass (27724 Da) of GFPUV incorporated with N

-methyl-L-lysine at Q204. No 
mass peak corresponding to GFPUV incorporated with lysine at Q204 was present. 
From the ESI-MS spectral data of deprotected Z-7, Z-8, and GFP-8, it is clear 
that deprotecting the photocaging group under UV light is very efficient. No additional 
treatment is necessary. We have also tried palladium black catalyzed hydrogenation to 
deprotect Z-6. However, the protein either aggregated or did not show any detectable 
deprotection. We are currently searching for homogenous hydrogenation catalysts that 
can efficient deprotect Cbz group from Z-6. 
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Figure II-4: Deconvoluted ESI-MS of Z-5, Z-6, UV deprotected Z-7, and UV 
deprotected Z-8. 
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Figure II-5: Mass determination of Protein Z-5 (A) ESI-MS spectrum of Z-5 (B) The 
deconvoluted ESI-MS spectrum of Z-5. 
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Figure II-6: Mass determination of Protein Z-6 (A) ESI-MS spectrum of Z-6 (B) The 
deconvoluted ESI-MS spectrum of Z-6.  
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Figure II-7. Mass determination of Protein Z-7 (A) ESI-MS spectrum of Z-7 (B) The 
deconvoluted ESI-MS spectrum of Z-7.
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Figure II-8: Mass determination of Protein Z-8 (A) ESI-MS spectrum of Z-8 (B) The 
deconvoluted ESI-MS spectrum of Z-8. 
  
 71 
 Figure II-9. Mass determination of Protein GFP-8 (A) ESI-MS spectrum of GFP-8 (B) 
The deconvoluted ESI-MS spectrum of GFP-8.  
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Figure II-10. Mass determination of Protein GFP-8 after photolysis. (A) ESI-MS 
spectrum of GFP-8 (B) The deconvoluted ESI-MS spectrum of GFP-8.  
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Conclusion 
In summary, we have demonstrated the genetic incorporation of a photocaged N-
methyl-L-lysine into proteins in E. coli. Since deprotecting the photocaging group to 
recover N-methyl-L-lysine only requires UV irradiation, this method is suitable to 
directly synthesize many proteins with monomethylated lysines. Given the fact that 
protein lysine methylation has a fundmental role in regulating functions of chromatin 
and many transcription factors, a broad application of this developed method is 
anticipated. Since wild type and evovled PylRS-       
   
  pairs have been directly used 
to incorproate NAAs into proteins in mammalian cells,85, 96 the evolved mKRS1-
       
   
  pair might also be applied to synthesize proteins with monomethylated lysines 
directly in mamalian cells. This will allow the functional analysis of lysine 
monomethylations directly in vivo. 
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CHAPTER III  
A FACILE METHOD TO SYNTHESIZE HISTONES WITH 
POSTTRANSLATIONAL MODIFICATION MIMICS 
 
Introduction 
Epigenetic changes are crucial for the development and differentiation of the 
various cell types in an organism and typically involve postreplicational modifications to 
DNA99-102 and posttranslational modifications to proteins that are closely associated with 
DNA.5, 6, 81, 82, 103, 104 Among posttranslational modifications of proteins, those on 
histones are probably the most diversified. These include several types of methylation on 
lysine and arginine, phosphorylation on serine and threonine, lysine acetylation, 
ubiquitination, glycosylation, etc.81, 105-107 Modifications of histones are central to the 
regulation of chromatin dynamics, and therefore, many biological processes involving 
chromatin, such as replication, repair, transcription, and genome stability, are regulated 
by histone modifications. The importance and complexity of histone modifications has 
also led to the coin of the term “the histone code”. In order to decipher “the histone 
code”, recently several methods have been introduced to synthesize histones with 
posttranslational modifications. It has been demonstrated that native chemical ligation 
and its derivative, expressed protein ligation, can be combined together with solid phase  
peptide synthesis to synthesize acetylated and ubiquitinated histones.19, 20, 108-110 
Although elegant, the general practice of this method is hard. Another method to 
synthesize histones with posttranslational modifications is to site-specifically incorporate 
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modified amino acids directly into histones at amber mutation sites during protein 
translation. Using evolved PylRS-        
   
  pairs,26, 111, 112 histones with lysine 
acetylation and lysine monomethylation have been recombinantly synthesized in E. 
coli.52, 53, 55, 66-69 Alternatively, dehydroalanine can be genetically installed at designated 
sites followed by reactions with thiol-containing molecules to install histones with 
different posttranslational mimics.70, 71, 113 Using the genetic incorporation of 
phenylselenocysteine followed by oxidative elimination to generate dehydroalanine that 
then undertook Michael additions with a series of cysteamine derivatives, Schultz and 
coworkers showed that histones with acetylated and methylated lysine mimics could be 
synthesized.71  
We have been primarily focusing on the dehydroalanine-based approach to 
synthesize histones with posttranslational modification mimics for its easy access to 
multiple types of modifications. In addition, the methods allowing the genetic 
incorporation of N,N-dimethyllysine and N,N,N-trimethyllysine directly into histones 
are not available so far. Although oxidative elimination of phenylselenocysteine in a 
histone protein to install dehydroalanine is straightforward, the genetic incorporation of 
phenylselenocysteine has relatively low efficiency. For wild type histone H3, its 
expression in E. coli can reach to 300 mg/L in LB medium. However, H3 with 
phenylselenocysteine incorporated could only reach to 15 mg/L in LB medium as shown 
in a previous publication.71 The low solubility of phenylselenocysteine at the 
physiological pH also excludes the possibility of boosting its incorporation level by 
increasing its concentration in the growth medium. For these reasons, we have been 
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searching alternative methods to incorporate dehydroalanine into histones for the site-
specific installation of posttranslational mimics on them. 
 
Experimental Section 
General Experimental 
All reactions involving moisture sensitive reagents were conducted in oven-dried 
glassware under an argon atmosphere. Anhydrous solvents were obtained through 
standard laboratory protocols. Analytical thin-layer chromatography (TLC) was 
performed on Whatman SiO2 60 F-254 plates. Visualization was accomplished by UV 
irradiation at 254 nm or by staining with ninhydrin (0.3% w/v in glacial acetic acid/n-
butyl alcohol 3:97). Flash column chromatography was performed with flash silica gel 
(particle size 32-63 m) from Dynamic Adsorbents Inc (Atlanta, GA). 
Specific rotations of chiral compounds were obtained at the designated 
concentration and temperature on a Rudolph Research Analytical Autopol II polarimeter 
using a 0.5 dm cell. Proton and carbon NMR spectra were obtained on Varian 300 and 
500 MHz NMR spectrometers. Chemical shifts are reported as  values in parts per 
million (ppm) as referenced to the residual solvents: chloroform (7.27 ppm for 1H and 
77.23 ppm for 13C) or water (4.80 ppm for 1H). A minimal amount of 1,4-dioxane  was 
added as the reference standard (67.19 ppm for 13C) for carbon NMR spectra in 
deuterium oxide, and a minimal amount of sodium hydroxide pellet or concentrated 
hydrochloric acid was added to the NMR sample to aid in the solvation of amino acids 
which have low solubility in deuterium oxide under neutral conditions. 1H NMR spectra 
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are tabulated as follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet), number of protons, and coupling 
constant(s). Mass spectra were obtained at the Laboratory for Biological Mass 
Spectrometry at the Department of Chemistry, Texas A&M University. 
H-Lys(Z)-OH (1) was obtained from Chem-Impex International, Inc. (Wood 
Dale, IL). O-Mesitylsulfonylhydroxylamine (MSH), 2-(methylamino)ethanethiol 
hydrochloride (monomethyllysine mimic precursor), 2-(dimethylamino)ethanethiol 
hydrochloride (dimethyllysine mimic precursor), and 2-(mercaptoethyl)trimethyl-
ammonium chloride (trimethyllysine mimic precursor) were prepared according to 
procudres by Bernardes and coworkers.113 All other reagents were obtained from 
commercial suppliers and used as received. 
Chemical Synthesis 
Compounds 2 was synthesized from 1 on multi-gram scale114, 115 (Scheme III-1). 
Compounds 3 and 4 were synthesized by nucleophilic substitution of 6 with appropriate 
precursors. Reductive cleavage of the diselenide bond in 8 with sodium borohydride116 
turned out to be incomplete, and was best effected with sodium in liquid ammonia. 
(S)-6-(((Benzyloxy)carbonyl)amino)-2-hydroxyhexanoic acid (2)
114  
Compound 1 (5.0 g, 17.8 mmol) was dissolved in a mixture of acetic acid and 
water (1:2, 445 mL) with heating and then cooled to room temperature. Sodium nitrite 
(3.1 g, 44.9 mmol) in water (20 mL) was added dropwise over 10 min. After about 30 
min gas evolution ceased and a yellow clear solution was formed. The solution was 
stirred at room temperature for 24 h and extracted with ethyl acetate (150 mL x 2). The  
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Scheme III-1. Synthesis of 2, 3, and 4.  
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combined organic layers were washed with brine, dried (Na2SO4), evaporated, 
redissolved in sodium hydroxide (2 N, ~ 30 mL) and stirred at room temperature 
overnight. The suspension was adjusted to pH 1with hydrochloric acid (6 N), extracted 
with ethyl acetate (150 mL x 2), washed with brine, dried (Na2SO4), evaporated, and 
recrystallized in ethyl acetate/hexanes (1:1) to give 2 (3.5 g, 70%) as a white solid. 1H 
NMR (DMSO-d6, 500 MHz)  7.38-7.30 (m, 5 H), 7.25 (t, 1 H, J = 5.7 Hz), 5.00 (s, 2 
H), 3.90 (dd, 1 H, J = 8.0, 4.5 Hz), 3.36 (bs, 1 H), 2.97 (dt, 2 H, J = 6.5, 6.5 Hz), 1.73-
1.44 (m, 2 H), 1.42-1.29 (m, 4 H); 13C NMR (DMSO-d6, 75 MHz) 175.8, 156.0, 
137.3, 128.3, 127.7, 69.5, 65.1, 40.2, 33.6, 29.2, 22.1HRMS (ESI) calcd for C14H20NO5 
([M+H]+) 282.3123, found 282.2140. 
Benzyl (2-bromoethyl)carbamate (6)
117, 118
  
To a solution of 5 (13.5 g, 64.6 mmol) in a mixture of sodium hydroxide (2.0 N, 
70 mL, 0.14 mol) and 1,4-dioxane (50 mL) cooled in an ice bath was added a solution of 
benzyl chloroformate (11.6 g, 64.6 mmol) in 1,4-dioxane (20 mL) dropwise over 15 min. 
The mixture was stirred at room temperature overnight, and most of the dioxane was 
evaporated. The residue was adjusted to pH 5 with hydrochloric acid (2 N) and extracted 
with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine, 
dried (Na2SO4), evaporated, chromatographed (EtOAc/hexanes, 1:9), and crystallized in 
hexanes to give 6 (8.9 g, 53%) as a white solid. 1H NMR (CDCl3, 500 MHz)  7.40-7.33 
(m, 5 H), 5.29 (bs, 1 H), 5.12 (s, 2 H), 3.60 (appar. q, 2 H, J = 6.0 Hz), 3.47 (t, 2 H, J = 
5.7 Hz); 13C NMR (CDCl3, 75 MHz) 156.3, 136.4, 128.8, 128.4, 128.3, 67.2, 43.0, 
32.7. 
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(R)-2-Amino-3-((2-(((benzyloxy)carbonyl)amino)ethyl)thio)propanoic acid (3)  
To a degassed solution of L-cysteine (7, 1.25 g, 10.0 mmol) in sodium hydroxide 
(2 N, 15.0 mL, 30.0 mmol) cooled in an ice bath was added 6 (2.85 g, 11.0 mmol) in 
degassed ethanol (10 mL) dropwise over 5 min. The mixture was stirred at room 
temperature overnight, and hydrochloric acid (3 N, 8.0 mL, 24.0 mmol) was added to 
give a white suspension. Filtration followed by washing with excessive water, ethanol, 
and dichloromethane and drying under vacuum afforded 3 (2.4 g, 81%) as a white solid. 
[]D
21 +2.4 (c 1.20, 1 N NaOH); 1H NMR (D2O, 500 MHz, pH > 10)  7.45-7.39 (m, 5 
H), 5.11 (s, 2 H), 3.38 (t, 1 H, J = 5.7 Hz), 3.36-3.28 (m, 2 H), 2.84 (dd, 1 H, J = 13.5, 
4.5 Hz), 2.76 (dd, 1 H, J = 13.2, 6.7 Hz), 2.68 (t, 2 H, J =  6.5 Hz); 13C NMR (D2O, 125 
MHz, pH > 10) 181.6, 159.0, 137.1, 129.4, 128.3, 67.5, 55.8, 40.5, 37.5, 32.2; HRMS 
(ESI) calcd for C13H19N2O4S ([M+H]
+) 299.1066, found 299.1074. 
(R)-2-Amino-3-((2-(((benzyloxy)carbonyl)amino)ethyl)selanyl)propanoic acid (4)  
To an argon-protected solution of seleno-L-cystine (8, 3.75 g, 11.0 mmol) in 
liquid ammonia (~ 80 mL) cooled in a dry ice/acetone bath was added sodium metal (1.3 
g, 56.5 mmol) in small pieces (CAUTION!) over 2 h, and a yellow suspension resulted in 
the end. The bath temperature was gradually raised up to room temperature and 
excessive ammonia was blown away with a gentle stream of argon inside a well-
ventilated fume hood. Residual ammonia was removed on a rotorvap inside a well-
ventilated fume hood, and the solid was cooled in an ice bath and carefully dissolved 
with degassed ice-cold water (25 mL). Compound  6 (5.85 g, 22.7 mmol) in degassed 
ethanol (15 mL) was added dropwise over 5 min, and the mixture was stirred at room 
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temperature for 20 h and then filtered to give a red solution. Hydrochloric acid (3 N, 38.0 
mL, 0.11 mol) was added to give a pink suspension, which was filtered, washed with 
plenty of water, ethanol, and dichloromethane, and dried under vacuum to afford 4 (6.6 
g, 87%) as a slightly pink solid. []D
21 +14.8 (c 1.42, 1 N NaOH); 1H NMR (D2O, 500 
MHz, pH < 1)  6.94-6.91 (m, 5 H), 4.62 (s, 2 H), 3.84 (m, 1 H), 2.91 (dt, 2 H, J = 6.7, 
1.5 Hz), 2.67-2.65 (m, 1 H), 2.57 (m, 1 H), 2.28 (t, 2 H, J =  6.5 Hz); 13C NMR (D2O, 
125 MHz, pH ~ 14) 181.4, 158.6, 136.8, 129.1, 128.7, 128.0, 66.9, 55.9, 41.0, 29.7, 
24.1; HRMS (ESI) calcd for C13H19N2O4Se ([M+H]
+) 349.0512/347.0510/345.0518 
(major Se isotopes), found 349.0521/347.0501/345.0506. 
DNA and Protein Sequences 
Gene and protein sequences of pylT, Methanosarcina mazei PylRS and GFPUV 
were listed in the DNA sequence of Experimental Section in Chapter II. 
DNA Sequences 
sfGFP: 
atgtagaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtcc
gtggagagggtgaaggtgatgctacaaacggaaaactcacccttaaatttatttgcactactggaaaactacctgttccgtggcc
aacacttgtcactactctgacctatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgcc
atgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggacctacaagacgcgtgctgaagtcaagtttgaa
ggtgatacccttgttaatcgtatcgagttaaagggtattgattttaaagaagatggaaacattcttggacacaaactcgagtacaac
tttaactcacacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacgttgaag
atggttccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgt
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cgacacaatctgtcctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattaca
catggcatggatgagctctacaaaggatcccatcaccatcaccatcactaa 
mkRS1: 
atggataaaaaaccactaaacactctgatatctgcaaccgggctctggatgtccaggaccggaacaattcataaaataaaacac
cacgaagtctctcgaagcaaaatctatattgaaatggcatgcggagaccaccttgttgtaaacaactccaggagcagcaggact
gcaagagcgctcaggcaccacaaatacaggaagacctgcaaacgctgcagggtttcggatgaggatctcaataagttcctcac
aaaggcaaacgaagaccagacaagcgtaaaagtcaaggtcgtttctgcccctaccagaacgaaaaaggcaatgccaaaatcc
gttgcgagagccccgaaacctcttgagaatacagaagcggcacaggctcaaccttctggatctaaattttcacctgcgataccg
gtttccacccaagagtcagtttctgtcccggcatctgtttcaacatcaatatcaagcatttctacaggagcaactgcatccgcactg
gtaaaagggaatacgaaccccattacatccatgtctgcccctgttcaggcaagtgcccccgcacttacgaagagccagactga
caggcttgaagtcctgttaaacccaaaagatgagatttccctgaattccggcaagcctttcagggagcttgagtccgaattgctct
ctcgcagaaaaaaagacctgcagcagatctacgcggaagaaagggagaattatctggggaaactcgagcgtgaaattaccag
gttctttgtggacaggggttttctggaaataaaatccccgatcctgatccctcttgagtatatcgaaaggatgggcattgataatgat
accgaactttcaaaacagatcttcagggttgacaagaacttctgcctgagacccatgcttgctccaaaccttatgaactacgcgc
gcaagcttgacagggccctgcctgatccaataaaaatttttgaaataggcccatgctacagaaaagagtccgacggcaaagaa
cacctcgaagagtttaccatgctgaacttcacgcagatgggatcgggatgcacacgggaaaatcttgaaagcataattaaggac
ttcctgaaccacctgggaattgatttcaagatcgtaggcgattcctgcatggtctttggggatacccttgatgtaatgcacggaga
cctggaactttcctctgcagtagtcggacccataccgcttgaccgggaatggggtattgataaaccctggataggggcaggtttc
gggctcgaacgccttctaaaggttaaacacgactttaaaaatatcaagagagctgcaaggtccgagtcttactataacgggattt
ctaccaacctgtaa 
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Xenopus laevis H3/C110A: 
Atggctcgtactaagcagaccgcccgttagtccaccggagggaaggctccccgcaaacagctggccaccaaggcagccag
gaagagcgctccggccacaggcggagtcaagaaacctcaccgttaccggcccggcacagtcgctctccgcgagatccgcc
gctaccagaaatccaccgagctgctcatccgcaaactgcctttccagcgcctggtccgggagatcgctcaggacttcaagacc
gacctgcgcttccagagctcggccgtcatggctctgcaggaggccagcgaggcttatctggtcggtttgtttgaggacaccaac
ctggccgccatccacgccaagagggtcaccatcatgcccaaggacatccagctggcccgcaggatccggggcgagagggc
tgagctccatcaccatcaccatcactaa 
Proteins Sequences 
sfGFP: 
MXKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLP
VPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDGTYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIK
ANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRD
HMVLLEFVTAAGITHGMDELYKGSHHHHHH 
X represents a noncanonical amino acid. 
mkRS1: 
MDKKPLNTLISATGLWMSRTGTIHKIKHHEVSRSKIYIEMACGDHLVVNNSRSS
RTARALRHHKYRKTCKRCRVSDEDLNKFLTKANEDQTSVKVKVVSAPTRTKK
AMPKSVARAPKPLENTEAAQAQPSGSKFSPAIPVSTQESVSVPASVSTSISSISTG
ATASALVKGNTNPITSMSAPVQASAPALTKSQTDRLEVLLNPKDEISLNSGKPFR
ELESELLSRRKKDLQQIYAEERENYLGKLEREITRFFVDRGFLEIKSPILIPLEYIER
MGIDNDTELSKQIFRVDKNFCLRPMLAPNLMNYARKLDRALPDPIKIFEIGPCYR
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KESDGKEHLEEFTMLNFTQMGSGCTRENLESIIKDFLNHLGIDFKIVGDSCMVFG
DTLDVMHGDLELSSAVVGPIPLDREWGIDKPWIGAGFGLERLLKVKHDFKNIKR
AARSESYYNGISTNL 
Xenopus laevis H3/C110A : 
MARTKQTARXSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRPGTVALREIR
RYQKSTELLIRKLPFQRLVREIAQDFKTDLRFQSSAVMALQEASEAYLVGLFEDT
NLAAIHAKRVTIMPKDIQLARRIRGERAELHHHHHH 
Plasmid Constructions 
Construction of pET-sfGFP2TAG  
The plasmid pET-sfGFP2TAG was derived from the plasmid pET-pylT-Z68 in 
which sfGFP has an amber mutation at S2.  This gene was amplified from the 
Superfolder GFP plasmid (Theranostech®). Two restriction sites, NdeI at the 5’ end and 
SacI at the 3’ end, were introduced in the PCR product which was subsequently digested 
and used to replace Z domain gene in pET-sfGFP2TAG. 
Construction of pBK-mKRS1 with the Y384F mutation  
The pBK-mKRS1 plasmid in which mKRS1 has the Y384 mutation was derived 
from a pBK plasmid containing p-iodo-L-phenylalanyl-tRNA synthetase94 that was 
initially evolved from M. jannaschii tyrosyl-tRNA synthetase. The PylRS gene is under 
the control of E. coli glnS promoter and terminator. This gene was amplified from the 
pBK-mKRS1 (Y306M/L309A/C348T/T364K) plasmid by flanking primers, pBK-
mmPylRS-NdeI-F and pBK-mmPylRS-PstI~NsiI-R. To construct the pBK-mkRS1F 
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plasmid Y384F mutation was introduced by overlap extension PCR. The following pairs 
of primers were used to generate an mKRS1 gene with the Y384F mutation: (1) pBK-
mmPylRS-NdeI-F (5'-gaatcccatatggataaaaaaccactaaacactctg-3') and mmPylRS-Y384F-R 
(5'-tacatcaagggtatccccaaagaccatgcaggaatcgcctacg-3'); (2) mmPylRS-Y384F-F (5'-
cgtaggcgattcctgcatggtctttggggatacccttgatgta-3') and pBK-mmPylRS-PstI~NsiI-R (5'-
gtttgaaaatgcatttacaggttggtagaaatccc-3'). The amplified gene was digested with the 
restriction enzymes NdeI and NsiI, gel-purified, and ligated back into the pBK vector 
digested by NdeI and PstI to afford plasmid pBK-mKRS1. 
Construction of pEVOL-pylT  
The pEVOL-pylT plasmid was derived from a pEVOL plasmid.119 The pylT 
gene with prok promoter and terminator was synthesized by overlap PCR with eight 
primers ((1) pEVOL-PylT-ApaLI-F-1 (5’-
gatatgatcagtgcacggctaactaagcggcctgctgactttctcg-3’); (2) pEVOL-PylT-R-2 (5’-
caatcccttaatagcaaaatgccttttgatcggcgagaaagtcagcag-3’); (3) pEVOL-pylT-F-3 (5’-
gctattaagggattgacgagggcgtatctgcgcagtaagatgcgcccc-3’); (4) pEVOL-pylT-R-4 (5’-
agtccattcgatctacatgatcaggtttccaatgcggggcgcatcttac-3’); (5) pEVOL-pylT-F-5 (5’-
gtagatcgaatggactctaaatccgttcagccgggttagattcccgggg-3’); (6) pEVOL-pylT-R-6 (5’-
ggcttttcgaatttggcggaaaccccgggaatctaac-3’); (7) pEVOL-pylT-F-7 (5’-
caaattcgaaaagcctgctcaacgagcaggcttttttg-3’); (8) pEVOL-pylT-Xho1-R-8 (5’-
ctgagctgctcgagcatgcaaaaaagcctgctc-3’) and introduce by two restriction sites, ApaLI at 
the 5’ end and XhoI at the 3’ end. Two pairs of restriction sites (SpeI and SalI sites 
between the pBAD promoter and terminator; NdeI and NotI between the glnS promoter 
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and terminator) were introduced using two pairs of primers ((1) pEVOL-SpeI-R (5’-
ttactagtaattcctcctgttagccc-3’) and pEVOL-SalI-F (5’-ccgtcgaccatcatcatcatcatc-3’); (2) 5’-
pEVOL-NdeI-R (5’-atcatatgggattcctcaaagcgtaaac-3’) and pEVOL-NotI-F (5’-
acgcggccgctttcaaacgctaaattgc-3’).  These restriction sites in pEVOL-pylT were 
constructed for further installations of two copies of mKRS1. 
Construction of pEVOL-mKRS1-pylT  
The pEVOL-mKRS1-pylT plasmid was derived from the pEVOL-pylT plasmid 
with sequential insertion of two copies of the mKRS1 gene.  The first copy of mKRS1 
gene was amplified from the pBK-mKRS1 plasmid by flanking primers, pEVOL-PylRS-
SpeI-F and pEVOL-PylRS-SalI-R, digested by SpeI and SalI restriction enzymes, and 
ligated to a precut pEVOL-pylT plasmid. The resulted plasmid was digested by NdeI 
and NotI enzymes and used to insert the second copy of the mKRS1 gene that was 
amplified using primers pEVOL-PylRS-NdeI-F and pEVOL-PylRS-NotI-R and digested 
by NdeI and NotI restriction enzymes.  The resulted plasmid is pEVOL-mKRS1-pylT. 
Construction of pET-H3K9TAG  
The plasmid pET-H3K9TAG was derived from the plasmid pET-pylT-GFP in 
which H3 has an amber mutation at K9.  This gene was amplified from the plasmid 
pET22b-xlH3.71 Two restriction sites, NdeI at the 5’ end and SacI at the 3’ end, were 
introduced in the PCR product which was subsequently digested and used to replace 
GFP gene in pET-H3K9TAG. 
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Construction of pET-H3  
The plasmid pET-H3 with wild type H3 gene was derived from the commercial plasmid 
pET-Duet1. This gene was amplified from the plasmid pET22b-xlH3/C110A. Two 
restriction sites, NdeI at the 5’ end and KpnI at the 3’ end, were introduced in the PCR 
product which was subsequently digested and used to install H3 gene in pET-Duet1 to 
afford pET-H3. 
Screening Procedures for mKRS and mKRS1 Strains 
The initial mKRS1 strain (designated as mKRS) and the mKRS1 strain with the 
Y384F mutation (designated as mKRS1) in pBK plasmid were cotransformed with pY+ 
to E. Coli TOP10 cells and tested for their ability to grow on plates with 102 μg/mL 
chloramphenicol (Cm), 25 μg/mL kanamycin (Kan), 12 μg/mL tetracycline (Tet), and 1 
mM of 1, 3, or 4. A plate without any noncanonical amino acid (NAA) supplement was 
used as the negative control. E. Coli cells containing the two plasmids were separately 
placed on LB agar plates with decreasing cell number by serial dilution from 3×106 to 1. 
The original cell solution was prepared with OD600 = 1.0 (~1×10
9 cells/mL). The cells on 
the plate were grown at 37 oC for 48 h. Images of colonies growing on different plates 
were shown in Figure III-1. 
GFPUV and sfGFP and H3 Protein Expression and Purification 
 GFPUV and sfGFP expressions and purifications are performed by the method in 
Chapter II. To express H3 incorporated with a NAA, E. Coli BL21(DE3) cells were 
cotransformed with pEVOL-mKRS1-pylT and pET-H3K9TAG. Cells were recovered in 
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1 mL of LB medium for 1 h at 37 ºC before being plated on LB agar plate containing 
Cm (34 μg/mL) and Amp (100 μg/mL). A single colony was then selected and grown 
overnight in a 10 mL culture. The culture was then used to inoculate 500 mL of 2YT 
media supplemented with 34 μg/mL Cm and 100 μg/mL Amp. Cells were grown at 37 
ºC in an incubator (300 r.p.m.) and protein expression was induced when OD600 reached 
0.7 - 1.0 by adding 1 mM IPTG, 0.2% arabinose and 2 mM 1. After 6-8 h induction, 
cells were harvested, resuspended in a lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 5 
mM EDTA, 0.1% NaN3, 0.5% Triton-X100, 0.1 mM PMSF and 1mM DTT, pH 
8.0) and sonicated. MgSO4 (final concentration 10 mM) was added to chelate EDTA, 
and 0.01 mg/ml DNase and 0.1 mg/ml lysozyme were then added to the solution. The 
mixture was incubated at room temperature for 20 min. The cell lysate was clarified by 
centrifugation (20 min, 6,000 r.p.m., 4 ºC). The centrifuged pellet was crushed with a 
spatula, then resuspended by sonication in the lysing buffer. Another portion of DNase 
and lysozyme was added at this point to improve the purity of the pellet. After 
centrifugation, the inclusion body was washed twice with the washing buffer (50 mM 
Tris-HCl, 100 mM NaCl, 5 mM EDTA, 0.1% NaN3, pH 8.0). The semi-purified H3 
protein inclusion body was dissolved by a dissolving buffer (100 mM NaH2PO4, 10 mM 
Tris HCl, 8 M urea, pH 8.0) and incubated for 1 h at 37 oC.  The solution was then 
centrifuged (20 min, 10,000 r.p.m). The supernatant was incubated with 3 mL Ni2+-NTA 
resin (Qiagen) (2 h, 4 ºC) and washed with 30 mL of washing buffer (dissolving buffer 
in pH = 6.2). The protein was finally eluted out by an elution buffer (dissolving buffer in 
pH = 4.5). The pure eluted fractions were collected and concentrated. The buffer was 
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Figure III-1: Growth of two strains, mKRS1 (a) and mKRS (b), on LB plates with 
different supplements. The LB agar plates contain 102 g/mL Cm, 25 g/mL Kan and 
12 g/mL Tet. The TOP10 cells with pBK-mkRS1 (a) 
(Y306M/L309A/C348T/T364K/Y384F) and pY+ or pBK-mkRS (b) 
(Y306M/L309A/C348T/T364K) and pY+ were plated with serial dilution from 3×106 
(1) cells to 0.3 (8) (10 fold for each dilution). The pY+ plasmid has a GFPUV gene under 
the control of a T7 promoter. The expression is promoted by the suppression of two 
amber mutations at positions 1 and 107 of a T7 RNA polymerase gene in pREP. The 
fluorescent intensity of the expression of GFPUV roughly represents the suppression 
efficiency at amber codons.  
 
a b a b a b a b 
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later changed to 10 mM ammonium bicarbonate and 8 M urea using an Amicon Ultra -
15 Centrifugal Filter Devices (10,000 MWCO cut, Millopore). The purified proteins 
were analyzed by 15% SDS-PAGE. H3 proteins incorporated with 3 and 4 were 
expressed in the presence of 2 mM 2 and 1.5 mM 4, respectively, and similarly purified. 
Synthesis of H3 Mimics with Posttranslational Modifications 
 H3K9Dha was synthesized from H3K9-4. Aqueous H2O2 solution (100 mM, 5 
L, 100 eq, 500 nmol) was added to the protein H3K9-4 (1.6 mg/mL, 100 M, 50 L, 5 
nmole) in a dissolving buffer (100 mM NaH2PO4, 10 mM Tris HCl, 8 M urea, pH 8.0), 
and the mixture was periodically agitated at room temperature for 1 h. The mixture was 
then dialyzed by Amicon Ultra -15 Centrifugal Filter Devices (10,000 MWCO cut, 
Millopore) against the dissolving buffer to terminated the reaction.  
To synthesize H3 mimics H3K9AcsK, H3K9mesK, H3K9m2sK, H3K9m3sK and 
H3K9pC, solutions of the corresponding thiol nucleophiles (400 mM, 12.5 L, 5 mole) 
in the dissolving buffer (100 mM NaH2PO4, 10 mM Tris HCl, 8 M urea, pH 8.0) were 
add into protein samples in the same buffer. The Michael addition reaction was 
performed at room temperature for 1 h and then terminated by dialysis against the 
dissolving buffer. 
Immunoprecipitation of wt-H3, H3K9mesK, H3K9m
2
sK and H3K9m
3
sK by 
HP1andWestern Blotting Assay 
HP1β (1 μM) was incubated with wt-H3, H3K9mesK, H3K9m2sK and 
H3K9m3sK, in 500 μl of binding buffer (0.5 M NaCl, 1% NP40, 0.5% sodium 
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deoxycholate, 0.1% SDS, 50 mM Tris HCl, pH 8.0). A portion of this sample (20 μl) 
was removed to check the total protein level (input). The remaining supernatant was 
incubated for 4 h at 4 ºC with 1 μg of a goat polyclonal antibody to CBX1/HP1 beta 
(Abcam, ab40828). After 1 h of incubation, 30 μl of protein A-agarose (Sigma) was 
added. The beads were pelleted, washed 5 times with 700 μl of RIPA buffer, and the 
bound protein was released by boiling in SDS-sample buffer. A Rabbit polyclonal 
antibody to C-terminus of H3 (9715, Cell Signaling Technology) was used to detect H3 
proteins immunoprecipitated by HP1β. 
  A Rabbit polyclonal antibody for histone H3 (acetyl K9) (Abcam, ab10812) was 
used to detect wtH3 or H3K9-AcsK. Further ECL test was carried out by treatment with 
a donkey polyclonal secondary antibody to rabbit IgG-H&L (HRP) (Abcam, ab16284). 
ESI-MS Analysis of Intact Proteins 
Protein samples were prepared by desalting the protein using C18 ZipTipTM 
(Millipore) following the manufacturer’s protocol and eluted with 60% acetonitrile 
containing 0.1% formic acid. The resulting solution was diluted to 1 μM with 50% 
methanol containing 0.1% formic acid, and then used for electrospray mass spectrometry 
(ESI-MS) analysis. ESI ion-mobility (IM) MS experiments were performed on a 
SYNAPT G2 HDMS mass spectrometer (Waters Corp., Milford, MA) equipped with a 
nano-ESI source.  The IM-MS data were acquired in positive ion mode (400-2500 Da) 
using spray voltage of +1800 V. Data analysis and protein signal extraction were 
performed using the MassLynxTM and DriftScopeTM software packages (Waters Corp., 
Milford, MA). For the histone H3 series, a mass range of m/z 500-1200 was used for 
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spectral deconvolution and the output range was 15000 to 19000 Da using a resolution 
of 0.1 Da per channel.  For the green fluorescent proteins, a mass range of m/z 700-1300 
was used for spectral deconvolution and the output range was 27000 to 29000 Da using a 
resolution of 0.1 Da per channel.  For top-down analysis of H3K9-AcsK by CID-IM-
MS, the precursor ion of m/z 655.54, corresponding to the 25+ charged state of H3K9-
AcsK, was selected to perform collision-induced dissociation (CID) experiment using 
argon as collision gas and 25 V of collision energy in the Trap region.  High-resolution 
MS experiments were performed on a SolariX 9.4 T: hybrid quadrupole-FTICR mass 
spectrometer (Burker Daltonik GmbH, Bremen, Germany) equipped with a nano-ESI 
source and acquired in positive ion mode (m/z 300-3000) using electrospray voltage of 
+1600 V.  All MS spectra were obtained by quadrupole mass selection of m/z 800 to 
1000 and accumulation of 100 spectra.  Data analysis and protein signal extraction were 
performed using the DataAnalysisTM software packages (Burker Daltonik GmbH, 
Bremen, Germany).  For spectral deconvolution to a singly charged spectrum, the output 
range was 5000 to 100000 m/z using an abundance cutoff of 0 %. 
Tandem Mass Spectrometry analysis 
GFP-4 from the SDS-PAGE gel was excised and digested with endoproteinase 
Asp-N (Roche Diagnostics Co., Indianapolis, IN) or trypsin (Promega, Madison, WI) at 
37 0C overnight using the following protocol: the gel slice was washed with 25 mM 
ammonium bicarbonate (ABC, pH 8) and dehydrated with a solution mixture of 
acetonitrile (ACN) and 50mM ABC (v/v, 2/1). The washing and dehydrating steps were 
repeated for another two times. Supernatant was removed and the gel slice was dried in a 
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vacuum centrifuge (SpeedVac Concentrator, Savant, Farmingdale, NY). 10 µL of 20 
ng/µL Asp-N or trypsin in 25 mM ABC was added to the dried gel slice. After the gel 
slice was completely rehydrated, 20 µL of 25mM ABC was added to cover gel slice and 
incubated at 37 °C overnight.  Peptides resulting from the Asp-N or trypsin digestion 
were mixed 1:1 (v/v) with matrix (5 mg/mL α-cyano-4-hydroxycinnamic acid, 50% (v/v) 
acetonitrile, 10 mM ammonium dihydrogen phosphate, 0.1% TFA) and 1 μL of the 
resulting mixture was spotted onto a stainless steel target plate. Mass spectra and tandem 
MS spectra were collected using an Applied Biosystems 4800 TOF/TOFTM Analyzer 
(Framingham, MA). Collision induced dissociation tandem MS spectra were acquired 
using air at the medium pressure setting and at 2 kV of collision energy. Tandem MS 
data was manually interpreted using the Data Explorer™ software package (Applied 
Biosystems, Framingham, MA). 
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Results and Discussion 
We previously showed that an evolved PylRS, mKRS1 together with 
       
   
 allows the specific incorporation of N-Cbz-lysine (1 in Figure III-2A) at an 
amber mutation site of a protein in E. coli. This mutant enzyme also shows high 
substrate promiscuity and is able to charge tRNAPyl with N-Cbz-N-methyllysine (75% 
protein yield of 1 incorporation), N-(o-nitrobenzyloxycarbonyl)-lysine (75% protein 
yield of 1 incorporation) , and N-(o-nitrobenzyloxycarbonyl)-N-methyllysine (63% 
protein yield of 1 incorporation).68 To test the substrate scope of mKRS1, we recently 
synthesized three N-Cbz-N-methyllysine analogues whose structures are shown in 
Figure III-2A as 2-4 and analyzed their uptake by the mKRS1-        
   
  pair to 
incorporate at amber mutation sites in E. coli. Two plasmids were constructed for the 
test. One plasmid pEVOL-mKRS1-pylT119 contains the        
   
 gene under control of 
the proK promoter and the proK terminator, one copy of the mKRS1 gene under control 
of the constitutive glnS promoter, and one copy of the mKRS1 gene under control of the 
pBAD promoter; the other plasmid pET-sfGFP2TAG contains a superfolder GFP 
(sfGFP) gene120, 121 that is under control of the T7 promoter and has an amber mutation 
at S2. One addition mutation Y384F was also introduced to mKRS1 given the fact that 
this mutation can increase the binding of PylRS or its mutants to substrates with 
hydrophobic side chains.122 When growing E. coli BL21 cells transformed with both 
plasmids in LB medium supplemented with 1, 2, 3, or 4, overexpression of sfGFP was 
observed. The expression levels for all four conditions are comparable. On the contrary,  
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Figure III-2: (A) Structures of 1-4 and (B) their specific incorporation at S2 of sfGFP. 
Proteins were expressed in BL21 cells transformed with pEVOL-mKRS1-pylT and pET-
sfGFP2TAG in LB medium supplemented with 1 mM 1, 2, 3, or 4.  
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only a trace amount of sfGFP was detected when growing same cells in LB medium 
without providing a noncanonical amino acid. As shown in Table III-1, the purified 
proteins all showed the expected molecular weight (MW) when analyzed by electrospray 
ionization mass spectrometry (ESI-MS). (Figure III-3-6) For sfGFP with 2 incorporated 
(sfGFP-2), the full-length protein was not the major component as detected by ESI-MS. 
2 is an -hydroxy acid instead of an -amino acid. Its incorporation into sfGFP at the S2 
position generates an ester bond between the first methionine (M1) and the incorporated 
2 which is highly susceptible to hydrolysis catalyzed by methionine aminopeptidase, an 
essential gene in E. coli. The mass peak for the major component of the purified sfGFP-2 
did match that of the protein without M1. To independently confirm the incorporation of 
4, 4 was genetically incorporated at the Q204 position of GFPUV. The purified protein 
was digested by Asp-N protease and the target fragment N-DNHYLSTXSALSK-C (X 
denotes 4) was analysed and confirmed by tandem mass spectrometry. (Figure III-7). 
Importantly, the isotope pattern observed for the selenium containing peptide fragment 
matches the theoretical isotope pattern. (Figure III-8)  
With our initial success, we next moved on to synthesize histone H3 with 3 or 4 
incorporated at its K9 position. Both 3 and 4 are susceptible to oxidative elimination to 
generate dehydroalanine after their incorporation into H3 (Scheme III-2). 3 is an S-
alkylcysteine that may be converted to dehydroalanine using O-
mesitylenesulfonylhydroxyl amine (MSH);113 4 is a Se-alkylselenocysteine that could be 
specifically oxidized by H2O2 to form dehydroalanine. To express H3 incorporated with  
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Table III-1: Theoretical and detected average molecular weight of sfGFP with different 
NAAs incorporated at its S2 position. 
Proteins[a] Theoretic MWavg (Da) Detected MWavg (Da) 
sfGFP-1 27903 27903 
sfGFP-2 27904[b] 
27773[c] 
27904[b] 
27774[c] 
sfGFP-3 27921 27922 
sfGFP-4 27968 27968 
[a] sfGFP-1 contains 1 at S2 position; sfGFP-3 contains 3 at its S2 position; sfGFP-4 
contains 4 at its S2 position. [b] Full length sfGFP-2. [c] sfGFP-2 without M1.  
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Figure III-3: Mass determination of the protein sfGFP-1: (A) ESI-IM-MS spectrum of 
sfGFP-1 and (B) the deconvoluted ESI-IM-MS spectrum of sfGFP-1. 
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Figure III-4: Mass determination of the protein sfGFP-2: (A) ESI-IM-MS spectrum of 
sfGFP-2 and (B) the deconvoluted ESI-IM-MS spectrum of sfGFP-2. 
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Figure III-5: Mass determination of the protein sfGFP-3: (A) ESI-IM-MS spectrum of 
sfGFP-3 and (B) the deconvoluted ESI-IM-MS spectrum of sfGFP-3. 
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Figure III-6: Mass determination of the protein sfGFP-4: (A) ESI-IM-MS spectrum of 
sfGFP-4 and (B) the deconvoluted ESI-IM-MS spectrum of sfGFP-4. 
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Figure III-7: GFP-4 MALDI-MS/MS analysis on fragment DNHYLSTXALSK. X 
represents 4. 
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Figure III-8: GFP-4 MALDI-MS/MS analysis on fragment DNHYLSTXALSK. X 
represents 4. The Se isotopic patterns were clear in fragments y7, y8, y9 and b8. 
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Scheme III-2: Oxidative elimination reactions to generate Dha that undergoes Michael 
addition reactions to form different posttranslational modification mimics. 
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3 or 4, the Xenopus laevis H3 gene with an amber mutation at its K9 position was used 
to replace the sfGFP gene in pET-sfGFP2TAG to afford pET-H3K9TAG. This plasmid 
together with pEVOL-mKRS1-pylT was used to cotransform E. coli BL21 cells that 
were subsequently grown in LB medium supplemented with either 3 or 4. Both 
conditions led to high H3 expression levels with 185 mg/L for 3 and 126 mg/L for 4 
(Figure III-9). Given that the expression level of wild type H3 at the same condition 
was 300 mg/L, these expression levels represented more than 50% of that of wild type 
H3 and are significantly better than the incorporation level of phenylselenocysteine. 
When both 3 and 4 were not provided in the medium, only a trace amount of H3 could 
be observed. The purified proteins both showed the expected mass when analyzed by 
ESI-MS. The observed mass peaks (H3 with 3 incorporated (H3K9-3): 16423 Da and 
16466 Da; H3 with 4 incorporated (H3K9-4): 16470 Da and 16513 Da) agreed well with 
the calculated mass (H3K9-3: 16423 Da and 16465 Da; H3K9-4: 16470 Da and 16512 
Da) (Figure III-10-11). 
Reaction of H3K9-3 with 8 M urea at pH 8.0 with 1000 eq. of MSH for 0.5 h 
failed to convert 3 to dehydroalanine. When the reaction time was prolonged, 
unexpected products were observed that did not correspond to the elimination product, 
indicating that MSH reacted with other amino acids in H3K9-3. Since H3K9-3 is fully 
denatured, the structure rigidity is not a factor that may influence the conversion.123 At 
this stage, we suspect the reaction itself is not favorable in 8 M urea. 
To convert 4 in H3K9-4 to dehydroalanine, we tried two oxidative reagents, 
sodium periodate and H2O2. Although it has been shown that sodium periodate can  
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Figure III-9.  The site-specific incorporation of 1, 3, and 4 at the K9 position of H3. 
Proteins were expressed in BL21 cells transformed with pEVOL-mKRS1-pylT and pET-
H3K9TAG in LB medium supplemented with 2 mM 1, 2 mM 3, or 1.5 mM 4. 
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1.5 mM 4 - - - +
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Figure III-10. Mass determination of the protein H3K9-3: (A) ESI-IM-MS spectrum of 
H3K9-3 and (B) the deconvoluted ESI-IM-MS spectrum of H3K9-3. 
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Figure III-11. Mass determination of the protein H3K9-4: (A) ESI-IM-MS spectrum of 
H3K9-4 and (B) the deconvoluted ESI-IM-MS spectrum of H3K9-4. 
  
(A) ESI-IMMS spectrum
(B) The deconvoluted result
m/z
600 650 700 750 800 850 900 950 1000 1050 1100 1150
%
0
100
22+
23+
24+
20+
19+
18+
17+
21+
16+
15+
mass
16200 16250 16300 16350 16400 16450 16500 16550
%
0
100
16469.6
16512.9
 109 
efficiently convert a derivatized selenocysteine to dehydroalanine in peptides, it 
apparently didn’t work on H3K9-4. Adducts that clearly indicated single and multiple  
oxygen atom(s) added to the protein were detected. On the contrary, oxidative 
elimination of H3K9-4 using H2O2 processed smoothly. In the presence of 100 eq. of 
H2O2, 4 in H3K9-4 was efficiently converted to dehydroalanine in 1 h. The ESI-MS 
analysis of the final product also indicated the oxidation of the two methionine residues 
in H3K9-4 to methionine sulfoxide (Figure III-12-14). The detected molecular mass 
(16244 Da and 16287 Da) agreed well with the calculated mass of H3 with 
dehydroalanine at its K9 position (H3K9Dha) that also has two oxidized methionine 
residues (16244 Da and 16286 Da). There is also one peak at 12229 Da that matched the 
mass of H3K9Dha with only one oxidized methionine residue (calculated mass: 16228 
Da). To convert dehydroalanine to N-acetylthialysine, a H3K9Dha was incubated 
together with 1500 eq. of N-acetylcysteamine at 25 degree for 1 h as shown in Scheme 
III-2. ESI-MS analysis of the final product indicated the quantitative conversion of 
dehydroalanine to N-acetylthialysine (Table III-2) (Figure III-15). Top down tandem 
MS analysis of the final product confirmed the site-specific installation of N-
acetylthialysine at the K9 position (Figure III-16-19).124-126 This top down tandem MS 
analysis also confirmed that an additional oxidation at M120 (Figure III-16-19). We 
performed similar reactions to convert dehydroalanine in H3K9Dha to N-
methylthialysine, N,N-dimethylthialysine, and N,N,N-trimethylthialysine by reacting 
H3K9Dha with corresponding cysteamine derivatives. (Figure III-20-22) The final  
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Figure III-12. Molecular weight determination of H3K9-4 after its treatment with 5eq 
H2O2. The deconvoluted singly charged ESI-MS spectrum by FT-ICR MS. Both H3K9-4 
and H3K9Dha were found. 
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Figure III-13. Molecular weight determination of H3K9Dha. The deconvoluted singly 
charged ESI-MS spectrum of H3K9Dha by FT-ICR MS. H3K9Dha was synthesized 
from H3K9-4 by treatment with 100 eq. H2O2 at room temperature for 1 h.  
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FigureIII- 14. Molecular weight determination of H3K9Dha: (A) ESI-IM-MS and (B) 
the deconvoluted spectra of H3K9Dha. H3K9Dha was synthesized from H3K9-4 by 
treatment with 100 eq. H2O2 at room temperature for 1 h.  
(A) ESI-IMMS spectrum
(B) The deconvoluted result
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products were analysed by Fourier transform ion cyclotron resonance (FT-ICR) MS.  As 
shown in Table III-2, the detected mass agreed well with the calculated mass. A similar 
reaction was also carried out to install phosphocysteine at the K9 position of H3 by 
reacting out to install phosphocysteine at the K9 position of H3 by reacting H3K9Dha 
with 1000 eq. of thiophosphate for 1 h at room temperature. The FT-ICR-MS analysis of 
the final product indicated a quantitative conversion. (Figure III-23) This chemically 
installed phosphocysteine was stable at the physiological pH. Storing the final product in 
a 4 degree fridge for a week did not show significant degradation. 
To demonstrate that N-methylthialysine, N,N-dimethylthialysine, and N,N,N-
trimethylthialysine can closely mimic their naturally counterparts, H3 with N-
methylthialysine installed at K9 (H3K9msK), H3 with N,N-dimethylthialysine installed 
at K9 (H3K9m2sK), and H3 with N,N,N-trimethylthialysine incorporated at K9 
(H3K9m3sK) were immunoprecipitated by heterochromatin protein 1HP-1that 
specifically binds to H3 with mono-, di-, or trimethylated lysine at K9 but not wild type 
H3. The immunoprecipitates were then probed by anti-H3 antibody that specifically 
recognizes the C-terminal domain of H3. All three proteins were pulled out by HP-1, 
showing intense bands when detected by anti-H3 antibody. Importantly, wild type H3 
was not immunoprecipitated by HP-1at all. To demonstrate N-acetylthialysine closely 
mimics N-acetyllysine, H3 with N-acetylthialysine incorporated at K9 (H3K9AcsK) 
was probed by anti-H3K9Ac antibody that was raised against H3 with N-acetyllysine at 
K9 in a Western blot analysis. The intense detected band for H3K9AcsK proved the 
specific interaction between H3K9AcsK and anti-H3K9Ac antibody. A similar assay for  
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Figure III-15. Molecular weight determination of the protein H3K9AcsK: (A) ESI-IM-
MS and (B) the deconvoluted spectra of H3K9AcsK. 
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Figure III-16. Top-down analysis of H3K9AcsK by CID-IM-MS. 
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Figure III-17. The extracted MS/MS spectrum for top-down analysis  
of H3K9AcsK by CID-IM-MS. The extracted MS/MS region was represented as red 
dotted line in Figure III-16. The spectrum was shown in zoom-in region of m/z 450-600. 
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Figure III-18. The extracted MS/MS spectrum for top-down analysis  
of H3K9AcsK by CID-IM-MS. The spectrum was shown in zoom-in region of m/z 250-
450. 
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Figure III-19. The summary of top-down analysis for H3K9AcsK by CID-IM-MS. This 
result indicates the AcsK modification site is between the protein sequences of R8 to 
S10.  ※ denotes the AcSK modification (M+60); +16  denotes methionine oxidation 
(M+16). The b fragment ions were represented in red and y in blue. 
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Table III-2. Theoretical and detected molecular weight of various H3 proteins. 
Proteins Theoretic MWavg (Da) Detected MWavg (Da) 
H3K9-3 16423[b] 
16465[c] 
16423[b] 
16466[c] 
H3K9-4 16470[b] 
16512[c] 
16470[b] 
16513[c] 
H3K9Dha 16228[d] 
16244[e] 
16270[f] 
16286[g] 
16229[d] 
16244[e] 
16287[g] 
H3K9AcsK 16347[d] 
16363[e] 
16389[f] 
16405[g] 
16363[e] 
H3K9mesK 16319[d] 
16335[e] 
16361[f] 
16377[g] 
16318[d] 
16334[e] 
16361[f] 
16377[g] 
H3K9m2sK 16333[d] 
16349[e] 
16375[f] 
16391[g] 
16332[d] 
16348[e] 
16391[g] 
H3K9m3sK 16348[d] 
16364[e] 
16390[f] 
16406[g] 
16347[d] 
16363[e] 
H3K9pC[a]  16342[d] 
16358[e] 
16384[f] 
16400[g] 
16341[d] 
16357[e] 
[a] H3K9pC contains phosphocysteine at its K9 position. [b] A full length protein without 
M1.  [c] A full length protein without M1 but containing the N-terminal acetylation. [d] A 
full length protein without M1 but containing one oxidized methionine residue. [e] A full 
length protein without M1 but containing two oxidized methionine residues. [f] A full 
length protein without M1 but containing one oxidized methionine residues and the N-
terminal acetylation. [g]. A full length protein without M1 but containing two oxidized 
methionine residues and the N-terminal acetylation. 
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Figure III-20. Molecular weight determination of Protein H3K9mesK. The 
deconvoluted singly charged ESI-MS spectrum of H3K9 H3K9mesK by FT-ICR MS. 
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Figure III-21. Molecular weight determination of Protein H3K9m2sK. The 
deconvoluted singly charged ESI-MS spectrum of H3K9 H3K9m2sK by FT-ICR MS. 
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Figure III-22. Molecular weight determination of Protein H3K9m3sK. The 
deconvoluted singly charged ESI-MS spectrum of H3K9 H3K9m3sK by FT-ICR MS. 
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Figure III-23. Molecular weight determination of Protein H3K9pC. The deconvoluted 
singly charged ESI-MS spectrum of H3K9 H3K9pC by FT-ICR MS.  
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wild type H3 did not give detectable signal. All these experiments clearly demonstrated 
that N-methylthialysine, N,N-dimethylthialysine, N,N,N-trimethylthialysine, and N-
acetylthialysine closely mimic their natural modified lysine counterparts in biological 
interactions. Given that all thialysine derivatives can be obtained from Michael addition 
reactions of dehydroalanine and the genetic incorporation of 3 into histones followed by 
oxidative elimination can lead to a large quantity of dehydroalanine-containing histones, 
the method we report here is an optimal choice to synthesize histones with different 
lysine modifications for their functional analysis. Although we did not do biochemistry 
analysis of H3 with phosphocysteine incorporated at K9, we believe phosphocysteine 
closely mimics phosphoserine and may mimic phosphothreonine. Since the reported 
method can be generalized to synthesize histones with phosphocysteine incorporated at 
sites that naturally have phosphoserine or phosphothreonine, this method can definitely 
be applied to study histone phosphorylation that is related to transcription regulation, 
DNA repair and cell division. 
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Conclusion 
In conclusion, we have developed a method to genetically incorporate a Se-
alkylselenocysteine into a histone protein in E. coli. The yield of the expressed histone 
can reach to 50% of its wild type counterpart. The selective oxidative elimination of Se-
alkylselenocysteine to form dehydroalanine and its following reaction with thiol-
containing small molecules allow the access of histones with several posttranslational 
modification mimics, including lysine methylation, lysine acetylation, and serine 
phosphorylation. The application of the reported method in the histone biology research 
area will facilitate addressing the questions such as how posttranslational modifications 
affect the chromatin structure, how these modifications regulate the interactions between 
chromatin and other non-chromatin regulatory proteins, and how modifications on 
chromatin cross regulate each other. 
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CHAPTER IV  
THE DE NOVO ENGINEERING OF PYRROLYSYL-TRNA SYNTHETASE FOR 
GENETIC INCORPORATION OF L-PHENYLALANINE AND ITS DERIVATIVES* 
 
Introduction 
Using orthogonal aminoacyl-tRNA synthetase (aaRS)-amber suppressor tRNA 
(tRNACUA) pairs, more than seventy NAAs have been site-specifically incorporated into 
proteins at amber mutation sites in E. coli, yeast, and mammalian cells.21, 23, 127-129 These 
NAAs provide new opportunities to generate proteins with novel properties and amend 
proteins with biochemical or biophysical probes for their structural and functional 
analysis. There are two broadly used aaRS-tRNACUA pairs for the NAA incorporation in 
E. coli, namely the MjTyrRS-       
   
 pair derived from Methanococcus jannaschii 
tyrosyl-tRNA synthetase-tRNATyr pair and the pyrrolysyl-tRNA synthetase (PylRS)-
        
   
 pair.26, 52, 112 Both pairs have their limitations. Although the MjTyrRS-
       
   
 pair has been proved powerful for the genetic code expansion in E. coli, NAAs 
that were genetically encoded using evolved MjTyrRS-       
   
 pairs must contain a - 
or -aromatic side chain24 and the MjTyrRS-       
   
 pair can not be directly used in  
____________ 
 
*Reprinted in part from “The de novo engineering of pyrrolysyl-tRNA synthetase for 
genetic incorporation of L-phenylalanine and its derivatives”, Yane-Shih Wang, William 
K. Russell, Zhiyong Wang, Wei Wan, Lindsey E. Dodd, Pei-Jing Pai, David H. Russell 
and Wenshe, R. Liu. Mol. Biosyst. 2011, 7, 714 - 717. Copyright 2011, with permission 
from The Royal Society of Chemistry. 
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yeast and mammalian cells (Liu W. R., unpublished data). It has been demonstrated that 
the PylRS-       
   
 pair is orthogonal in E. coli, yeast and mammalian cells.85, 96, 130, 131  
However, NAAs that were genetically encoded using the wild-type and evolved PylRS-
       
   
 pairs either are N-acylated lysine derivatives or contain a long aliphatic side 
chain.56, 66, 68, 85, 86, 96, 130, 131 An ideal aaRS-tRNACUA pair that resolves the 
aforementioned limitations would fulfill the two following requirements. First, it should 
be orthogonal in E. coli, yeast and mammalian cells. Therefore, the pair could be 
evolved simply and quickly in E. coli and subsequently transferred directly to yeast and 
mammalian cells, avoiding identification and evolution of every aaRS-tRNACUA pair in 
different cell lines. Second, the pair could be evolved for genetic incorporation of NAAs 
with diversified side chains that could be either short aromatic, long aromatic, or 
aliphatic. This would relieve the burden to identify unique orthogonal aaRS-tRNACUA 
pairs for NAAs with different side chains. Herein, we demonstrate that the PylRS-
       
   
 pair fulfills both requirements and can be engineered for genetic incorporation 
of NAAs with short aromatic side chains into proteins. The radical change of substrate 
specificity of PylRS from pyrrolysine (1 in Scheme IV-1) to L-phenylalanine, p-iodo-L-
phenylalanine, and p-bromo-L-phenylalanine (2, 3, 4 in Scheme IV-1) indicates 
powerful potentials of engineering PylRS for genetic incorporation of other NAAs with 
short aromatic side chains. This development is expected to greatly expand the inventory 
of NAAs that can be genetically incorporated into proteins in E. coli, yeast, and 
mammalian cells. Given that derivatives of an evolved MjTyrRS-       
   
 pair and a 
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wild-type or evolved PylRS-       
   
 pair can be coupled together for genetic 
incorporation of two different NAAs into one protein in E. coli,88, 132 this development 
makes it possible to incorporate two L-phenylalanine derivatives into one protein and 
will have potential applications in protein folding dynamics and enzyme mechanism 
studies.47, 133 
 
Experimental Section 
General Experimental 
The p-iodo-L-phenylalanine and p-bromo-L-phenylalanine were purchased form 
ChemImpex. 3-(Dansylamino)phenylbornic acid (DaFBA) was purchased from Sigma-
Aldrich. Z Domain, GFPUV, pylT and Methanosarcina mazei PylRS gene and protein 
sequences are the same as described in Chapter II, as well as plasmids pET-pylT-GFP, 
pET-pylT-GFP, pY+, pY- and pRS1 library used in the chapter.   
Plasmid Constructions 
The construction methods of plasmids pET-pylT-Z, pET-pylT-GFP, pY+ and 
pY- used in the work was described in the General Experimental section of Chapter II.  
Construction of pET-Z. The pET-Z plasmid was derived from pETDuet-1 
(NovagenTM).  Wild type Z domain gene was amplified from the pLeiZ plasmid. Two 
restriction sites, NdeI at the 5’ end and SacI at the 3’ end, were introduced in the PCR 
product which was subsequently digested and used to replace GFPUV in pET-pylT-GFP. 
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Selection Procedure for Evolving Pyrrolysyl-tRNA Synthetase 
The selections followed the scheme shown in Scheme II-2 by 1 mM 3. Five 
alternative selections (three positive (P) + two negative (N) with P-N-P-N-P order) 
finally yielded many colonies. 16 single colonies after the third positive selection were 
selected and the plasmids were isolated for sequencing. 4 single colonies from the third 
positive selection were also chosen for testing their ability to grow on plates with 102 
μg/mL chloramphenicol, 25 μg/mL Kan, 12 μg/mL Tet, and 1 mM of 3 or 5 mM of 4. A 
plate without NAA supplementary was used as a control. Images of colonies growing on 
different plates were shown in Figure IV-1. The positive selection of PylRS mutants 
specific for L-phenylalanine was carried out similarly as that for p-iodo-L-phenylalanine 
except that no noncanonical amino acid was supplemented into the medium. 
GFPUV and Z domain Protein Expression and Purification 
 To express GFPUV and Z domain incorporated with a NAA were performed by 
the method in the Experimental Section of Chapter II. To express wild-type Z-domain 
proteins (Z-wt), we transformed E. Coli BL21(DE3) cells with pET-Z. Cells were 
recovered in 1 mL LB medium for 1 h at 37 ºC before being plated on a LB agar plate 
containing Kan (50 μg/mL) and Amp (100 μg/mL). A single colony was then selected 
and grown overnight in a 10 mL culture. This overnight culture was used to inoculate 
100 mL LB medium supplemented with 100 μg/mL Amp. Cells were grown at 37ºC in 
an incubating shaker and protein expression was induced when OD600 reached 0.7 by 
adding IPTG to a final concentration of 1 mM. After 6 h induction, cells were harvested  
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Figure IV-1. Growth of 4 selected IFRS mutants from the third positive selection of 3 
on LB plates with different supplements. (1) Growth on LB/3CKT (LB agar plates 
containing 102 g/mL Cm, 25 g/mL Kan, and 12 g/mL Tet); (2) Growth on plates 
containing 1 mM 3, 102 g/mL Cm, 25 g/mL Kan, and 12 g/mL Tet; (3) Growth on 
plates containing 5 mM 4, 102 g/mL Cm, 25 g/mL Kan, and 12 g/mL Tet. All the 
colonies were cultured at 37oC for 24 hours.  Images were taken under UV 365 nm 
radiation. The pY+ plasmid has a GFPUV gene under control of a T7 promoter and a T7 
RNA polymerase gene that contains two amber mutations at positions 1 and 107. The 
expression of GFPUV is promoted by the suppression of two amber mutations in the T7 
RNA polymerase. The fluorescent intensity of the expression of GFPUV roughly 
represents the suppression efficiency at amber codons. 
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and resuspended in PBS buffer. Further protein purification was the same as that for Z-3.  
The purified protein was analyzed by 15% SDS-PAGE. 
Suzuki Coupling on the Z-domain Proteins 
A water-souble palladium catalyst using 2-amino-4,6-dihydroxyprimidine as its 
ligand was prepared according to the literature protocol, and the coupling of Z-3 with 3-
(dansylamino)phenylboronic acid (DaFBA) was carried out accordingly with minor 
modification. Z-wt was used as a control. To a protein sample of The buffer of 50 L of 
Z-3 (0.5 mg/mL, 80 L, 4.9 nmol) or Z-wt (0.4 mg/mL, 80 L, 3.9 nmol) in 0.1× PBS 
solution (1 mM Na2HPO4, 0.18 mM KH2PO4, 13.7 mM NaCl, 0.27 mM KCl, pH 7.4) 
was added the palladium catalyst in water (10 mM, 7 L, 70 nmol), aqueous formic acid 
(20 mM, 3 L, 60 nmol)  and DaFBA in DMSO (20 mM, 20 L, 400 nmol). The 
mixture was vortexed and then heated in a 35 oC water bath for 6 h. After dialysis 
against 0.1× PBS overnight (2L × 2, 8 h each time) to remove excessive dye and 
catalyst, the protein samples were lyophilized, redissolved in 10 L of 8 M urea, and 
analyzed by the SDS-PAGE (15%) electrophoresis. 
Protein LC-ESI-MS Analysis 
An Agilent (Santa Clara, CA) 1200 capillary HPLC system was interfaced to an 
API QSTAR Pulsar Hybrid QTOF mass spectrometer (Applied Biosystems/MDS Sciex, 
Framingham, MA) equipped with an electrospray ionization (ESI) source. Liquid 
chromatography (LC) separation was achieved using a Phenomenex Jupiter C4 
microbore column (150 × 0.50 mm, 300 Å) (Torrance, CA) at a flow rate of 10 μL per 
 132 
min. The proteins were eluted using a gradient of (A) 0.1% formic acid versus (B) 0.1% 
formic acid in acetonitrile. The gradient timetable was as follows: 2% B for 5 min, 2-
30% in 3 min, 30-60% in 44 min, 60-95% in 8 min, followed by holding the gradient at 
95% for 5 min, for a total run time of 65 min. The MS data were acquired in positive ion 
mode (500-1800 Da) using spray voltage of +5000 V. BioAnalyst software (Applied 
Biosystems) was used for spectral deconvolution. For the GFPuv protein analysis, a 
mass range of m/z 500-1800 was used for deconvolution and the output range was 
10000-50000 Da using a step mass of 0.1 Da and a S/N threshold of 20. For the Z-
Domain protein analysis, a mass range of m/z 500-2000 was used for deconvolution and 
the output range was 5000-15000 Da for Z-domain-His6X using a step mass of 0.1 Da 
and a S/N threshold of 20. 
Tandem Mass Spectrametry analysis 
GFPUV variants from the SDS-PAGE gels was cut, dissolved in 25 mM 
Ammonia bicarbonate, and denatured at 90 degree for 15 min. Proteinase Asp-N 
(Roche) was dissolved in 0.01% TFA (pH 3). Proteinase Asp-N solution was added to 
the substrate protein solution (w/w=1:50), and incubated at 37 degree overnight. 
Peptides resulting from the proteinase Asp-N digestion were mixed 1:1 (v/v) with matrix 
(5 mg mL-1 α-cyano-4-hydroxycinnamic acid, 50% (v/v) acetonitrile, 10 mM 
ammonium dihydrogen phosphate, 1% TFA) and 1 μL of the resulting mixture was 
spotted onto a stainless steel target plate. Mass spectra and tandem MS spectra were 
collected using an Applied Biosystems 4800 Tof/Tof (Framingham, MA). Collision 
induced dissociation tandem MS spectra were acquired using air at the medium pressure 
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setting and at 2 kV of collision energy. Tandem MS data was manually interpreted using 
the Data Explorer™ software package (Applied Biosystems, Framingham, MA). 
 
Results and Discussion 
In order to evolve a PylRS mutant that specifically acylates        
   
 with L-
phenylalanine, we carried out a standard positive selection of the pRS1 plasmid library 
in E. coli. The pRS1 plasmid library contains the Methanosarcina mazei PylRS gene 
with randomization at six active-site residues (L305, Y306, L309, N346, C348, and 
W417; Figure II-1).68 The selection was based on the resistance to chloramphenicol, 
which was conferred by suppressing a permissive amber mutation in the 
chloramphenicol acetyltransferase gene in the minimal medium.23, 52 Cells containing 
PylRS mutants that acylate        
   
 with natural amino acids survive the selection. 
Screening the survived clones revealed two PylRS mutants (FRS1 and FRS2 in Table 
IV-1) that are specific for L-phenylalanine. Both clones contain the mutation N346A. 
This mutation apparently removes the steric clashes between the -amide of N346 and 
the aromatic side chain of L-phenylalanine that prevent the binding of L-phenylalanine to 
the wild-type PylRS. C348 in both FRS1 and FRS2 is mutated to a larger amino acid that 
reduces the size of the active site to better accommodate L-phenylalanine. Site-specific 
incorporation of L- phenylalanine at an amber mutation at Q204 of GFPUV using the 
FRS1-       
   
 pair or the FRS2-       
   
 pair in the GMML medium (liquid glycerol 
minimal medium containing 0. 3 mM L-leucine) supplemented with 1 mM L-  
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Scheme IV-1. Structures of pyrrolysine, L-phenylalanine, p-iodo-L-phenylalanine, and 
p-bromo-L-phenylalanine 
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Table VI-1. Selected PylRS mutants.  
PylRS L305 Y306 L309 N346 C348 W417 
FRS1 L Y L A L W 
FRS2 L Y L A K W 
IFRS1 (9/16)a M L S S M W 
IFRS2 (3/16) a L Y L A M L 
IFRS3 (3/16) a L T A S M W 
IFRS4 (1/16) a L T R S M W 
a The occurring frequency of a selected mutant in all sequenced clones. 
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Figure IV-2: Suppression of the amber mutation at Q204 of GFPUV by the FRS1-, 
FRS2-, and IFRS1-       
   
 pairs at different conditions. The gel was stained by 
Gelcode blue. All GFPUV proteins are expressed in 500 mL GMML, purified and 
concentrated to 250 L. 10 L of each sample was loaded and analyzed by the SDS-
PAGE.  
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phenylalanine afforded the full-length GFPUV (Figure IV-2). The yields of the full-
length GFPUV expression were ~1.6 mg/L for the FRS1-       
   
 pair and ~2.9 mg/L for 
the FRS2-       
   
 pair. In the absence of L-phenylalanine in the GmmL medium, only 
a trace amount of the full-length GFPUV could be detected. The electrospray ionization 
mass spectrometry (ESI-MS) analysis of the expressed full-length GFPUV proteins show 
molecular weights (27,730 Da for the FRS1-       
   
 pair and 27,729 Da for the FRS2-
       
   
 pair) that agree well with the calculated mass (27,729 Da) of the full-length 
GFPUV with L-phenylalanine incorporated at Q204 but without the N-terminal 
methionine (Figures IV-3 & 4). The hydrolysis of the N-terminal methionine from 
GFPUV has been observed in several similar studies.
55, 68, 96, 134 The incorporation of L-
phenylalanine at Q204 was also independently confirmed by the tandem mass spectral 
(MS-MS) analysis of endoproteinase Asp-N-digested fragments of the purified full-
length GFPUV proteins. The tandem mass spectra of the fragment of 
DNHYLSTF*SALSK (F* denotes the designated L-phenylalanine) validated the 
incorporation of L-phenylalanine at Q204. The observed F*-containing ions (y6 to y13 
and b8 to b13) all had expected mass (Figures IV-5A & B).  
Since L-phenylalanine is a canonical aromatic amino acid, we further tested 
whether PylRS could be evolved to specifically acylate        
   
  with a noncanonical 
short aromatic amino acid. We chose to work on p-iodo-L-phenylalanine because its 
genetic incorporation into proteins may facilitate protein structure determination and 
serve as an anchor to label proteins through the Suzuki-Miyaura cross-coupling  
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Figure IV-3. Mass determination of GFPUV incorporated with L-phenylalanine at Q204 
using the FRS1-       
    pair. (A) The ESI-MS spectrum and (B) the deconvoluted ESI-
MS spectrum. 
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Figure IV-4. Mass determination of GFPUV incorporated with L-phenylalanine at Q204 
using the FRS2-       
    pair. (A) The ESI-MS spectrum and (B) the deconvoluted ESI-
MS spectrum. 
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Figure IV-5: Tandem mass spectra of the DNHYLSTF*SALSK (F* denotes L-
phenylalanine or its derivatives) fragments from the full-length GFPUV protein. (A) The 
full-length GFPUV was expressed using the evolved FRS1-       
    pair in the presence 
of 1 mM L-phenylalanine. (B) The full-length GFPUV was expressed using the evolved 
FRS2-       
    pair in the presence of 1 mM L-phenylalanine. (C) The full-length 
GFPUV was expressed using the evolved IFRS1-       
    pair in the presence of 1 mM 
p-iodo-L-phenylalanine. (D) The full-length GFPUV was expressed using the evolved 
IFRS1-       
   
 pair in the presence of 5 mM p-bromo-L-phenylalanine.  
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reaction.94, 135 The pRS1 plasmid library was passed through rounds of alternative 
positive and negative selections according to a standard protocol23 to identify PylRS  
mutants that are specific for p-iodo-L-phenylalanine. The positive selection was carried 
out similarly to the selection of L-phenylalanine-specific PylRS mutants except that 1 
mM p-iodo-L-phenylalanine was supplemented in the medium. The negative selection 
utilized the toxic barnase gene with amber mutations at two permissive sites and was 
carried out in the LB medium with the absence of p-iodo-L-phenylalanine. PylRS 
mutants that acylate        
   
 selectively with p-iodo-L-phenylalanine survive both 
positive and negative selections. After five rounds of selections, sixteen survived clones 
were validated and sequenced. They converged to four unique mutants (IFRS1-IFRS4 in 
Table IV-1). The most abundant mutant, IFRS1, was further characterized. When the 
IFRS1-       
   
 pair was used to suppress the amber mutation at Q204 of GFPUV in the 
presence of 1 mM p-iodo-L-phenylalanine, full-length GFPUV was produced. The 
expression yield of the full-length GFPUV in the GMML medium was ~1.0 mg/L (Figure 
IV-2). The ESI-MS detected mass (27,855 Da) of the purified protein matched perfectly 
well with the calculated mass (27,855 Da) of the full-length GFPUV with p-iodo-L-
phenylalanine incorporated at Q204 but without the N-terminal methionine (Figure IV-
6). In contrast, only a negligible amount of full-length GFPUV was expressed when p-
iodo-L-phenylalanine was absent. These results indicate that the IFRS1-       
   pair 
specifies p-iodo-L-phenylalanine but not any canonical amino acids. Since p-bromo-L-
phenylalanine and p-iodo-L-phenylalanine are structurally similar, we suspected that  
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Figure IV-6. Mass characterization of GFP-3. (A) The ESI-MS spectrum and (B) the 
deconvoluted ESI-MS spectrum. 
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Figure IV-7. Mass characterization of GFP-4. (A) The ESI-MS spectrum and (B) the 
deconvoluted ESI-MS spectrum. 
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IFRS1 might also acylate        
   
  with p-bromo-L- phenylalanine. When the IFRS1-
       
   pair was used to suppress the amber mutation at Q204 of GFPUV in the 
presence of 5 mM p-bromo-L-phenylalanine, the full-length GFPUV was also produced. 
The expression yield in GMML medium was ~0.8 mg/L. The ESI-MS detected mass 
(27,809 Da) of the purified protein agreed well with the calculated mass (27,808 Da) of 
the full-length GFPUV with p-bromo-L-phenylalanine incorporated at Q204 but without 
the N-terminal methionine (Figure IV-7). The observed small peak at 26,210 Da may 
due to a protein contaminant. To independently confirm the incorporation of p-iodo-L-
phenylalanine and p-bromo-L-phenylalanine at Q204 of the expressed GFPUV proteins, 
the purified proteins were digested by endoproteinase Asp-N. The digested fragments 
were then subjected to the MS-MS analysis. As Figure IV-5C shows, the tandem mass 
spectrum of the p-iodo-L-phenylalanine-containing fragment of DNHYLSTF*SALSK 
(F* denotes p-iodo-L-phenylalanine) validated the incorporation of L-phenylalanine at 
Q204. The observed F*-containing ions (y6 to y13 and b8 to b13) all had expected mass. 
Similarly, the observed F*-containing ions of the p-bromo-L-phenylalanine-containing 
fragment of DNHYLSTF*SALSK (F* denotes p-bromo-L-phenylalanine) all had 
expected mass (Figure IV-5D). The mass peaks for two bromine isotopes were clearly 
observed, supporting the site-specific incorporation of p-bromo-L-phenylalanine at Q204 
(Figure IV-8-9). 
Davis et al. recently demonstrated that a palladium complex with 2-amino-4,6-
dihydroxypyrimidine could efficiently catalyze the cross-coupling between an 
arylboronic acid and an aryl iodide that was covalently installed on a protein.135 We  
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 Figure IV-8. Tandem mass spectrametry analysis predicted two bromine isotopes is 
observed in the y8 fragment of p-bromo-L-phenylalanine-containing DNHYLSTF*SALSK 
(F* denotes p-bromo-L-phenylalanine).  
 
  
 146 
 
 
 
 
 
 
Figure IV-9. Tandem mass spectrametry analysis predicted two bromine isotopes is 
observed in the y7 fragment of p-bromo-L-phenylalanine-containing DNHYLSTF*SALSK 
(F* denotes p-bromo-L-phenylalanine). 
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suspected that similar reactions might allow the labeling of proteins containing p-iodo-L-
phenylalanine. The palladium complex was synthesized according to the literature 
procedure.135 This catalyst was subsequently used to catalyze the reaction between the Z-
domain protein containing p-iodo-L-phenylalanine and a dye, 3- 
 (dansylamino)phenylboronic acid. The incorporation of p-iodo-L-phenylalanine at an 
amber mutation at K7 of Z-domain was achieved in E. coli using the IFRS1-
       
   
 pair. The ESI-MS analysis of the expressed Z-domain indicated three forms: 
the full-length Z domain without the N-terminal methionine, the full-length Z-domain, 
and the full-length Z-domain without the N-terminal methionine but with an N-terminal 
acetylation (Table IV-2 & Figure IV-10-11), which have also been observed in other 
similar studies.68, 93, 94, 97 This mutant Z-domain protein does not contain any cysteine 
that can potentially toxify the synthesized palladium catalyst. The 5h reaction between 
the mutant Z-domain and 3-(dansylamino)phenylboronic acid yielded a labeled Z-
domain protein. When the labeled protein was denatured and analyzed in a SDS-PAGE 
gel, it showed a strong yellow fluorescence band under long wavelength UV light (365 
nm) (Figure IV-12). The same labeling reaction between the wild-type Z-domain 
protein and the dye did not give any detectable yellow fluorescent protein. These results 
indicate that the labeling reaction was site-specific at p-iodo-L-phenylalanine in the 
mutant Z-domain protein. 
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Figure IV-10. The expression of Z-domain containing an amber mutation at K7. 
Proteins were expressed in BL21(DE3) cells that grew in minimal media supplemented 
with 1% glycerol and 1 mM 3. The proteins were analyzed by SDS-PAGE (15%) gel 
electrophoresis with gelcole blue staining. 
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Figure IV-11. Mass characterization of Z-3. (A) The ESI-MS spectrum and (B) the 
deconvoluted ESI-MS spectrum. 
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Table IV-2. GFPUV and Z-domain expression yields and MS characterizations 
Proteins Yield (mg/L)j Calculated Mass (Da) Detected Mass (Da) 
GFP-3
 a
 1.0 27855f 27855 
GFP-4
 b 0.8 27808f 27810 
Z-3
 c
 1.5 
8281g 
8192h 
8150i 
8280 
8191 
8149 
GFP-F
d
 1.6 27729f 27730 
GFP-F
e
 2.9 27729f 27729 
aGFPUV incorporated with p-iodo-L-phenylalanine at Q204.  
bGFPUV incorporated with p-bromo-L-phenylalanine at Q204.  
cZ-domain incorporated with p-iodo-L-phenylalanine at K7.  
dGFPUV incorporated with L-phenylalanine at Q204 that was expressed in the LB 
medium using the FRS1- PylCUAtRNA pair.  
eGFPUV incorporated with l-phenylalanine at Q204 that was expressed in the LB medium 
using the FRS2- PylCUAtRNA pair.  
fFull-legnth GFPUV proteins without N-terminal methionine.  
gFull-legnth Z domain proteins.   
hFull-length Z domain without N-terminal methionine but with an N-terminal 
acetylation.  
iFull-length Z-domain without N-terminal methionine.  
jThe yields were determined by the BCA protein assay. 
 
 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV-12: Site-selective labeling of Z-domain incorporated with p-iodo-L-
phenylalanine (Z-3). (A) The Suzuki-Miyaura cross-coupling reaction between a p-iodo-
L-phenylalanine-containing protein and 3-(dansylamino)phenylboronic acid (5). (B) The 
Gelcode blue staining of Z-3 and the wild-type Z-domain protein (Z-wt) that were 
labeled with 5. (C) Thhe fluorescent imaging of the same gel when excited by 365 nm 
UV light. The fluorescent image shows real colors captured by a regular camera.   
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Conclusion 
In summary, we have demonstrated that PylRS can be mutated to 
acylated         
   
 with L-phenylalanine and its derivatives whose side-chain structures 
are drastically different from pyrrolysine. We expect the structural information obtained 
from these PylRS mutants will further facilitate the engineering of PylRS for genetic 
incorporation of other NAAs with short aromatic side chains, including 3-nitro-L-
tyrosine, O-sulfo-L-tyrosine, 3,4-dihydro-L-phenylalanine, 3-amino-L-tyrosine, p-cyano-
L-phenylalanine, etc. Given the fact that the PylRS-       
   
 pair has been used to 
genetically incorporate NAAs into proteins in E. coli, yeast, and mammalian cells, this 
breakthrough will greatly expand the inventory of genetically encoded NAAs and our 
abilities to do protein engineering in these cells. This development also makes it possible 
to incorporate two different L-phenylalanine derivatives into one protein in E. coli using 
an evolved MjTyrRS-       
    pair and an evolved PylRS-       
   
 pair and has 
potential applications in enzyme mechanism and protein dynamics analysis. For 
example, two tyrosine derivatives that have different redox potentials or different pKa’s 
can be incorporated at two catalytic tyrosine sites in the ribonucleotide reductase to 
clarify the catalytic roles of these tyrosine residues in the enzyme. 
 153 
CHAPTER V  
A RATIONALLY DESIGNED PYRROLYSYL-TRNA SYNTHETASE MUTANT 
HAS A BROAD SUBSTRATE SPECIFICITY* 
Introduction 
In the past decade, we have seen the genetic incorporation of many noncanonical 
amino acids (NAAs) into proteins at nonsense mutation sites in Escherichia coli, 
Saccharomyces cerevisiae, and mammalian cells using unique aminoacyl-tRNA 
synthetase (aaRS)-nonsense suppressing tRNA pairs that do not cross interact with 
endogenous aaRS-tRNA pairs.21, 23, 24, 52, 128, 129, 136 Except the wild-type pyrrolysyl-tRNA 
synthetase (PylRS) that has been directly used for the genetic incorporation  >10 
NAAs26, 83, 85, 112, 131, most of these unique aaRSs were evolved via complicated positive 
and negative selection systems.21, 23, 92, 98, 137, 138 So far, evolution is still the primary 
approach to identify NAA-specific aaRSs. The prerequisites of the referred aaRS 
evolution are the construction of a large mutant aaRS gene library and a readily available 
selection system.23 Although several easily accessible selection systems have been 
developed for E. coli and S. cerevisiae cells, constructing a large mutant aaRS gene 
library that most of time needs to cover random variations of 5-6 aaRS active site 
residues is not straightforward and needs an experienced molecular biologist to practice 
____________ 
 
*Reprinted in part from “A rationally designed pyrrolysyl-tRNA synthetase mutant with a 
broad substrate spectrum”, Yane-Shih Wang, Xinqiang Fang, Ashley L. Wallace, Bo 
Wu, and Wenshe, R. Liu. J. Am. Chem. Soc. 2012, 134, 2950 - 2953. Copyright 2012, 
with permission from American Chemical Society. 
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many times to achieve close to the coverage of the library variations.97 Statistically, full 
coverage is not likely. One factor that also significantly influences the aaRS evolution is 
the selection pressure. Positive and negative selections used in the evolution are based 
on either antibiotic resistance or toxic gene expression. Varying concentrations of 
antibiotics and inducers that are used to trigger toxic gene expression could lead to 
dramatic different evolution results. In comparison to the evolution approach, rational 
design of aaRSs is relatively more straightforward and easier to be carried out by 
following standardized site-directed mutagenesis protocols. However, attempts to 
rationally design unique NAA-specific aaRSs often led to mutant aaRSs with 
nonexclusive recognition of endogenous canonical amino acids. 139, 140 139, 140 138, 139, 140, 89 
In this work, we show that a rationally designed PylRS mutant N346A/N348A displays 
exclusive binding toward NAAs and has a broad substrate spectrum.  
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Experimental Sections 
Chemical Synthesis 
Compounds 1 and 2 were synthesized according to literature procedures. 
Compounds 3 and 4 were synthesized via the route showed in Scheme 1. Compounds 5-
7, 9-15 are commercial available from Chem-Impex International Inc. 
Typically, to a 500 mL of round-bottom-flask was added L-Tyrosine (18.2 g, 0.1 
mol), followed by THF (100 mL) and NaOH aqueous (1.0 M, 110 mL, 0.11 mol). The 
reaction mixture was cooled to 0oC. Di-tert-butyl dicarbonate (24.2 g, 0.11 mol) was 
dissolved in THF (100 mL) and added to the above mixture dropwise over 40 min. Then 
the resulting mixture was stirred at room temperature for 20 h. THF was removed under 
reduced pressure. The residue was diluted with water (100 mL), and extracted with 
EtOAc (100 mL). The aqueous layer was collected and acidified to pH = 3 with HCl (1.0 
M in water), then extracted with EtOAc (100 mL × 3). The combined organic layers 
were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 
compound 9 (22.7 g, 81% yield). Compound 9 was pure enough for the next step 
without further purification. 
To a 500 mL of round-bottom-flask was added compound 9 (22.7 g, 0.081 mol), 
4-(dimethyl- amino)pyridine (DMAP, 4.9 g, 0.04 mol), p-toluenesulfonic acid 
monohydrate (p-TSA, 7.7g, 0.04 mol) and MeOH (250 mL). N,N′-
dicyclohexylcarbodiimide (DCC, 16.7 g, 0.081 mol) was dissolved in CH2Cl2 (50 mL) 
and added dropwise to the above solution over 1 h. Then the resulting mixture was 
stirred at room temperature for 20 h. The solvents were removed under reduced pressure  
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Scheme V-1. Synthesis of compounds 3 and 4. 
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and the residue was diluted with EtOAc (150 mL). Then the reaction mixture was 
filtered through Celite and washed with EtOAc (100 mL × 3). The filtrate was dried over 
anhydrous Na2SO4 and then concentrated under reduced pressure to afford product 10 
(18.7 g, 78% yield). Compound 10 was pure enough fot the next step without further 
purification. 
To a 100 mL of round-bottom-flask was added sequentially compound 10 (2.9 g, 
0.0098 mol), K2CO3 (1.63g, 0.0118 mol), 4-bromo-1-butene (1.19 mL, 0.118 mol) and 
anhydrous DMF (10 mL). The resulting mixture was stirred at room temperature for 24 
h. Then diluted with EtOAc (30 mL), and washed with HCl (1.0 M in water, 10 mL × 3). 
The organic layer was collected and dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. The residue was purified via column chromatography on silica 
gel with hexanes/EtOAc (10:1 v/v) as eluent to afford the pure product 11 (1.3g, 38% 
yield). 
  Compound 11 (1.3g, 0.00372 mol) was dissolved in THF (5 mL), and NaOH 
aqueous (1.0 M, 4.8 mL) was added dropwise. The mixture was stirred at room 
temperature for 2 h, and then diluted with water (10 mL), extracted with Et2O (20 mL). 
The aqueous layer was collected, and adjusted to pH = 1 with HCl (3.0 M in water). 
Then the resulting mixture was extracted with EtOAc (10 mL × 2) and the combined 
organic layers were dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to get compound 13, which was used directly in the next step without further 
purification.  
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  Compound 13 obtained from the above step was all dissolved in anhydrous 
dioxane (5 mL), and followed by an injection of HCl/dioxane solution (4.0 M, 1.86 mL). 
The resulting mixture was stirred at room temperature for 12 h. The white solid was 
collected by filtration and washed sequentially with EtOAc (5 mL) and CH2Cl2 (5 mL), 
then dried under vacuum using oil pump to afford the final product 3 as a white solid 
(0.5g, 47% over two steps). 1H NMR (CD3OD, 300 MHz) 2.35-2.41 (m, 2 H), 2.99 (dd, 
1H, J = 7.5, 14.7 Hz), 3.12 (dd, 1H, J = 5.4, 14.7 Hz), 3.88 (t, 2H, J = 6.6 Hz), 4.08 (dd, 
1H, J = 5.4, 7.5 Hz), 4.92-5.06 (m, 2H), 5.75-5.84 (m, 1H), 6.78 (d, 2H, J = 8.7 Hz), 
7.09 (d, 2H, J = 8.7 Hz); 13C NMR (CD3OD, 75 MHz) 34.7, 36.4, 55.2, 68.4, 116.1, 
117.2, 127.3, 131.6, 135.9, 160.0, 171.3; HRMS (ESI) calcd for C13H18NO3 (M
+-Cl) 
236.1287, found 236.1282. 
Compound 4 was synthesized using the similar procedure showed above, except 
that 5-bromo-1-butene was used instead of 4-bromo-1-butene. Product 4 was gotten as a 
white solid. 1H NMR (CD3OD, 300 MHz) 1.59-1.68 (m, 2H), 1.98-2.05 (m, 2H), 1.98-
2.05 (m, 2H), 2.93 (dd, 1H, J = 7.5, 14.7 Hz), 3.05 (dd, 1H, J = 5.7, 14.7 Hz), 3.76 (t, 
2H, J = 6.3 Hz), 4.00 (dd, 1H, J = 5.7, 7.5 Hz), 4.75-4.81 (m, 2H), 5.59-5.72 (m, 1H), 
6.70 (d, 2H, J = 8.7 Hz), 7.02 (d, 2H, J = 8.7 Hz); 13C NMR (CD3OD, 75 MHz) 29.6, 
31.2, 36.4, 55.2, 68.2, 115.6, 116.0, 127.1, 131.6, 139.1, 160.1, 171.2; HRMS (ESI) 
calcd for C14H20NO3 (M
+-Cl) 250.1443, found 250.1438. 
DNA and Protein Sequence 
Gene and protein sequences of pylT, Methanosarcina mazei PylRS and sfGFP 
were listed in the DNA sequence of Experimental Section in Chapter III. 
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Methanosarcina mazei PylRS: 
MDKKPLNTLISATGLWMSRTGTIHKIKHHEVSRSKIYIEMACGDHLVVNNSRSS
RTARALRHHKYRKTCKRCRVSDEDLNKFLTKANEDQTSVKVKVVSAPTRTKK
AMPKSVARAPKPLENTEAAQAQPSGSKFSPAIPVSTQESVSVPASVSTSISSISTG
ATASALVKGNTNPITSMSAPVQASAPALTKSQTDRLEVLLNPKDEISLNSGKPFR
ELESELLSRRKKDLQQIYAEERENYLGKLEREITRFFVDRGFLEIKSPILIPLEYIER
MGIDNDTELSKQIFRVDKNFCLRPMLAPNLYNYLRKLDRALPDPIKIFEIGPCYR
KESDGKEHLEEFTMLNFCQMGSGCTRENLESIITDFLNHLGIDFKIVGDSCMVYG
DTLDVMHGDLELSSAVVGPIPLDREWGIDKPWIGAGFGLERLLKVKHDFKNIKR
AARSESYYNGISTNL 
The bold and underline letters indicate the chosen amino acids, N346 and C348 
for mutations. 
Construction of Plasmids 
The construction of pET-pylT-sfGFPS2TAG was described in Experimental 
Section of Chapter III. 
Construction of pBK- PylRS(N346A/C348A) 
To construct the pBK-PylRS(N346A/C348A) plasmid with N346A and C348A 
mutation was introduced by overlap extension PCR from pBK- mmPylRS plasmid. The 
following pairs of primers were used to generate a PylRS(N346A/C348A) gene: (1) 
pBK-mmPylRS-NdeI-F (5'-gaatcccatatggataaaaaaccactaaacactctg-3') and PylRS-
N346A/C348A-R -R (5'- cccgtgtgcatcccgatcccatctgcgcgaacgccagcatggtaaactcttcgaggtg -
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3'); (2) PylRS-N346A/C348A-F (5'- cacctcgaagagtttaccatgctggcgttcgcgcagatgggatc 
gggatgcacacggg -3') and pBK-mmPylRS-PstI~NsiI-R (5'-gtttgaaaatgcatttacaggt 
tggtagaaatccc-3'). The gene PylRS(N346A/C348A) was digested with the restriction 
enzymes NdeI and NsiI, gel-purified, and ligated back into the pBK vector digested by 
NdeI and PstI to afford plasmid pBK- PylRS(N346A/C348A). 
Construction of pEVOL-pylT-PylRS(N346A/C348A) 
The pEVOL-pylT-PylRS(N346A/C348A) plasmid was derived from the 
pEVOL-pylT plasmid with sequential insertion of two copies of the PylRS-
N346A/C348A gene.  The PylRS-N346A/C348A gene was amplified from the pBK- 
PylRS-N346A/C348A plasmid by flanking primers, pEVOL-PylRS-SpeI-F and pEVOL-
PylRS-SalI-R, digested by SpeI and SalI restriction enzymes, and ligated to a precut 
pEVOL-pylT plasmid. The resulted plasmid is pEVOL-pylT-PylRS-N346A/C348A. 
sfGFP Expression and Purification and Fluorescence Intensity Test 
sfGFP proteins incorporated with 2-6, 8-15 in 2 mM and 7 in 1 mM were 
expressed and purified similarly as the method of GFPUV in Protein Expression and 
Purification of  Experimental Section in Chapter II. To express sfGFP incorporated with 
a natural amino acid (AA), E. Coli BL21(DE3) cells were cotransformed with pEVOL-
pylT-PylRS(N346A/C348A) and pET-sfGFP2TAG. Cells were recovered in 1 mL of LB 
medium for 1 h at 37 ºC before being plated on LB agar plate containing 
chloramphenicol (Cm) (34 μg/mL) and ampicillin (Amp) (100 μg/mL). A single colony 
was then selected and grown overnight in a 10 mL culture. This overnight culture was 
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used to inoculate 500 mL of GmmL minimal medium supplemented with 34 μg/mL Cm 
and 100 μg/mL Amp. Cells were grown at 37 ºC in an incubator (300 r.p.m.) and protein 
expression was induced when OD600 reached 1.0 by adding 1 mM IPTG, 0.2% arabinose 
and 5 mM AAs for 6 h. Cell lysate was purified by 1 mL bench-top Ni2+-NTA column 
and detected the fluorescence emission intensity at 510 nm by excitation wavelength 450 
nm. 
sfGFP-1 Protein Labeling 
To a solution of sfGFP-1 (0.03 mM, 270 μL) in PBS (pH 7.4) buffer was added 
CuSO4 ( 100 μM), NiCl2 (1 mM), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA, in DMSO, 500 μM) and 8 (50 equiv. to the protein) sequentially, followed by 
sodium ascorbate (5 mM). The reaction was performed under room temperature for 3 h. 
Then ethylenediaminetetraacetic acid (EDTA, 0.5 M, pH 8.0, 5 μL) was added to the 
reaction mixture to chelate the two metals. The reaction product was added into lysis 
buffer (50 mM HEPES, 500 mM NaCl, 10 mM imidazole, 10 mL, pH 7.8) with 1 mL 
Ni2+-NTA resin and incubated at 4 oC for 1 h. The resin was washed by lysis buffer (100 
mL), and then labeled sfGFP-1 was eluted out by elution buffer (50 mM HEPES, 500 
mM NaCl, 250 mM imidazole, 6 mL, pH 7.8), concentrated, dialysed against PBS buffer 
(pH 7.4). Wild type sfGFP was used as a control and the same reaction was performed 
on it with the same manner. The two product were then analyzed by the SDS-PAGE 
(12%) electrophoresis for fluorescence image (BioRadTM ChemiDoc XRS+ ) and further 
coomassie blue staining. 
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Results and Discussion 
We previously evolved two PylRS mutants that display specific recognition of 
phenylalanine.141 In both mutants, N346 is mutated to alanine and C348 is mutated to a 
larger amino acid, leucine or lysine. No mutation at other sites was found. Figure V-1 
shows the structure of the PylRS complex with pyrrolysyl-AMP. Phenylalanyl-AMP was 
also modeled into the active site of the N346A mutant of PylRS and is shown as an 
overlay with pyrrolysyl-AMP in Figure V-1. The structure in Figure V-1 clearly 
explains how two mutations N346A and C348L (or C348K) instigate the substrate 
specificity change from pyrrolysine to phenylalanine. The side-chain amide nitrogen of 
N346 forms a hydrogen bond with the side-chain amide oxygen of pyrrolysine, an 
interaction that anchors pyrrolysine at the active site. The amide of N346 also has a 
steric clash with the modeled phenylalanine in the active site and excludes its binding to 
the wild-type PylRS. The N346A mutation not only significantly decreases the binding 
of PylRS to pyrrolysine and also relieves the steric hindrance that prevents the binding 
of phenylalanine. Since both the aromatic side chain of Y384 and two backbone amides 
of residues 419-421 could form π-π stacking interactions with the phenyl group of a 
bound phenylalanine, we think that diminish the steric hindrance between a bound 
phenylalanine and N346 is the major contributing factor for the direct binding of two 
PylRS mutants to phenylalanine. The mutation of C348 to an amino acid with a larger 
side chain that apparently occupies the space of pyrrolidine of pyrrolysine in the active 
site simply brings more van der Waals interactions with the bound phenylalanine and 
increases its binding potential. Since the N346A mutation relieves the steric hindrance  
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Figure V-1. Structure of the PylRS complex with pyrrolysyl-AMP. Phenylalanyl-AMP 
that potentially binds the N346A mutant is shown as an overlay with pyrrolysyl-AMP. 
The structure is based on the PDB entry: 2Q7H142  
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that prevents the binding of phenylalanine and there is left a large empty space at the 
active site around the para position of phenylalanine when it binds to the N346A mutant 
of PylRS, we speculate that the N346A mutant could bind a phenylalanine derivate with 
a large para substituent better than phenylalanine itself. Given that mutations at C348 
were prevalent in almost all evolved NAA-specific PylRS mutants and its mutation to 
alanine was observed for PylRS mutants specific for NAAs with large side chains,68, 96, 
130, 143 we think an extra C348A mutation to the N346A mutant will generate a much 
larger active site pocket that provides a para-substituted phenylalanine with more 
structural flexibility to bind to the active site.  
To test the idea of large binding pocket, we constructed a plasmid pBK-
N346A/C348A that carries the gene coding the PylRS mutant N346A/C348A and used it 
together with pET-pylT-sfGFP2TAG to transform BL21 cells. The plasmid pET-pylT-
sfGFP2TAG carries genes coding        
    and an IPTG-inducible superfolder green 
fluorescent protein (sfGFP) with an amber mutation at the S2 position. The transformed 
BL21 cells were then used to examine the recognition of N346A/C348A toward twenty 
natural amino acids by expressing sfGFP in liquid glycerol minimal media (GMML) 
supplemented with 5 mM of a designated canonical amino acid. The sfGFP expression 
was induced by the addtion of 1 mM IPTG. Since the sfGFP expression levels at all 
twenty conditions were very low, we chose to detect the fluorescent emission of the 
expressed sfGFP at these conditions and show their relative intensities to represent the 
corresponding sfGFP expression levels in Figure V-2. The condition that contained 5 
mM phenylalanine displayed the highest sfGFP expression level, confirming our initial  
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Figure V-2. Relative fluorescence emission intensities of sfGFP expressed in BL21 cells 
transformed with pBK-N346A/C348A and pET-pylTsfGFP2TAG and grown in GMML 
supplemented with different amino acids. Cell lysates were excited at 450 nm and 
fluorescence emission intensities were detected at 510 nm. Background emission from 
cell lysate of same cells grown in GMML and induced with the addition of 1 mM IPTG 
was subtracted from each data set. Twenty CAAs are shown as one-letter abbreviations 
in the x-axis labels. 
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speculation that the N346A mutation will result in stronger binding of PylRS toward 
phenylalanine. Although stronger than the wild-type PylRS, the binding of 
phenylalanine to N346A/C348A is still relatively low. This low binding affinity is not a 
surprise since phenylalanine is expected less engaged in interactions with 
N346A/C348A than N346A/C348L and N346A/C348K. These data show that 
N346A/C348A has low binding affinities toward all twenty canonical amino acids, 
suggesting its potential application for the genetic incorporation of NAAs. To see 
whether N346A/C348A can recognize a phenylalanine derivative with a large para 
substituent, the same BL21 cells were let grown in liquid glycerol minimal medium 
supplemented with 5 mM p-propargyloxy phenylalanine (1 in Figure V-3). SfGFP was 
overexpressed 6 h after induction with 1 mM IPTG. 
With our initial success with 1, we then either purchased or synthesized several 
other para-substituted phenylalanine derivatives shown as 2-7 in Figure V-3 and tested 
their recognition by N46A/C348A. To better quantify the expression levels of sfGFP 
incorporated with these NAAs, another plasmid pEVOL-pylT-N346A/C348A was 
constructed. This plasmid carries genes coding both        
   
 and N346A/C348A. Its 
       
    is under control of a strong proK promoter that can boost up the expression 
level of        
    in E. coli.119 Together with pET-pylT-sfGFP2TAG, this plasmid was 
used to transform BL21 cells. The transformed cells were grown in GMML 
supplemented with 2 mM of a designated NAA. As shown in Figure V-3, all seven 
NAAs promoted sfGFP overexpression 10 h after induction with 1 mM IPTG. The 
molecular weights of the expressed sfGFP variants determined by electrospray  
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Figure V-3. Structures of 1-7 and their specific incorporation into sfGFP at the S2 
position. 
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Table V-1.sfGFP protein molecular weight determination by ESI-MS. 
Protein  Calculated Molecular Weight (Da) Found Molecular Weight (Da) 
sfGFP-1 27843 27845 
sfGFP-2 27845 27845 
sfGFP-3 27858 27857 
sfGFP-4 27872 27871 
sfGFP-5 27818 27818 
sfGFP-6 27802 27803 
sfGFP-7 27860 27861 
sfGFP-8 27894 27894 
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Figure V-4. Molecular weight determination of the protein sfGFP-1: (A) ESI-MS 
spectrum of sfGFP-1 and (B) the deconvoluted ESI-MS spectrum of sfGFP-1. 
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Figure V-5. Molecular weight determination of the protein sfGFP-2: (A) ESI-MS 
spectrum of sfGFP-2 and (B) the deconvoluted ESI-MS spectrum of sfGFP-2. 
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Figure V-6. Molecular weight determination of the protein sfGFP-3: (A) ESI-MS 
spectrum of sfGFP-3 and (B) the deconvoluted ESI-MS spectrum of sfGFP-3. 
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Figure V-7. Molecular weight determination of the protein sfGFP-4: (A) ESI-MS 
spectrum of sfGFP-4 and (B) the deconvoluted ESI-MS spectrum of sfGFP-4. 
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Figure V-8. Molecular weight determination of the protein sfGFP-5: (A) ESI-MS 
spectrum of sfGFP-5 and (B) the deconvoluted ESI-MS spectrum of sfGFP-5. 
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Figure V-9. Molecular weight determination of the protein sfGFP-6: (A) ESI-MS 
spectrum of sfGFP-6 and (B) the deconvoluted ESI-MS spectrum of sfGFP-6. 
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Figure V-10. Molecular weight determination of the protein sfGFP-7: (A) ESI-MS 
spectrum of sfGFP-7 and (B) the deconvoluted ESI-MS spectrum of sfGFP-7. 
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ionization spectrometry (ESI-MS) analysis agree well with their theoretic molecular 
weights (Table V-1)(Figure V-4-10). Without a NAA, no sfGFP was expressed. Since 1 
contains a terminal alkyne that undergoes the Cu(I)-catalyzed azide-alkyne cyclization 
reaction,144 the expressed sfGFP incorporated with 1 (sfGFP-1) was also used separately 
to label with a fluorescein azide (8 in Figure V-11) in an optimized labeling condition 
that contained 0.1 mM Cu(I):tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) 
complex, 0.5 mM additional TBTA, 5 mM ascorbate, and  1 mM NiCl2.
145 3 h 
incubation led to specific labeling of sfGFP-1. A parallel labeling reaction of the wild-
type sfGFP in the same condition gave non-detectable labeling with 8. 
One intriguing question is whether N346A/C348A could also recognize a 
phenylalanine derivative with a small para-substituent. Given that 5 has a relatively 
small para-substituent and providing 5 led to reasonable sfGFP expression, one would 
expect N346A/C348A also recognizes a phenylalanine derivative with a small para-
substituent such as Cl, Br, I, CN, etc. To test this possibility, we examined the genetic 
incorporation of 9-15 shown in Figure V-12 into sfGFP at S2 using the N346A/C348A-
       
    pair. As shown in Figure V-12, providing 2 mM of any of these NAAs in 
GMML led to sfGFP expression levels that are significantly lower than those for NAAs 
shown in Figure V-3 but still higher than the background expression level in GMML in 
which no NAA was provided. Therefore, N346A/C348A recognizes 9-15 but with 
relatively lowbinding affinities. Since the expression levels of sfGFP incorporated with 
9-15 are low, we did not attempt to characterize these proteins by the ESI-MS analysis. 
Although the current analysis suggests that it is not applicable to use the  
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Figure V-11. Site-selective labeling of sfGFP-1 with 8. (A) SDS-PAGE analysis of 
sfGFP-1 and wild-type (wt) sfGFP after their reactions with 8. The gel was stained with 
Coomassie blue. (B) Fluorescent imaging of the same gel under 365 nm UV irradiation. 
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Figure V-12. Structures of 9-14 and their incorporation into sfGFP at S2.The protein 
expression yields are lower than 1 mg/L for all NAAs. 
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N346A/C348A-       
    pair to express proteins incorporated with 9-15, it clearly 
indicates PylRS can be engineered to recognize phenylalanine derivatives with small 
para substitutes. Since a PylRS mutant specific for 5 evolved by Wang and co-workers 
contains mutations at A302 and V401,146 we are now introducing additional mutations to 
N346A/N348A to generate PylRS mutants that show high binding affinities toward 
phenylalanine derivatives with small para substituents. 
 
Conclusion 
In summary, we have rationally designed a PylRS mutant N346A/C348A that 
shows very low recognition toward canonical amino acids but, together with        
   , 
mediates efficient incorporation of NAAs 1-7 into proteins at amber mutation sites in E. 
coli. These NAAs contain functional groups such as alkyne and alkene and can be 
applied to install different biochemical and biophysical probes to proteins for their 
structural and functional analysis. Since the PylRS-       
    pair has been successfully 
introduced into S. cerevisiae, mammalian cells, and even the multiple cellular 
organisms,85, 96, 130, 147, 148 the N346A/C348A-       
   
 pair could be potentially used in 
these systems to genetically encode 1-7. Although many phenylalanine derivatives have 
been incorporated into proteins in E. coli using evolved Methanococcus jannaschii 
tyrosyl-tRNA synthetase (MjTyrRS)-       
   
 pairs,127, 149, 150 specifically evolved 
MjTyrRS variants for individual phenylalanine derivatives are usually required and the 
MjTyrRS-       
   
 pair cannot be used in eukaryotic cells because of the recognition of 
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 by endogenous eukaryotic aaRSs (Liu & Schultz, unpublished data). Using the 
N346A/C348A-       
   
 pair will resolve both issues. In addition, phenylalanine 
derivatives 3, 4, 6 and 7 that are taken by N346A/C348A are also genetically encoded in 
E. coli for the first time. Given that N346A/C348A has a relatively deep and big binding 
pocket, the current study also opens a gate to test the recognition of this mutant toward 
other large phenylalanine derivatives. Another potential application of N346A/C348A is 
to couple its pair with        
   
 together with evolved MjTyrRS-       
   
 pairs for the 
genetic incorporation of two different phenylalanine derivatives into one protein.88 This 
may find applications in enzyme mechanistic studies, protein FRET labeling, and phage 
displayed unnatural peptide library construction.  
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CHAPTER VI  
A PYRROLYSYL-TRNA SYNTHETASE MUTANT RECOGNIZES META-
SUBSTITUTED PHENYLALANINE DERIVATIVES 
 
Introduction 
Using evolved TyrRSs that were originally from Methanococcus jannaschii and 
Escherichia coli and their corresponding amber suppressor tRNAs, Schultz and 
coworkers showed that more than twenty para-substituted phenylalanine derivatives 
could be genetically incorporated into proteins at amber mutation sites in E. coli, 
Saccharomyces cerevisiae, and mammalian cells.21, 23, 29, 43, 44, 92-94, 128, 151-164 These para-
substituted phenylalanine derivatives contain functional groups that can serve as 
biophysical probes for structural and functional investigations of proteins and 
biochemical probes for protein modifications.24, 127, 165 Compared to para-substituted 
phenylalanine derivatives, genetic incorporation of meta-substituted phenylalanine 
derivatives is far less explored. Zhang et al. demonstrated that a meta-substituted 
phenylalanine derivative, meta-acetyl-phenylalanine, could be genetically encoded in E. 
coli using an evolved M jTyrRS.166 However, there has been no following study since 
this work was published in 2003. Developing methods for genetic incorporation of other 
meta-substituted phenylalanine derivatives will not only expand the genetically encoded 
NAA inventory, leaving more choices for protein engineering when subtle variations are 
necessary, but also help understand the NAA tolerance scope of the cellular protein 
translation machinery. In a previous study, we showed that a rationally designed PylRS 
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mutant N346A/C346A together with        
    mediates genetic incorporation of seven 
para-substituted phenylalanine derivatives into proteins at amber mutation sites in E. 
coli. Here, we reveal that the same enzyme also recognizes seven meta-substituted 
phenylalanine derivatives and when coupled with        
   , it can be applied to 
genetically encode these NAAs in E. coli. 
In our previous study, we show that N346A/C348A has an enhanced recognition 
of phenylalanine in comparison to the wild-type PylRS. We believe this recognition 
enhancement is due to the removal of the N346 amide that can potentially prevent the 
binding of phenylalanine to the active site of the wild-type PylRS. 141, 167-169 141, 167-169  140- 
141, 166-169 
Figure VI-1A shows a modeled phenylalanyl-AMP at the active site of 
N346A/C348A. The aromatic side chain of phenylalanine is sandwiched between the 
Y384 phenol group and the two backbone amides of residues 419-421, forming strong π-
π interactions that likely contribute to the recognition of phenylalanine by 
N346A/C348A. Although N346A/C348A shows an enhanced recognition of 
phenylalanine in comparison to the wild-type PylRS, its binding toward phenylalanine is 
still very weak. In addition, there is left a large empty hydrophobic pocket formed by 
residues A302, Y306, L309, A348 and W417 at the active site after the binding of 
phenylalanine. After carefully examining this pocket that is shown in Figure VI-1B and 
obviously located around the meta position of the bound phenylalanine side chain, we 
suspected that a phenylalanine derivative with a hydrophobic meta-substituent might 
also show a better binding potential toward N346A/C348A than phenylalanine.  
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Figure VI-1. (A) N346A/C348A with a modeled phenylalanyl-AMP (Phe-AMP) in the 
active site and (B) the active site cavity of N346A/C348A. 
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Experimental Section 
General Experimental 
DNA and protein sequences of sfGFP, mmPylRS-N346A/C348A, pylT and 
plasmid constructions of pET-sfGFP2TAG, pEVOL-pylT-PylRS(N346A/C348A) were 
listed in Chapter III and V. sfGFP proteins incorporated with 1-7 in 2 mM in GmmL or 1 
mM in LB were expressed and purified similarly as the method of GFPUV in Protein 
Expression and Purification of  Experimental Section in Chapter II. In the 15N labeling 
sfGFP27-6 protein expression, the BL21 (DE3) cells were culture in similar condition. 
The cells cultured in LB medium were centrifuged when OD600 reached 0.7 - 0.8 and 
replace by GmmL with 15N-labeled ammonium chloride (15N, 99%, Cambridge Isotope 
Laboratories Inc.). The protein expression was induced by adding 1 mM IPTG, 0.2% 
arabinose and 1 mM 6 for 6 h. Samples for folding studies by 19F NMR contained 0.7 
mM sfGFP27-6, 12 mM phosphate buffer (pH 7.0), 140 mM NaCl, 3 mM KCl. 
Chemical shifts were referenced against an external standard of trifluoroacetic acid 
at -75.2 ppm in D2O. 
19F spectra were recorded on a 400 MHz spectrometer equipped 
with a Broadband Observe (BBO) probe (Bruker Biospin). 
Construction of pBAD-sfGFP27TAG, pBAD-sfGFP8TAG, pBAD-sfGFP130TAG 
The pBAD-sfGFP27TAG plasmid was derived from the pBAD-sfGFP plasmid 
with quickchange method. Primers pBAD-sfGFP-F27TAG-F (5'-
tctgttcgtggtgaaggtgaaggtgatg-3') and pBAD-sfGFP-F27TAG-R (5'-
ctatttatgaccattaacatcaccatcaagttc-3') are used for the construction of pBAD-
sfGFP27TAG. Primers pBAD-sfGFP-F8TAG-F (5'- actggtgttgttcctattcttgttgaacttg -3') 
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and pBAD-sfGFP-F8TAG-R (5'- ctaaagttcttcacctttagaaaccatggttaattcc -3') are used for 
pBAD-sfGFP8TAG, as well as primers pBAD-sfGFP-F130TAG-F (5'- 
aaagaagatggtaatattcttggtcataaacttg-3') and pBAD-sfGFP-F130TAG-R (5'- 
ctaatcaatacctttaagttcaatacgattaac -3') for pBAD-sfGFP130TAG. 
Equilibrium Fluorescence of sfGFP 
Equilibrium fluorescence values were measured by adding different 
concentration GndCl between 1.0 and 7.0 M to folded sfGFP variants in increments of 
0.5 to 1 M GndCl, and allowing equilibrium to procee up to 12 to 48 hr in room 
temperature. Fluorescence values were measured using a FL600 Microplate 
Fluorescence Reader (450-nm excitation, 510-nm emission, 0.5-nm band pass). 
Midpoint recovery concentrations of GndCl Cm (recovery of 50% of the initial 
fluorescence) were determined from sigmoidal fits using SOLVER in EXCEL, to the 
scaled fluorescence value F using the equation Fj = ¼ a + b/(1 + (Cj/Cm)
h), where a, b, 
Cm and h are adjustable parameters, and Cj is the molarity of the GndCl in the unfolding 
experiment j. 
ESI-MS Analysis of Intact Proteins 
Nanoelectrospray ionization in positive mode was performed using an Applied 
Biosystems QSTAR Pulsar (Concord, ON, Canada) equipped with a nanoelectrospray 
ion source.  Solution was flowed at 700 nL/min through a 50 µm ID fused-silica 
capillary that was tapered at the tip. Electrospray needle voltage was held at 2100 V. 
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Results and Discussion 
To test the possibility of meta-substituted phenylalanine, we employed BL21 
cells transformed with two plasmids pEVOL-pylT-N346A/C348A and pET-pylT-
sfGFP2TAG. Plasmid pEVOL-pylT-N346A/C348A carried a        
    gene under 
control of a strong proK promoter and a N346A/C348A gene under control of a pBAD 
promoter; plasmid pET-pylT-sfGFP2TAG carried a        
    gene under control of a 
lpp promoter and a superfolder green fluorescent protein (sfGFP) gene with an amber 
mutation at its S2 position under control of an IPTG-inducible T7 promoter. Since 
N346A/C348A has low binding affinities toward twenty canonical amino acids (CAAs), 
growing the transformed cells in liquid glycerol minimal medium (GMML) and inducing 
with the addition of 1 mM IPTG and 0.2% arabinose led to no detectable sfGFP due to 
the premature translation termination at the S2 position. However, providing 2 mM 
meta-chloro-phenylalanine, meta-bromo-phenylalanine, or meta-iodo-phenylalanine (2, 
3, and 4 in Figure VI-2) in the medium promoted sfGFP overexpression (Figure VI-2). 
All three purified sfGFP variants had detected molecular weights determined by the 
electrospray ionization mass spectrometry (ESI-MS) analysis that agreed well with their 
theoretical molecular weights (Table VI-1 and Figures VI-3-6). We also tested the 
uptake of meta-fluoro-phenylalanine (1 in Figure VI-2) by N346A/C348A. Although 
providing 1 in GMML promoted sfGFP expression in BL21 cells transformed with 
pEVOL-pylT-N346A/C348A and pET-pylT-sfGFP2TAG, the yield was significantly 
lower than for 2-4. Given that 1 could be misincorporated at phenylalanine sites, which 
leads to disruption of cellular function, we think this low sfGFP expression yield is  
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Figure VI-2. The specific incorporation of 1-4 at the S2 position of sfGFP. The 
expression was induced by the addition of 1 mM IPTG, 0.2% arabinose and 2 mM of a 
designated NAA. Cells were collected 6h after induction.. 
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Table VI- 1. sfGFP protein molecular weight (MW) determination by ESI-MS. 
Proteina  Calculated Molecular 
Weight (Da) 
Found Molecular Weight 
(Da) 
sfGFP-1 27806 27806 
27826b 
27844b 
27788b 
sfGFP-2 27822 27822 
sfGFP-3 27867 27868 
sfGFP-4 27914 27912 
sfGFP-5 27802 27802 
sfGFP-6 27856 27856 
sfGFP-7 27818 27818 
a Protein expression was performing in GmmL medium with 2 mM NAA 
b There are other 13 F in sfGFP primary sequence. The MW 27826 Da indicates another 
NAA 1 incorporated into one of 13 F of sfGFP sequence. MW 27844 indicates other two 
F replaced by NAA 1.  MW 27788 indicated F incorporated at S2 position.  
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Figure VI-3. Molecular weight determination of the protein sfGFP-1: (A) ESI-MS 
spectrum of sfGFP-1 and (B) the deconvoluted ESI-MS spectrum of sfGFP-1. 
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Figure VI-4. Molecular weight determination of the protein sfGFP-2: (A) ESI-MS 
spectrum of sfGFP-2 and (B) the deconvoluted ESI-MS spectrum of sfGFP-2. 
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Figure VI-5. Molecular weight determination of the protein sfGFP-3: (A) ESI-MS 
spectrum of sfGFP-3 and (B) the deconvoluted ESI-MS spectrum of sfGFP-3. 
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Figure VI-6. Molecular weight determination of the protein sfGFP-4: (A) ESI-MS 
spectrum of sfGFP-4 and (B) the deconvoluted ESI-MS spectrum of sfGFP-4.  
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partly due to the toxicity effect of 1.  Indeed, the collected cells grown in the presence of 
1 were considerably fewer than those grown in GMML supplemented with either of 2-4. 
In addition, except for the expected molecular weight, the ESI-MS spectrum of the 
purified sfGFP incorporated with 1 displayed several side peaks that clearly indicate 
misincorporation of 1 at phenylalanine sites (Figure VI-3).  
Given the success with 1-4, we anticipated that N346A/C348A would also 
recognize other phenylalanine derivatives with small meta-substituents such as 5-7 
shown in Figure VI-7. Growing BL21 cells transformed with pEVOL-pylT- 
N346A/C348A and pET-pylT-sfGFP2TAG in GMML supplemented with 2 mM of 
either of 5-7 and inducing with the addition of 1 mM IPTG and 0.2% arabinose led to 
overexpression of sfGFP (Figure VI-7). The detected molecular weights of the purified 
sfGFP variants determined by the ESI-MS analysis agreed well with their theoretic 
molecular weights (Table VI-1 and Figures VI-8-10). Among all meta-substituted 
phenylalanine derivatives we tested, 6 had the best corresponding sfGFP expression 
yield. 6 apparently has the most hydrophobic meta-substituent that likely contributes to 
its strong interaction with the hydrophobic active site of N346A/C348A and its high 
incorporation rate. In comparison to seven para-substituted phenylalanine derivatives we 
tested previously, 2-6 gave much better incorporation levels. We think this is due to the 
fact that the hydrophobic meta-substituents of these NAAs can fit well in the 
hydrophobic pocket shown in Figure VI-1B. 
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Figure VI-7. The specific incorporation of 5-7 at the S2 position of sfGFP 
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Figure VI-8. Molecular weight determination of the protein sfGFP-5: (A) ESI-MS 
spectrum of sfGFP-5 and (B) the deconvoluted ESI-MS spectrum of sfGFP-5 
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Figure VI-9. Molecular weight determination of the protein sfGFP-6: (A) ESI-MS 
spectrum of sfGFP-6 and (B) the deconvoluted ESI-MS spectrum of sfGFP-6. 
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Figure VI-10. Molecular weight determination of the protein sfGFP-7: (A) ESI-MS 
spectrum of sfGFP-7 and (B) the deconvoluted ESI-MS spectrum of sfGFP-7.  
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Among seven meta-substituted phenylalanine derivative substrates of 
N346A/C348A we tested so far, 3 and 4 can undergo Suzuki coupling reactions with 
organoboronic acids and Sonogashira coupling reactions with terminal alkynes using 
biocompatible palladium complex catalysts, and 1 and 6 contain fluorine so that they can 
serve as 19F NMR sensors for protein folding/conformation rearrangement and protein-
protein/ligand interaction investigations. Since we previously showed that a para-halo-
phenylalanine that was incorporated into a protein using an evolved PylRS-       
    
pair could be fluorescently labeled using a Suzuki coupling reaction, here we focused to 
demonstrate the application of 6 in protein folding/unfolding analysis. sfGFP was chosen 
as a model protein for this study. A plasmid pBAD-sfGFP27TAG was constructed. This 
plasmid carried a sfGFP gene with an amber mutation at F27. F27 is located at the 
second strand of sfGFP. Its side chain faces towards the protein interior and 
issurrounded by several hydrophobic residues of sfGFP. During its unfolding process, 
sfGFP is expected to completely expose F27 to a hydrophilic environment. We 
anticipated 6 at F27 of sfGFP would show a large chemical shift variation during this 
unfolding process. The structure of GFP also indicates there is additional space around 
F27 to accommodate a small substituent at the meta position of its side chain. Thus, 
replacing F27 with 6 was anticipated not to significantly perturb the sfGFP fold. 
Together with pEVOL-pylT-N346A/C348A, pBAD-sfGFP27TAG was used to 
transform E. coli Top10 cells. The transformed cells were then grown in LB medium 
supplemented with 1 mM 6 and induced by the addition of 0.2% arabinose to express 
sfGFP with 6 incorporated at F27 (sfGFP27-6). The expression level was 79 mg/L 
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(Figure VI-11). Only a minimal amount of sfGFP was expressed in LB medium without 
a NAA supplement. The purified sfGFP-6 had a fluorescent spectrum and intensity 
similar to sfGFP (Figure VI-12), and a sample of 15N-sfGFP-6 also showed a similar 
(but not identical, with differences including small shifts in various peaks such as e.g. 
those near 10 ppm / 112 ppm and the appearance of a weak peak near 10.2 ppm / 128 
ppm) fingerprint as sfGFP in a [15N,1H] correlation spectrum (Figure VI-13).170 These 
observations suggest that replacing F27 with 6 does not significantly affect the protein 
folding and chromophore formation processesThe purified sfGFP27-6 was then used to 
undergo unfolding analysis in the presence of guanidinium chloride (GndCl). In 
titrations of stepwise increasing concentrations of GndCl, 19F NMR signals of sfGFP27-
6 were detected. Figure VI-14A shows the dependence of 19F chemical shifts on the 
concentration of GndCl for sfGFP27-6. Prior to denaturation, the chemical shift of 
folded sfGFP27-6 was dependent on GndCl concentration. This chemical shift change is 
significantly larger than that observed  in a titration of the free amino acid, even though 
the latter may contain contributions from binding of guanidinium to the carboxylate of 
the amino acid, a process that cannot occur in the polypeptide (Figure VI-15). The 
GndCl concentration dependent shift in folded sfGFP27-6 may likely be explained by a 
local structural change prior to denaturation. The appearance of the peak at 61.5 ppm 
indicates that the unfolding transition in this titration occurred at 4.6 M GndCl, which 
based on the time of 1 h between titrated points appears consistent with an unfolding 
hysteresis observed in the work of Jennings and co-workers.170 Likewise, a stepwise 
titration of decreasing GndCl indicates the presence of unfolded sfGFP27-6 to a much  
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Figure VI-11. The expression of sfGFP containing an amber mutation at F8 and F27. 
Proteins were expressed in BL21(DE3) cells that grew in LB medium and 1 mM 5 or 6. 
The proteins were analyzed by SDS-PAGE (15%) gel electrophoresis with Coomassie 
blue staining. 
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Figure VI-12. The fluorescence intensity of wt-sfGFP and sfGFP27-6. The same protein 
concentration 500 nM was prepared in PBS buffer in pH = 7.0. Excitation and emission 
wavelength are 450 nm and 520 nm respectively.  The fluorescence intensity of sfGFP2-
6 was 95% of wt-sfGFP. 
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Figure VI-13. [15N,1H]-HMQC spectrum of 15N-sfGFP27-6 in 12 mM phosphate buffer 
(pH 7.0) with 140 mM NaCl and 3 mM KCl, acquired at a temperature of 35 ºC, at 500 
MHz. Chemical shifts are referenced against an internal standard of 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS). 
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Figure VI-14. (A) Unfolding of sfGFP27-6, by stepwise addition of GndCl, 
characterized by 19F NMR. (B) Spectra of unfolded sfGFP27-6 upon stepwise reduction 
of GndCl. Precipitation occurred below 1.6 M GndCl. In A and B, time between each 
point was 1h, and measurement temperature was 298 K. 
 
 
. 
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Figure VI-15. Titration of 6 in 12 mM phosphate buffer (pH 7.0) with 140 mM NaCl 
and 3 mM KCl with 0 M – 5.4 M GndCl. Chemical shifts are referenced against an 
external standard of trifluoroacetic acid at -75.2 ppm in D2O.  
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lower GndCl concentration of 1.6 M (Figure VI-14B). The significant change in 19F 
chemical shift observed illustrates that 6 can be used as a sensitive site specific probe for 
protein folding, or potentially for protein-ligand interaction. 19F allows for highly 
receptive, background free NMR detection, and the chemical shift of this nucleus is 
sensitive to structural changes. Therefore, a single probe inserted at a known position 
will in particular be useful for measurements with large proteins, or with dilute samples, 
where chemical shift assignments typically cannot be obtained. 
 In order to study local structural change prior to denaturation of sfGFP.  5 
different positions, S2, F8, F27, F130 and N134, of sfGFP were chose to study.  S2 
indicated non-structured amino acid, as well as F8 for first  helix from N-termini, F27 
for second b sheet; F130 and N135 for loop region amino acids. (Figure VI-16-17) 
pBAD-sfGFP8TAG, pBAD-sfGFP130TAG, pBAD-sfGFP135TAG,  pET-sfGFPS2TAG 
and pBAD-sfGFP27TAG were constructed to incorporated NAA 6 into assigned 
position of sfGFP.  Cotransformed with pEVOL- PylRS-N346A/C348A, 5 different  
sfGFP variants are expressed in LB in 19-81 mg/L of sfGFP-6 and 14-35 mg/L of 
sfGFP-5. (Figure VI-11 and VI-18) In S2 and N135 sfGFP variants, sfGFP-F has 
expression by adding 5 mM L-phenylalanine in the GmmL medium during protein   
induction.  
 Unfolding equilibrium fluorescence and 19F-NMR experiments are performed for 
all sfGFP variants.  Equilibrium fluorescence profiles in S2 and F8 sfGFP variants 
showed high sensitivity of the hydrophobicity of local structure in first  helix cap. 
(Figure VI-19-20 and Figure VI-24) sfGFP-S2F and sfGFP-5 variant shows better local 
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structure to maintain the hydrophobic chamber keeping the fluorescence of sfGFP.  In 
sfGFP2-6, although Cm is better than wild type sfGFP, the result imply fluoro atoms on 
m-trifluoromethyl group may disturb the local structure by hydrogen bonding.  sfGFP8-5 
and sfGFP8-6 unfolding experiment in GndCl  were similar pattern but in different 
chemical shift. (Figure VI-25-26)  sfGFP-27TAG, sfGFP-130TAG, sfGFP-134TAG 
variants show limited change in unfolding equilibrium fluorescence pattern and midpoint 
recovery concentrations of GndCl Cm. (Figure VI-21-23) However, the unfolding 
profile in19F-NMR experiments, it provides rich and detail informations for local 
structure environment.(Figure VI-27-29) In sfGFP27-6 and sfGFP130-6, the unfolding 
spectrums show the interconversion between locked and the soft folding structures in 
proposed dual-basin folding mechanism.170 The results in sfGFP27-6 and sfGFP130-6 of 
19F-NMR unfolding experiments, the iso-state intermediate with fast frustrated signal 
between native folded signal was observed in the change of chemical shift as increasing 
of GndCl concentration. The fast interconversion between native and iso-state shows 
average signals. However, the chemical shift changing in GndCl denatural experinment 
may also cause the GndCl concentration change. The refolding 19F-NMR spectrum of 
sfGFP27-6 indicated the influerence of GndCl concentration to chemical shift of 
unfolded sfGFP27-6 was little.   
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Figure VI-16. sfGFP x-ray crystal structure.  The five sites, S2, F8, F27, F130 and N135 
were labeled in red color in the structure. PDB code: 2B3P. 
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Figure VI-17. sfGFP x-ray crystal structure.  (A) The local structure near S2 and  F8 
were labeled in red. (B) The local structure near  F27, F130 and  N135 were labeled in 
red. PDB code: 2B3P. 
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Figure VI-18. The expression of sfGFP containing an amber mutation at F130 and 
N135. Proteins were expressed in BL21(DE3) cells that grew in LB medium and 1 mM 
5 or 6. The proteins were analyzed by SDS-PAGE (15%) gel electrophoresis with 
Coomassie blue staining.  
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Figure VI-19. Unfolding of sfGFP, sfGFP2-F, sfGFP2-5 and sfGFP2-6, by stepwise 
addition of GndCl, characterized by equilibrium fluorescence values. It was measured by 
adding various final GndCl concentrations to sfGFP variants into to between 1.0 and 7.0 
M in increments of 0.5 M GndCl, and allowing equilibrium to process up to 48 hr in 
room temperature. 
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 Figure VI-20. Unfolding of sfGFP, sfGFP8-5 and sfGFP8-6, by stepwise addition of 
GndCl, characterized by equilibrium fluorescence values. It was measured by adding 
various final GndCl concentrations to sfGFP variants into to between 1.0 and 7.0 M in 
increments of 0.5 M GndCl, and allowing equilibrium to process up to 48 hr in room 
temperature. 
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Figure VI-21. Unfolding of sfGFP, sfGFP27-5 and sfGFP27-6, by stepwise addition of 
GndCl, characterized by equilibrium fluorescence values. It was measured by adding 
various final GndCl concentrations to sfGFP variants into to between 1.0 and 7.0 M in 
increments of 0.5 M GndCl, and allowing equilibrium to process up to 48 hr in room 
temperature. 
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Figure VI-22. Unfolding of sfGFP, sfGFP130-5 and sfGFP130-6, by stepwise addition 
of GndCl, characterized by equilibrium fluorescence values. It was measured by adding 
various final GndCl concentrations to sfGFP variants into to between 1.0 and 7.0 M in 
increments of 0.5 M GndCl, and allowing equilibrium to process up to 48 hr in room 
temperature. 
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Figure VI-23. Unfolding of sfGFP, sfGFP134F, sfGFP134-5 and sfGFP134-6, by 
stepwise addition of GndCl, characterized by equilibrium fluorescence values. It was 
measured by adding various final GndCl concentrations to sfGFP variants into to 
between 1.0 and 7.0 M in increments of 0.5 M GndCl, and allowing equilibrium to 
process up to 48 hr in room temperature. 
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Figure VI-24. Midpoint recovery concentrations of GndCl Cm (recovery of 50% of the 
initial fluorescence) of sfGFP variants in unfolding equilibrium fluorescence 
experiments. 
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Figure VI-25. Unfolding of sfGFP2-6, by stepwise addition of GndCl, characterized by 
19F NMR. Y axis indicates the concentration of GndCl from 0 to 6 M by in increments of 
1 M GndCl. 
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Figure VI-26. Unfolding of sfGFP8-6, by stepwise addition of GndCl, characterized by 
19F NMR. Y axis indicates the concentration of GndCl from 0 to 6 M by in increments of 
1 M GndCl. 
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Figure VI-27. Unfolding of sfGFP27-6, by stepwise addition of GndCl, characterized by 
19F NMR. Y axis indicates the concentration of GndCl from 0 to 6 M by in increments of 
1 M GndCl. 
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Figure VI-28. Unfolding of sfGFP130-6, by stepwise addition of GndCl, characterized 
by 19F NMR. Y axis indicates the concentration of GndCl from 0 to 6 M by in 
increments of 1 M GndCl. 
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Figure VI-29. Unfolding of sfGFP135-6, by stepwise addition of GndCl, characterized 
by 19F NMR. Y axis indicates the concentration of GndCl from 0 to 6 M by in 
increments of 1 M GndCl. 
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Conclusion 
In summary, we have demonstrated genetic incorporation of seven meta-
substituted phenylalanine derivatives into proteins at amber mutation sites in E. coli 
using a rationally designed PylRS mutant N346A/C348A and        
   . These NAAs 
contain functional groups that can serve as biophysical and biochemical probes and 
therefore enable a variety of studies involving proteins. Given that all seven NAAs 
contain meta-substituents that are substantially smaller than the hydrophobic pocket in 
N346A/C48A that accommodates them, the current study also leads the way to search 
for phenylalanine derivative substrates of N346A/C348A that have larger meta-
substituents and better binding affinities to the enzyme. Currently, we are synthesizing 
other meta-substituted phenylalanine derivatives, their genetic encoding using the 
N346A/C348A-       
    pair will be reported later. In the present study, we also 
demonstrated the application of a site-specifically incorporated 6 in protein 
folding/unfolding analysis using 19F NMR. Given its strong NMR signal, free 
background NMR detection, and high chemical shift variation due to local environment 
change, this 19F probe can be potentially applied for investigating thermodynamics and 
kinetics of protein-ligand, protein-protein, and protein-DNA/RNA interactions, in 
addition to protein structure and dynamics. 
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CHAPTER VII  
CONCLUDING REMARKS AND FUTURE OUTLOOK 
 
We have recently demonstrated that the PylRS-       
   
  pair can be evolved for 
genetic incorporation of phenylalanine derivatives68, p-iodophenylalanine and p-
bromophenylalanine and guide the direction to evolve this pair for the incorporation of 
sulfotyrosine and pCMF. Since the PylRS-       
   
  pair is orthogonal in both yeast and 
mammalian cells, direct applications of the evolved pairs in these cells will allow 
synthesizing proteins with defined tyrosine sulfation and phosphorylation mimics for 
their cellular function analysis. This work also achieved the incorporation of N-
methyllysine using indirect methods. Despite the efforts of other groups and us, direct 
incorporation of N-methyllysine is not successful. We may argue that it is difficult to 
evolve an aminoacyl-tRNA synthetase that thermodynamically favors the binding to N-
methyllysine than lysine. But another explanation is also possible. N-methyllysine may 
have a difficulty to be transported into E. coli cells by ABC transporters. Since no NAA 
with a positively charged side chain has been evolved so far, we can not rule out this 
possibility. If this was real, it would rule out the possibility to directly incorporate N,N-
dimethyllysine and N,N,N-trimethyllysine into proteins. We have tried to evolve 
PylRS mutants specific for N,N-dimethyllysine and N,N,N-trimethyllysine but no 
positive clones have beenidentified. We think a thorough investigation of membrane 
transportation of these NAAs is necessary before further efforts are carried out. Since 
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arginine also undergoes methylation with several distinctive patterns, an interesting 
question is whether we could evolve an aaRS-tRNA pair for genetic incorporation of 
methylated arginines. Given the structure similarity between lysine and arginine, it is 
highly possible to evolve PylRS mutants that are specific for protected or unprotected 
methylated arginines. Another challenge in this research area is the installation of 
multiple different modifications to proteins. Concomitant modifications in one protein 
are prevalent in cells. It is an interesting question whether these modifications crosstalk 
to each others, reinforce each others’ effects, or counteract each others’ effects. To 
synthesize a protein with two different modifications, two orthogonal aaRS-tRNA pairs 
and two different blank codons have to be used. Recently, we and Chin et al. 
independently developed two systems for genetic incorporation of two different NAAs. 
The method developed by Chin et al. uses one amber codon and one quadruple AGGA 
codon to code two different NAAs. Our method uses one amber codon and one ochre 
codon. Two orthogonal pairs in both systems were derived from the MjTyrRS- TyrCUAtRNAMj  
pair and the PylRS-       
   
  pair. These two methods make it possible to synthesize a 
protein containing one sulfotyrosine/phosphotyrosine mimic and one N-acetyllysine/N-
methyllysine. However, it will require developing an additional aaRS-tRNA pair 
orthogonal to the PylRS-       
   
  pair for synthesis of a protein containing both N-
acetyllysine and N-methyllysine. Searching additional orthogonal aaRS-tRNA pairs 
may be necessary. 
 
 
 224 
REFERENCES 
 
1. Walsh, C. T. (2005) Posttranslational Modification of Proteins: Expanding 
Nature's Inventory, Roberts & Company Publishers, Englewood, CO. 
2. Walsh, C. T., Garneau-Tsodikova, S., and Gatto, G. J., Jr. (2005) Protein 
posttranslational modifications: The chemistry of proteome diversifications. 
Angew Chem Int Ed Engl 44, 7342-7372. 
3. Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., and Gu, W. (2004) 
Acetylation of p53 augments its site-specific DNA binding both in vitro and in 
vivo. Proc Natl Acad Sci U S A 101, 2259-2264. 
4. Jansson, M., Durant, S. T., Cho, E. C., Sheahan, S., Edelmann, M., Kessler, B., 
and La Thangue, N. B. (2008) Arginine methylation regulates the p53 response. 
Nat Cell Biol 10, 1431-1439. 
5. Latham, J. A., and Dent, S. Y. (2007) Cross-regulation of histone modifications. 
Nat Struct Mol Biol 14, 1017-1024. 
6. Yang, X. J., and Seto, E. (2008) Lysine acetylation: codified crosstalk with other 
posttranslational modifications. Mol Cell 31, 449-461. 
7. Gu, W., and Roeder, R. G. (1997) Activation of p53 sequence-specific DNA 
binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606. 
8. Dastugue, B., Tichonicky, L., and Kruh, J. (1972) Effect of enzymatic 
phosphorylation of histone on its ability to bind to RNA. Biochimie 54, 1435-
1441. 
 225 
9. Hicke, L. (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Bio 2, 
195-201. 
10. Thrower, J. S., Hoffman, L., Rechsteiner, M., and Pickart, C. M. (2000) 
Recognition of the polyubiquitin proteolytic signal. Embo J 19, 94-102. 
11. Hoffhines, A. J., Damoc, E., Bridges, K. G., Leary, J. A., and Moore, K. L. 
(2006) Detection and purification of tyrosine-sulfated proteins using a novel anti-
sulfotyrosine monoclonal antibody. J Biol Chem 281, 37877-37887. 
12. Puente, L. G., and Megeney, L. A. (2008) Isolation of phosphoproteins. Methods 
Mol Biol 424, 365-372. 
13. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, 
T. D., and Berger, S. L. (2001) Acetylation of p53 activates transcription through 
recruitment of coactivators/histone acetyltransferases. Mol Cell 8, 1243-1254. 
14. Goodman, R. H., and Smolik, S. (2000) CBP/p300 in cell growth, 
transformation, and development. Genes Dev 14, 1553-1577. 
15. Tang, Y., Zhao, W., Chen, Y., Zhao, Y., and Gu, W. (2008) Acetylation is 
indispensable for p53 activation. Cell 133, 612-626. 
16. Lu, X., Simon, M. D., Chodaparambil, J. V., Hansen, J. C., Shokat, K. M., and 
Luger, K. (2008) The effect of H3K79 dimethylation and H4K20 trimethylation 
on nucleosome and chromatin structure. Nat Struct Mol Biol 15, 1122-1124. 
17. Simon, M. D., Chu, F. X., Racki, L. R., de la Cruz, C. C., Burlingame, A. L., 
Panning, B., Narlikar, G. J., and Shokat, K. M. (2007) The site-specific 
 226 
installation of methyl-lysine analogs into recombinant histones. Cell 128, 1003-
1012. 
18. Huang, R., Holbert, M. A., Tarrant, M. K., Curtet, S., Colquhoun, D. R., Dancy, 
B. M., Dancy, B. C., Hwang, Y., Tang, Y., Meeth, K., Marmorstein, R., Cole, R. 
N., Khochbin, S., and Cole, P. A. (2010) Site-specific introduction of an acetyl-
lysine mimic into peptides and proteins by cysteine alkylation. J Am Chem Soc 
132, 9986-9987. 
19. Dawson, P. E., Muir, T. W., Clark-Lewis, I., and Kent, S. B. (1994) Synthesis of 
proteins by native chemical ligation. Science 266, 776-779. 
20. McGinty, R. K., Kim, J., Chatterjee, C., Roeder, R. G., and Muir, T. W. (2008) 
Chemically ubiquitylated histone H2B stimulates hDot1L-mediated 
intranucleosomal methylation. Nature 453, 812-U812. 
21. Chin, J. W., Cropp, T. A., Anderson, J. C., Mukherji, M., Zhang, Z., and Schultz, 
P. G. (2003) An expanded eukaryotic genetic code. Science 301, 964-967. 
22. Furter, R. (1998) Expansion of the genetic code: site-directed p-fluoro-
phenylalanine incorporation in Escherichia coli. Protein science : a publication 
of the Protein Society 7, 419-426. 
23. Wang, L., Brock, A., Herberich, B., and Schultz, P. G. (2001) Expanding the 
genetic code of Escherichia coli. Science 292, 498-500. 
24. Wang, L., and Schultz, P. G. (2004) Expanding the genetic code. Angew Chem 
Int Ed Engl 44, 34-66. 
 227 
25. Herring, S., Ambrogelly, A., Polycarpo, C. R., and Soll, D. (2007) Recognition 
of pyrrolysine tRNA by the Desulfitobacterium hafniense pyrrolysyl-tRNA 
synthetase. Nucleic Acids Res 35, 1270-1278. 
26. Srinivasan, G., James, C. M., and Krzycki, J. A. (2002) Pyrrolysine encoded by 
UAG in Archaea: charging of a UAG-decoding specialized tRNA. Science 296, 
1459-1462. 
27. Gaston, M. A., Jiang, R., and Krzycki, J. A. (2011) Functional context, 
biosynthesis, and genetic encoding of pyrrolysine. Current opinion in 
microbiology 14, 342-349. 
28. Liu, C. C., Choe, H., Farzan, M., Smider, V. V., and Schultz, P. G. (2009) 
Mutagenesis and evolution of sulfated antibodies using an expanded genetic 
code. Biochemistry 48, 8891-8898. 
29. Liu, C. C., and Schultz, P. G. (2006) Recombinant expression of selectively 
sulfated proteins in Escherichia coli. Nat Biotechnol 24, 1436-1440. 
30. Stone, M. J., Chuang, S., Hou, X., Shoham, M., and Zhu, J. Z. (2009) Tyrosine 
sulfation: an increasingly recognised post-translational modification of secreted 
proteins. New biotechnology 25, 299-317. 
31. Bettelheim, F. R. (1954) Tyrosine-o-sulfate in a peptide from fibrinogen. J Am 
Chem Soc 76, 2838-2839. 
32. Martin, K. A., Wyatt, R., Farzan, M., Choe, H., Marcon, L., Desjardins, E., 
Robinson, J., Sodroski, J., Gerard, C., and Gerard, N. P. (1997) CD4-independent 
binding of SIV gp120 to rhesus CCR5. Science 278, 1470-1473. 
 228 
33. Huang, C. C., Lam, S. N., Acharya, P., Tang, M., Xiang, S. H., Hussan, S. S., 
Stanfield, R. L., Robinson, J., Sodroski, J., Wilson, I. A., Wyatt, R., Bewley, C. 
A., and Kwong, P. D. (2007) Structures of the CCR5 N terminus and of a 
tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930-1934. 
34. Choe, H., Li, W., Wright, P. L., Vasilieva, N., Venturi, M., Huang, C. C., 
Grundner, C., Dorfman, T., Zwick, M. B., Wang, L., Rosenberg, E. S., Kwong, 
P. D., Burton, D. R., Robinson, J. E., Sodroski, J. G., and Farzan, M. (2003) 
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 
binding region of HIV-1 gp120. Cell 114, 161-170. 
35. Huang, C. C., Venturi, M., Majeed, S., Moore, M. J., Phogat, S., Zhang, M. Y., 
Dimitrov, D. S., Hendrickson, W. A., Robinson, J., Sodroski, J., Wyatt, R., Choe, 
H., Farzan, M., and Kwong, P. D. (2004) Structural basis of tyrosine sulfation 
and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-
binding site on gp120. Proc Natl Acad Sci U S A 101, 2706-2711. 
36. Pouyani, T., and Seed, B. (1995) PSGL-1 recognition of P-selectin is controlled 
by a tyrosine sulfation consensus at the PSGL-1 amino terminus. Cell 83, 333-
343. 
37. Wilkins, P. P., Moore, K. L., McEver, R. P., and Cummings, R. D. (1995) 
Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity 
binding to P-selectin. J Biol Chem 270, 22677-22680. 
38. Young, T., and Kiessling, L. L. (2002) A strategy for the synthesis of sulfated 
peptides. Angew Chem Int Ed Engl 41, 3449-3451. 
 229 
39. Liu, C. C., Brustad, E., Liu, W., and Schultz, P. G. (2007) Crystal structure of a 
biosynthetic sulfo-hirudin complexed to thrombin. J Am Chem Soc 129, 10648-
10649. 
40. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) 
The protein kinase complement of the human genome. Science 298, 1912-1934. 
41. Tong, L., Warren, T. C., Lukas, S., Schembri-King, J., Betageri, R., Proudfoot, J. 
R., and Jakes, S. (1998) Carboxymethyl-phenylalanine as a replacement for 
phosphotyrosine in SH2 domain binding. J Biol Chem 273, 20238-20242. 
42. Xie, J., Supekova, L., and Schultz, P. G. (2007) A genetically encoded 
metabolically stable analogue of phosphotyrosine in Escherichia coli. ACS 
chemical biology 2, 474-478. 
43. Chin, J. W., Santoro, S. W., Martin, A. B., King, D. S., Wang, L., and Schultz, P. 
G. (2002) Addition of p-azido-L-phenylalanine to the genetic code of Escherichia 
coli. J Am Chem Soc 124, 9026-9027. 
44. Deiters, A., Cropp, T. A., Mukherji, M., Chin, J. W., Anderson, J. C., and 
Schultz, P. G. (2003) Adding amino acids with novel reactivity to the genetic 
code of Saccharomyces cerevisiae. J Am Chem Soc 125, 11782-11783. 
45. Serwa, R., Wilkening, I., Del Signore, G., Muhlberg, M., Claussnitzer, I., Weise, 
C., Gerrits, M., and Hackenberger, C. P. (2009) Chemoselective Staudinger-
phosphite reaction of azides for the phosphorylation of proteins. Angew Chem Int 
Ed Engl 48, 8234-8239. 
 230 
46. Radi, R. (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl 
Acad Sci U S A 101, 4003-4008. 
47. Yokoyama, K., Uhlin, U., and Stubbe, J. (2010) Site-specific incorporation of 3-
nitrotyrosine as a probe of pKa perturbation of redox-active tyrosines in 
ribonucleotide reductase. J Am Chem Soc 132, 8385-8397. 
48. Schopfer, F. J., Baker, P. R., and Freeman, B. A. (2003) NO-dependent protein 
nitration: a cell signaling event or an oxidative inflammatory response? Trends 
Biochem Sci 28, 646-654. 
49. Sokolovsky, M., Riordan, J. F., and Vallee, B. L. (1966) Tetranitromethane. A 
reagent for the nitration of tyrosyl residues in proteins. Biochemistry 5, 3582-
3589. 
50. Neumann, H., Hazen, J. L., Weinstein, J., Mehl, R. A., and Chin, J. W. (2008) 
Genetically encoding protein oxidative damage. J Am Chem Soc 130, 4028-4033. 
51. Yakovlev, V. A., Bayden, A. S., Graves, P. R., Kellogg, G. E., and Mikkelsen, R. 
B. (2010) Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes 
p53 oligomerization and activation. Biochemistry 49, 5331-5339. 
52. Neumann, H., Peak-Chew, S. Y., and Chin, J. W. (2008) Genetically encoding 
N(epsilon)-acetyllysine in recombinant proteins. Nat Chem Biol 4, 232-234. 
53. Neumann, H., Hancock, S. M., Buning, R., Routh, A., Chapman, L., Somers, J., 
Owen-Hughes, T., van Noort, J., Rhodes, D., and Chin, J. W. (2009) A method 
for genetically installing site-specific acetylation in recombinant histones defines 
the effects of H3 K56 acetylation. Mol Cell 36, 153-163. 
 231 
54. Lammers, M., Neumann, H., Chin, J. W., and James, L. C. (2010) Acetylation 
regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. 
Nat Chem Biol 6, 331-337. 
55. Huang, Y., Russell, W. K., Wan, W., Pai, P. J., Russell, D. H., and Liu, W. 
(2010) A convenient method for genetic incorporation of multiple noncanonical 
amino acids into one protein in Escherichia coli. Mol Biosyst 6, 683-686. 
56. Huang, Y., Wan, W., Russell, W. K., Pai, P. J., Wang, Z., Russell, D. H., and 
Liu, W. (2010) Genetic incorporation of an aliphatic keto-containing amino acid 
into proteins for their site-specific modifications. Bioorg Med Chem Lett 20, 878-
880. 
57. Allfrey, V. G., Faulkner, R., and Mirsky, A. E. (1964) Acetylation + Methylation 
of Histones + Their Possible Role in Regulation of Rna Synthesis. P Natl Acad 
Sci USA 51, 786-&. 
58. Cheung, P., and Lau, P. (2005) Epigenetic regulation by histone methylation and 
histone variants. Mol Endocrinol 19, 563-573. 
59. Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., 
McKinney, K., Tempst, P., Prives, C., Gamblin, S. J., Barlev, N. A., and 
Reinberg, D. (2004) Regulation of p53 activity through lysine methylation. 
Nature 432, 353-360. 
60. Huang, J., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. 
A., Kubicek, S., Opravil, S., Jenuwein, T., and Berger, S. L. (2006) Repression of 
p53 activity by Smyd2-mediated methylation. Nature 444, 629-632. 
 232 
61. Huang, J., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., 
Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., and Berger, S. L. 
(2007) p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108. 
62. Masatsugu, T., and Yamamoto, K. (2009) Multiple lysine methylation of PCAF 
by Set9 methyltransferase. Biochemical and biophysical research 
communications 381, 22-26. 
63. Nolz, J. C., Gomez, T. S., and Billadeau, D. D. (2005) The Ezh2 
methyltransferase complex: actin up in the cytosol. Trends Cell Biol 15, 514-517. 
64. Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) 
How chromatin-binding modules interpret histone modifications: lessons from 
professional pocket pickers. Nat Struct Mol Biol 14, 1025-1040. 
65. He, S., Bauman, D., Davis, J. S., Loyola, A., Nishioka, K., Gronlund, J. L., 
Reinberg, D., Meng, F. Y., Kelleher, N., and McCafferty, D. G. (2003) Facile 
synthesis of site-specifically acetylated and methylated histone proteins: 
Reagents for evaluation of the histone code hypothesis. P Natl Acad Sci USA 
100, 12033-12038. 
66. Nguyen, D. P., Garcia Alai, M. M., Kapadnis, P. B., Neumann, H., and Chin, J. 
W. (2009) Genetically encoding N(epsilon)-methyl-L-lysine in recombinant 
histones. J Am Chem Soc 131, 14194-14195. 
67. Groff, D., Chen, P. R., Peters, F. B., and Schultz, P. G. (2010) A genetically 
encoded epsilon-N-methyl lysine in mammalian cells. Chembiochem 11, 1066-
1068. 
 233 
68. Wang, Y. S., Wu, B., Wang, Z., Huang, Y., Wan, W., Russell, W. K., Pai, P. J., 
Moe, Y. N., Russell, D. H., and Liu, W. R. (2010) A genetically encoded 
photocaged Nepsilon-methyl-L-lysine. Mol Biosyst 6, 1557-1560. 
69. Ai, H. W., Lee, J. W., and Schultz, P. G. (2010) A method to site-specifically 
introduce methyllysine into proteins in E. coli. Chem Commun (Camb) 46, 5506-
5508. 
70. Wang, J., Schiller, S. M., and Schultz, P. G. (2007) A biosynthetic route to 
dehydroalanine-containing proteins. Angew Chem Int Ed Engl 46, 6849-6851. 
71. Guo, J., Wang, J., Lee, J. S., and Schultz, P. G. (2008) Site-specific incorporation 
of methyl- and acetyl-lysine analogues into recombinant proteins. Angew Chem 
Int Ed Engl 47, 6399-6401. 
72. Chau, V., Tobias, J. W., Bachmair, A., Marriott, D., Ecker, D. J., Gonda, D. K., 
and Varshavsky, A. (1989) A multiubiquitin chain is confined to specific lysine 
in a targeted short-lived protein. Science 243, 1576-1583. 
73. Nagy, V., and Dikic, I. (2010) Ubiquitin ligase complexes: from substrate 
selectivity to conjugational specificity. Biological chemistry 391, 163-169. 
74. Li, W., and Ye, Y. (2008) Polyubiquitin chains: functions, structures, and 
mechanisms. Cell Mol Life Sci 65, 2397-2406. 
75. Chatterjee, C., McGinty, R. K., Pellois, J. P., and Muir, T. W. (2007) Auxiliary-
mediated site-specific peptide ubiquitylation. Angew Chem Int Ed Engl 46, 2814-
2818. 
 234 
76. Chatterjee, C., McGinty, R. K., Fierz, B., and Muir, T. W. (2010) Disulfide-
directed histone ubiquitylation reveals plasticity in hDot1L activation. Nat Chem 
Biol 6, 267-269. 
77. Chen, J., Ai, Y., Wang, J., Haracska, L., and Zhuang, Z. (2010) Chemically 
ubiquitylated PCNA as a probe for eukaryotic translesion DNA synthesis. Nat 
Chem Biol 6, 270-272. 
78. Li, X., Fekner, T., Ottesen, J. J., and Chan, M. K. (2009) A pyrrolysine analogue 
for site-specific protein ubiquitination. Angew Chem Int Ed Engl 48, 9184-9187. 
79. Virdee, S., Ye, Y., Nguyen, D. P., Komander, D., and Chin, J. W. (2010) 
Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU 
deubiquitinase. Nat Chem Biol 6, 750-757. 
80. Couture, J. F., and Trievel, R. C. (2006) Histone-modifying enzymes: encrypting 
an enigmatic epigenetic code. Curr Opin Struct Biol 16, 753-760. 
81. Kouzarides, T. (2007) Chromatin modifications and their function. Cell 128, 
693-705. 
82. Lall, S. (2007) Primers on chromatin. Nat Struct Mol Biol 14, 1110-1115. 
83. Blight, S. K., Larue, R. C., Mahapatra, A., Longstaff, D. G., Chang, E., Zhao, G., 
Kang, P. T., Green-Church, K. B., Chan, M. K., and Krzycki, J. A. (2004) Direct 
charging of tRNA(CUA) with pyrrolysine in vitro and in vivo. Nature 431, 333-
335. 
84. Fekner, T., Li, X., Lee, M. M., and Chan, M. K. (2009) A pyrrolysine analogue 
for protein click chemistry. Angew Chem Int Ed Engl 48, 1633-1635. 
 235 
85. Mukai, T., Kobayashi, T., Hino, N., Yanagisawa, T., Sakamoto, K., and 
Yokoyama, S. (2008) Adding l-lysine derivatives to the genetic code of 
mammalian cells with engineered pyrrolysyl-tRNA synthetases. Biochemical and 
biophysical research communications 371, 818-822. 
86. Nguyen, D. P., Lusic, H., Neumann, H., Kapadnis, P. B., Deiters, A., and Chin, J. 
W. (2009) Genetic encoding and labeling of aliphatic azides and alkynes in 
recombinant proteins via a pyrrolysyl-tRNA Synthetase/tRNA(CUA) pair and 
click chemistry. J Am Chem Soc 131, 8720-8721. 
87. Tatsu, Y., Shigeri, Y., Ishida, A., Kameshita, I., Fujisawa, H., and Yumoto, N. 
(1999) Synthesis of caged peptides using caged lysine: application to the 
synthesis of caged AIP, a highly specific inhibitor of calmodulin-dependent 
protein kinase II. Bioorg Med Chem Lett 9, 1093-1096. 
88. Wan, W., Huang, Y., Wang, Z., Russell, W. K., Pai, P. J., Russell, D. H., and 
Liu, W. R. (2010) A facile system for genetic incorporation of two different 
noncanonical amino acids into one protein in Escherichia coli. Angew Chem Int 
Ed Engl 49, 3211-3214. 
89. Wiejak, S., Masiukiewicz, E., and Rzeszotarsk, B. (2001) Improved scalable 
syntheses of mono- and bis-urethane derivatives of ornithine. Chem Pharm Bull 
49, 1189-1191. 
90. Dyer, R. G., and Turnbull, K. D. (1999) Hydrolytic Stabilization of Protected p-
Hydroxybenzyl Halides Designed as Latent Quinone Methide Precursors. The 
Journal of organic chemistry 64, 7988-7995. 
 236 
91. Yamamoto, H., and Yang, J. T. (1974) The thermal induced helix--beta transition 
of poly(N epsilon-methyl-L-lysine) and poly(N delta-ethyl-L-ornithine) in 
aqueous solution. Biopolymers 13, 1109-1116. 
92. Santoro, S. W., Wang, L., Herberich, B., King, D. S., and Schultz, P. G. (2002) 
An efficient system for the evolution of aminoacyl-tRNA synthetase specificity. 
Nat Biotechnol 20, 1044-1048. 
93. Wang, L., Zhang, Z., Brock, A., and Schultz, P. G. (2003) Addition of the keto 
functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci U S 
A 100, 56-61. 
94. Xie, J., Wang, L., Wu, N., Brock, A., Spraggon, G., and Schultz, P. G. (2004) 
The site-specific incorporation of p-iodo-L-phenylalanine into proteins for 
structure determination. Nat Biotechnol 22, 1297-1301. 
95. Tam, J. P., Yu, Q., and Miao, Z. (1999) Orthogonal ligation strategies for peptide 
and protein. Biopolymers 51, 311-332. 
96. Chen, P. R., Groff, D., Guo, J., Ou, W., Cellitti, S., Geierstanger, B. H., and 
Schultz, P. G. (2009) A facile system for encoding unnatural amino acids in 
mammalian cells. Angew Chem Int Ed Engl 48, 4052-4055. 
97. Xie, J., Liu, W., and Schultz, P. G. (2007) A genetically encoded bidentate, 
metal-binding amino acid. Angew Chem Int Ed Engl 46, 9239-9242. 
98. Umehara, T., Kim, J., Lee, S., Guo, L. T., Soll, D., and Park, H. S. (2012) N-
acetyl lysyl-tRNA synthetases evolved by a CcdB-based selection possess N-
acetyl lysine specificity in vitro and in vivo. FEBS Lett 586, 729-733. 
 237 
99. Bird, A. (2002) DNA methylation patterns and epigenetic memory. Gene Dev 16, 
6-21. 
100. Jones, P. A., and Takai, D. (2001) The role of DNA methylation in mammalian 
epigenetics. Science 293, 1068-1070. 
101. Laird, P. W., and Jaenisch, R. (1996) The role of DNA methylation in cancer 
genetics and epigenetics. Annu Rev Genet 30, 441-464. 
102. Nakao, M. (2001) Epigenetics: interaction of DNA methylation and chromatin. 
Gene 278, 25-31. 
103. Bhaumik, S. R., Smith, E., and Shilatifard, A. (2007) Covalent modifications of 
histones during development and disease pathogenesis. Nat Struct Mol Biol 14, 
1008-1016. 
104. Turner, B. M. (2002) Cellular memory and the histone code. Cell 111, 285-291. 
105. Fischle, W. (2008) Talk is cheap--cross-talk in establishment, maintenance, and 
readout of chromatin modifications. Genes Dev 22, 3375-3382. 
106. Lee, J. S., Smith, E., and Shilatifard, A. (2010) The language of histone crosstalk. 
Cell 142, 682-685. 
107. Suganuma, T., and Workman, J. L. (2008) Crosstalk among Histone 
Modifications. Cell 135, 604-607. 
108. Manohar, M., Mooney, A. M., North, J. A., Nakkula, R. J., Picking, J. W., Edon, 
A., Fishel, R., Poirier, M. G., and Ottesen, J. J. (2009) Acetylation of histone H3 
at the nucleosome dyad alters DNA-histone binding. J Biol Chem 284, 23312-
23321. 
 238 
109. Muir, T. W., Sondhi, D., and Cole, P. A. (1998) Expressed protein ligation: a 
general method for protein engineering. Proc Natl Acad Sci U S A 95, 6705-
6710. 
110. Shogren-Knaak, M., Ishii, H., Sun, J. M., Pazin, M. J., Davie, J. R., and Peterson, 
C. L. (2006) Histone H4-K16 acetylation controls chromatin structure and 
protein interactions. Science 311, 844-847. 
111. Nozawa, K., O'Donoghue, P., Gundllapalli, S., Araiso, Y., Ishitani, R., Umehara, 
T., Soll, D., and Nureki, O. (2009) Pyrrolysyl-tRNA synthetase-tRNA(Pyl) 
structure reveals the molecular basis of orthogonality. Nature 457, 1163-1167. 
112. Polycarpo, C. R., Herring, S., Berube, A., Wood, J. L., Soll, D., and Ambrogelly, 
A. (2006) Pyrrolysine analogues as substrates for pyrrolysyl-tRNA synthetase. 
FEBS Lett 580, 6695-6700. 
113. Bernardes, G. J., Chalker, J. M., Errey, J. C., and Davis, B. G. (2008) Facile 
conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: 
versatile and switchable access to functionalized proteins. J Am Chem Soc 130, 
5052-5053. 
114. Arnaud, O., Koubeissi, A., Ettouati, L., Terreux, R., Alame, G., Grenot, C., 
Dumontet, C., Di Pietro, A., Paris, J., and Falson, P. (2010) Potent and fully 
noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. 
Journal of medicinal chemistry 53, 6720-6729. 
115. Karanewsky, D. S., Badia, M. C., Cushman, D. W., DeForrest, J. M., Dejneka, 
T., Loots, M. J., Perri, M. G., Petrillo, E. W., Jr., and Powell, J. R. (1988) 
 239 
(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme 
(ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-
phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active 
inhibitor of ACE. Journal of medicinal chemistry 31, 204-212. 
116. Foster, S. J., Kraus, R. J., and Ganther, H. E. (1986) The metabolism of 
selenomethionine, Se-methylselenocysteine, their selenonium derivatives, and 
trimethylselenonium in the rat. Arch Biochem Biophys 251, 77-86. 
117. Brouwer, A. J., and Liskamp, R. M. J. (2005) Synthesis of Novel Dendrimeric 
Systems Containing NLO Ligands. European Journal of Organic Chemistry 
2005, 487-495. 
118. Michael, F. E., Sibbald, P. A., and Cochran, B. M. (2008) Palladium-catalyzed 
intramolecular chloroamination of alkenes. Organic letters 10, 793-796. 
119. Young, T. S., Ahmad, I., Yin, J. A., and Schultz, P. G. (2010) An enhanced 
system for unnatural amino acid mutagenesis in E. coli. Journal of molecular 
biology 395, 361-374. 
120. Miyake-Stoner, S. J., Refakis, C. A., Hammill, J. T., Lusic, H., Hazen, J. L., 
Deiters, A., and Mehl, R. A. (2010) Generating permissive site-specific unnatural 
aminoacyl-tRNA synthetases. Biochemistry 49, 1667-1677. 
121. Pedelacq, J. D., Cabantous, S., Tran, T., Terwilliger, T. C., and Waldo, G. S. 
(2006) Engineering and characterization of a superfolder green fluorescent 
protein. Nat Biotechnol 24, 79-88. 
 240 
122. Yanagisawa, T., Ishii, R., Fukunaga, R., Kobayashi, T., Sakamoto, K., and 
Yokoyama, S. (2008) Multistep engineering of pyrrolysyl-tRNA synthetase to 
genetically encode N(epsilon)-(o-azidobenzyloxycarbonyl) lysine for site-
specific protein modification. Chemistry & biology 15, 1187-1197. 
123. Chalker, J. M., Gunnoo, S. B., Boutureira, O., Gerstberger, S. C., Fernandez-
Gonzalez, M., Bernardes, G. J. L., Griffin, L., Hailu, H., Schofield, C. J., and 
Davis, B. G. (2011) Methods for converting cysteine to dehydroalanine on 
peptides and proteins. Chemical Science 2, 1666-1676. 
124. Reid, G. E., and McLuckey, S. A. (2002) 'Top down' protein characterization via 
tandem mass spectrometry. Journal of mass spectrometry : JMS 37, 663-675. 
125. Zhang, J., Dong, X., Hacker, T. A., and Ge, Y. (2010) Deciphering modifications 
in swine cardiac troponin I by top-down high-resolution tandem mass 
spectrometry. Journal of the American Society for Mass Spectrometry 21, 940-
948. 
126. Zinnel, N. F., Pai, P. J., Russell, W. K., and Russell, D. H. (2012) in preparation. 
127. Liu, C. C., and Schultz, P. G. (2010) Adding new chemistries to the genetic code. 
Annu Rev Biochem 79, 413-444. 
128. Liu, W., Brock, A., Chen, S., and Schultz, P. G. (2007) Genetic incorporation of 
unnatural amino acids into proteins in mammalian cells. Nature methods 4, 239-
244. 
129. Wu, N., Deiters, A., Cropp, T. A., King, D., and Schultz, P. G. (2004) A 
genetically encoded photocaged amino acid. J Am Chem Soc 126, 14306-14307. 
 241 
130. Gautier, A., Nguyen, D. P., Lusic, H., An, W., Deiters, A., and Chin, J. W. 
(2010) Genetically encoded photocontrol of protein localization in mammalian 
cells. J Am Chem Soc 132, 4086-4088. 
131. Yanagisawa, T., Ishii, R., Fukunaga, R., Kobayashi, T., Sakamoto, K., and 
Yokoyama, S. (2008) Crystallographic studies on multiple conformational states 
of active-site loops in pyrrolysyl-tRNA synthetase. Journal of molecular biology 
378, 634-652. 
132. Neumann, H., Wang, K., Davis, L., Garcia-Alai, M., and Chin, J. W. (2010) 
Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding 
ribosome. Nature 464, 441-444. 
133. Miyake-Stoner, S. J., Miller, A. M., Hammill, J. T., Peeler, J. C., Hess, K. R., 
Mehl, R. A., and Brewer, S. H. (2009) Probing protein folding using site-
specifically encoded unnatural amino acids as FRET donors with tryptophan. 
Biochemistry 48, 5953-5962. 
134. Guo, J., Melancon, C. E., 3rd, Lee, H. S., Groff, D., and Schultz, P. G. (2009) 
Evolution of amber suppressor tRNAs for efficient bacterial production of 
proteins containing nonnatural amino acids. Angew Chem Int Ed Engl 48, 9148-
9151. 
135. Chalker, J. M., Wood, C. S., and Davis, B. G. (2009) A convenient catalyst for 
aqueous and protein Suzuki-Miyaura cross-coupling. J Am Chem Soc 131, 
16346-16347. 
 242 
136. Anderson, J. C., Wu, N., Santoro, S. W., Lakshman, V., King, D. S., and Schultz, 
P. G. (2004) An expanded genetic code with a functional quadruplet codon. Proc 
Natl Acad Sci U S A 101, 7566-7571. 
137. Wang, L., and Schultz, P. G. (2002) Expanding the genetic code. Chem Commun 
(Camb), 1-11. 
138. Melancon, C. E., 3rd, and Schultz, P. G. (2009) One plasmid selection system for 
the rapid evolution of aminoacyl-tRNA synthetases. Bioorg Med Chem Lett 19, 
3845-3847. 
139. Zhang, D., Vaidehi, N., Goddard, W. A., 3rd, Danzer, J. F., and Debe, D. (2002) 
Structure-based design of mutant Methanococcus jannaschii tyrosyl-tRNA 
synthetase for incorporation of O-methyl-L-tyrosine. Proc Natl Acad Sci U S A 
99, 6579-6584. 
140. Tanrikulu, I. C., Schmitt, E., Mechulam, Y., Goddard, W. A., 3rd, and Tirrell, D. 
A. (2009) Discovery of Escherichia coli methionyl-tRNA synthetase mutants for 
efficient labeling of proteins with azidonorleucine in vivo. Proc Natl Acad Sci U 
S A 106, 15285-15290. 
141. Wang, Y. S., Russell, W. K., Wang, Z., Wan, W., Dodd, L. E., Pai, P. J., Russell, 
D. H., and Liu, W. R. (2011) The de novo engineering of pyrrolysyl-tRNA 
synthetase for genetic incorporation of L-phenylalanine and its derivatives. Mol 
Biosyst 7, 714-717. 
 243 
142. Kavran, J. M., Gundllapalli, S., O'Donoghue, P., Englert, M., Soll, D., and Steitz, 
T. A. (2007) Structure of pyrrolysyl-tRNA synthetase, an archaeal enzyme for 
genetic code innovation. Proc Natl Acad Sci U S A 104, 11268-11273. 
143. Zhang, M., Lin, S., Song, X., Liu, J., Fu, Y., Ge, X., Fu, X., Chang, Z., and Chen, 
P. R. (2011) A genetically incorporated crosslinker reveals chaperone 
cooperation in acid resistance. Nat Chem Biol 7, 671-677. 
144. Kolb, H. C., Finn, M. G., and Sharpless, K. B. (2001) Click chemistry: Diverse 
chemical function from a few good reactions. Angew Chem Int Edit 40, 2004-+. 
145. Wu, B., Wang, Z., Huang, Y., and Liu, W. R. (2012) Manuscript inpreparation. 
146. Takimoto, J. K., Dellas, N., Noel, J. P., and Wang, L. (2011) Stereochemical 
basis for engineered pyrrolysyl-tRNA synthetase and the efficient in vivo 
incorporation of structurally divergent non-native amino acids. ACS chemical 
biology 6, 733-743. 
147. Hancock, S. M., Uprety, R., Deiters, A., and Chin, J. W. (2010) Expanding the 
genetic code of yeast for incorporation of diverse unnatural amino acids via a 
pyrrolysyl-tRNA synthetase/tRNA pair. J Am Chem Soc 132, 14819-14824. 
148. Greiss, S., and Chin, J. W. (2011) Expanding the genetic code of an animal. J Am 
Chem Soc 133, 14196-14199. 
149. Xie, J., and Schultz, P. G. (2006) A chemical toolkit for proteins--an expanded 
genetic code. Nature reviews. Molecular cell biology 7, 775-782. 
150. Wang, L., Xie, J., and Schultz, P. G. (2006) Expanding the genetic code. Annu 
Rev Biophys Biomol Struct 35, 225-249. 
 244 
151. Bose, M., Groff, D., Xie, J., Brustad, E., and Schultz, P. G. (2006) The 
incorporation of a photoisomerizable amino acid into proteins in E. coli. J Am 
Chem Soc 128, 388-389. 
152. Brustad, E., Bushey, M. L., Lee, J. W., Groff, D., Liu, W., and Schultz, P. G. 
(2008) A genetically encoded boronate-containing amino acid. Angew Chem Int 
Ed Engl 47, 8220-8223. 
153. Brustad, E. M., Lemke, E. A., Schultz, P. G., and Deniz, A. A. (2008) A general 
and efficient method for the site-specific dual-labeling of proteins for single 
molecule fluorescence resonance energy transfer. J Am Chem Soc 130, 17664-
17665. 
154. Chin, J. W., Cropp, T. A., Chu, S., Meggers, E., and Schultz, P. G. (2003) 
Progress toward an expanded eukaryotic genetic code. Chemistry & biology 10, 
511-519. 
155. Chin, J. W., Martin, A. B., King, D. S., Wang, L., and Schultz, P. G. (2002) 
Addition of a photocrosslinking amino acid to the genetic code of 
Escherichiacoli. Proc Natl Acad Sci U S A 99, 11020-11024. 
156. Deiters, A., Groff, D., Ryu, Y., Xie, J., and Schultz, P. G. (2006) A genetically 
encoded photocaged tyrosine. Angew Chem Int Ed Engl 45, 2728-2731. 
157. Deiters, A., and Schultz, P. G. (2005) In vivo incorporation of an alkyne into 
proteins in Escherichia coli. Bioorg Med Chem Lett 15, 1521-1524. 
158. Fleissner, M. R., Brustad, E. M., Kalai, T., Altenbach, C., Cascio, D., Peters, F. 
B., Hideg, K., Peuker, S., Schultz, P. G., and Hubbell, W. L. (2009) Site-directed 
 245 
spin labeling of a genetically encoded unnatural amino acid. Proc Natl Acad Sci 
U S A 106, 21637-21642. 
159. Schultz, K. C., Supekova, L., Ryu, Y., Xie, J., Perera, R., and Schultz, P. G. 
(2006) A genetically encoded infrared probe. J Am Chem Soc 128, 13984-13985. 
160. Taskent-Sezgin, H., Chung, J., Patsalo, V., Miyake-Stoner, S. J., Miller, A. M., 
Brewer, S. H., Mehl, R. A., Green, D. F., Raleigh, D. P., and Carrico, I. (2009) 
Interpretation of p-cyanophenylalanine fluorescence in proteins in terms of 
solvent exposure and contribution of side-chain quenchers: a combined 
fluorescence, IR and molecular dynamics study. Biochemistry 48, 9040-9046. 
161. Tippmann, E. M., Liu, W., Summerer, D., Mack, A. V., and Schultz, P. G. (2007) 
A genetically encoded diazirine photocrosslinker in Escherichia coli. 
Chembiochem 8, 2210-2214. 
162. Tsao, M. L., Summerer, D., Ryu, Y., and Schultz, P. G. (2006) The genetic 
incorporation of a distance probe into proteins in Escherichia coli. J Am Chem 
Soc 128, 4572-4573. 
163. Turner, J. M., Graziano, J., Spraggon, G., and Schultz, P. G. (2006) Structural 
plasticity of an aminoacyl-tRNA synthetase active site. Proc Natl Acad Sci U S A 
103, 6483-6488. 
164. Zeng, H., Xie, J., and Schultz, P. G. (2006) Genetic introduction of a diketone-
containing amino acid into proteins. Bioorg Med Chem Lett 16, 5356-5359. 
165. Xie, J., and Schultz, P. G. (2005) An expanding genetic code. Methods 36, 227-
238. 
 246 
166. Zhang, Z., Smith, B. A., Wang, L., Brock, A., Cho, C., and Schultz, P. G. (2003) 
A new strategy for the site-specific modification of proteins in vivo. 
Biochemistry 42, 6735-6746. 
167. Wang, Y.-S., Fang, X., Wallace, A., Wu, B., and Liu, W. R. (2012) A Rationally 
Designed Pyrrolysyl-tRNA Synthetase Has a Broad Substrate Spectrum. in 
preparation. 
168. Wang, Y. S., Fang, X., Wallace, A. L., Wu, B., and Liu, W. R. (2012) A 
rationally designed pyrrolysyl-tRNA synthetase mutant with a broad substrate 
spectrum. J Am Chem Soc 134, 2950-2953. 
169. Wang, Y.-S., Wang, Z., Wan, W., Lee, Y.-J., Dodd, L. E., Russell, W. K., Pai, P. 
J., Russell, D. H., and Liu, W. R. (2010) The de novo engineering of pyrrolyl-
tRNA synthetase for genetic incorporation of L-phenylalanine and its derivatives. 
Mol Biosyst submitted. 
170. Andrews, B. T., Gosavi, S., Finke, J. M., Onuchic, J. N., and Jennings, P. A. 
(2008) The dual-basin landscape in GFP folding. Proc Natl Acad Sci U S A 105, 
12283-12288. 
 
 
  
 247 
VITA 
 
Yane-Shih Wang received his Bachelor of Science and Master of Science 
degrees from National Cheng-Kung University, Taiwan in 1999 and 2001. He entered 
the Ph.D. program at Texas A&M University in 2007, where he joined the group 
directed by Dr. Wenshe Liu from Department of Chemistry. His research interests 
include bioinorganic chemistry, as well as the expanding genetic code for protein 
modifications of epigenetic researchs. Yane-Shih Wang graduated with his Ph.D. degree 
in Chemistry in August, 2012. 
Yane-Shih Wang may be reached at No. 1-7, Neighborhood 15, Tayuan 
Twonship, Taoyuan, 337 Taiwan.  His  e-mail address is ericyswang@gmail.com. 
 
